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Introduction 
Mycobacterium tuberculosis is a highly sucessful pathogen that has plagued 
mankind and animals for thousands of years.  Each year, there are an estimated 
nine million new cases of tuberculosis (TB) and about 1.8 million deaths due to TB. 
Although diagnostic tests, chemotherapy and vaccination are available, the 
disease is far from being eradicated. Recent data suggest that the propensity to 
gain drug resistance as well as the pathogen’s transmissibility profile may be 
influenced by the genetic and evolutionary background of M. tuberculosis strains. 
Therefore, understanding the relationships and dynamics of the M. tuberculosis 
complex  lineages will undoubtedly help to control TB. 
 
The molecular epidemiology of tuberculosis 
The development of molecular techniques has allowed investigators to determine 
the genetic relatedness of Mycobacterium tuberculosis complex isolates. 
Previously it was believed that M. tuberculosis complex was genetically highly 
conserved, but on basis of an unprecedented DNA polymorphism, thousands of 
different M. tuberculosis strains have been recognised. A standardized 
methodology exploiting this polymorphism to discriminate M. tuberculosis strains 
was introduced in 1993 (1). This method, called restriction fragment length 
polymorphisms (RFLP) is based on a variable number of IS6110 insertion elements 
in the genome of different M. tuberculosis complex strains and the high degree of 
variation in the genomic sites of integration. The use of RFLP analysis has 
revolutionized outbreak investigations and conventional epidemiology (2). In 
particular, IS6110 RFLP typing has been used to generate fingerprints in various 
epidemiological studies of institutional and community outbreaks (3). However, 
this technique is laborious and time-consuming, and it has insufficient capacity to 
discriminate M. tuberculosis strains with low copy numbers of IS6110. 
In 1991, an extensive polymorphism was observed between M. tuberculosis 
isolates in the direct repeat (DR) chromosomal region. This region comprises 
multiple identical 36-bp DR sequences interspersed by unique spacer regions 
ranging from 35 to 41 bp in length (4). Spacer oligonucleotide typing (also called: 
spologotyping) is  a simple technique to determine the presence or absence of 43 
spacer regions in M. tuberculosis isolates, targetting the spacer sequences that 
separate the Direct Repeats (DRs) in the spacer interspersed direct repeats 
(SPIDRs).  This technique was introduced in 1995 as an alternative fingerprinting 
technique (5). Spoligotyping has several advantages over IS6110-based 
genotyping. First, because it is a PCR based fingerprinting technique, the DNA can 
be of lower purity, which makes spoligotypping much easier to perform than 
other genotyping techniques. Second, because small amounts of DNA are 
required, it can be performed on bacteria in clinical samples or on strains of M. 
tuberculosis shortly after their inoculation into liquid culture or bacteria in Ziehl-
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Neelsen slides (6). Third, the results of spoligotyping, which are expressed as 
positive or negative for each spacer, constitute a digital format, so that patterns 
can easily be compared and analyzed.  Fourth, although spoligotyping gives a 
more limited level of strain discrimination than some other techniques, it is highly 
informative regarding the phylogeny of the M. tuberculosis isolates. Therefore it 
been used all over the world besides RFLP, culminating in a global database (7). 
Spoligo patterns have been used for phylogenetic studies, analyzing evolutionary 
relationships, and indirectly to unravel mechanisms of virulence of M. tuberculosis 
complex strains.  
Nowadays, another direct repeat driven fingerprinting technique has been 
introduced, namely Variable Number of Tandem Repeat (VNTR) typing. VNTR 
seems to be the most suitable typing technique for the coming period because it 
is PCR-based and offers sufficient discrimination for strain typing as well as 
phylogenetical analysis of M. tuberculosis complex strains (8-10). 
 
Mycobacterium tuberculosis Beijing genotype 
One clade of Mycobacterium tuberculosis, the ‘Beijing genotype’ family, first 
described in 1995 (2), is one of the most successful clades in the current 
worldwide tuberculosis (TB) epidemic. The Beijing genotype was recognized on 
basis of the highly conserved spoligo patterns and characteristic IS6110 RFLP 
patterns of M. tuberculosis isolates from the Beijing region and Mongolia. Since 
then, the Beijing genotype has been found in many different countries, especially 
in Asia, the former Soviet republics, and (South) Africa, but also Northern 
American cities. Typical RFLP and spoligo patterns of M. tuberculosis Beijing 
strains are shown in Figure 1. 
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Figure 1. Dendogram showing similarity of RFLP patterns of M. tuberculosis isolates, in 
combination with spoligopatterns. The branch in the dendogram representing M. 
tuberculosis Beijing genotype is indicated with an asterix (11). 
 
Beijing genotype strains represent group 1 of the original grouping of Sreevatsan 
based on a limited number of single nucleotide polymorphisms (12), but are 
considered a grouping of the “modern” lineage of M. tuberculosis according to the 
grouping of the M. tuberculosis complex based on large sequence polymorphisms 
(13). The Beijing clade consists of at least two major groupings; the “typical and 
“atypical” Beijing strains, which differ in their distribution in different countries 
and age groups, and which may have different properties. Typical (“modern”) 
Beijing strains, including W strains, exhibit highly similar, multicopy IS 6110 RFLP 
patterns Atypical (“ancestral”) Beijing strains more closely resemble the common 
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ancestor of the Beijing clade (14-17). Beijing strains can also be subdivided in 
various evolutionary lineages through large sequence polymorphisms (LSPs), 
which help to divide the Beijing family into four monophyletic subgroups, on basis 
of so-called ‘Regions of Difference’ (RD), namely RD105, RD181, RD150, and 
RD142 (18). The Beijing genotype of M. tuberculosis has recently also been 
recognized as the major part of  the ‘East-Asian lineage’ (19, 20). 
The fourth International Spoligotyping Database (SpolBD4), which classified 
39,295 strains of M. tuberculosis from 141 countries into 62 clades/lineages, has 
indicated that Beijing and Beijing-like strains represent at least 50% of strains in 
East Asia, and 13% of the isolates globally (7). However, because spoligotyping has 
mostly been used in Western countries, the data from many high prevalence 
settings are missing. It is possible that the true contribution of Beijing strains to 
the worldwide TB epidemic may even be higher.  
A recent study determined the time of divergence, population diversity and 
spread of M. tuberculosis complex by MIRU-typing of a collection of 355 strains 
representing all well-defined primary branches of M. tuberculosis complex. 
Compared to other clades, the Beijing genotype displayed the largest population 
increase taken place in the last 180 years (21). Investigation of archived specimens 
in South Africa has confirmed the recent expansion of the Beijing genotype in the 
last decades. Spoligotyping was applied to paraffin-embedded clinical material 
from consecutive time periods. In this area, Beijing strains were absent in 
histological samples from the period 1930–1965, rare in samples from 1966–1995, 
but increasingly common in samples from the period 1996–2005, showing a 20% 
increase since 2000 (22). 
Many studies have been conducted to investigate why the Beijing genotype has 
spread globally in a relatively limited ti me period. Different animal models have 
shown that Beijing strains are more virulent, causing more histopathology, higher 
outgrowth and increased mortality (23-25). Studies in human patients have found 
higher rates of drug resistance among Beijing strains in some, but not all 
geographic areas (26).[the systematic review..] Studies examining the virulence of 
Mycobacterium tuberculosis  Beijing genotype have also met with conflicting 
results. Some studies found more radiological abnormalities (reflecting more 
extensive lung damage), while others did not. Some studies found a relationship 
with BCG-vaccination, suggesting that the Beijing genotype is an ‘escape’-variant, 
but others did not. A limited number of studies have linked the Beijing genotype 
with treatment failure, but most are cross-sectional and should therefore be 
interpreted with caution. The geographic variation of M. tuberculosis might also 
be related to the human population structure, but so far only one study has 
directly examined this hypothesis (27). Because the population structure of M. 
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tuberculosis is still unclear in many areas, our understanding of mechanism 
underlying the success of this lineage of M. tuberculosis is far from complete.  
 
Tuberculosis in Indonesia 
After China and India, Indonesia has the third highest case load of tuberculosis, 
with more than half a million new cases per year, and an estimated 150.000 
attributable deaths  (28). However, very litte research related to TB in Indonesia 
has focussed on molecular and other aspects of its cause: Mycobacterium 
tuberculosis. For instance, there are hardly any data about about the population 
structure of M. tuberculosis in this country; except for one small study including 
92 isolates from a single clinic in Jakarta (11), no data have been published on M. 
tuberculosis genotypes in Indonesia. In addition, as culture is not routinely 
performed, and additional characterization of isolates, including drug 
susceptibility testing is rarely done, drug resistance data are lacking. Finally, no 
studies have examined the clinical phenotype of different M. tuberculosis 
genotype families.  
 
Thesis outline 
This thesis focuses on genetic analysis, risk factors and host interactions of 
Mycobacterium tuberculosis strains, especially those belonging to the Beijing 
genotype. The patients described in this thesis were recruited in Indonesia, partly 
in the context of a case-control study exploring immunogenetic determinants of 
susceptibility to tuberculosis (29). Most of the bioanalysis was conducted in 
Indonesia.  
This thesis consists of three parts; the first part deals with the development and 
application of spoligotyping for the molecular epidemiology of M. tuberculosis in 
Indonesia (chapters 2 - 4). The second part focusses on the clinical phenotype of 
the Beijing genotype (chapters 5 and 6), and the third on possible explanations for 
its success (chapters 7 and 8). 
In chapter 2 I examined the reproducibility of spoligotyping, implementing this as 
the first molecular technique in a clinical laboratory in Bandung, Indonesia. We 
encountered problems of reproducibility and examined how spoligotyping can be 
optimized for different purposes.  
In chapter 3 I examined the population structure of M. tuberculosis in patient 
cohorts on two different Indonesian islands, to answer the question what 
proportion of patients was infected with Beijing genotype strains.  
Drug resistance possibly contributes to the emergence of Beijing strains in 
different areas around the world. In Chapter 4 I examined if Beijing strains display 
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more- or another distribution of  mutations in drug resistance genes which 
account for resistance to three different tuberculosis drugs.  
Chapter 5 and 6 describe the clinical phenotype of patients infected with M. 
tuberculosis Beijing genotype strains. In chapter 5 I examined if Beijing strains are 
associated with  TB treatment failure.  
In chapter 6 I examined the long term effects of pulmonary TB by comparing ex-
TB patients with matched controls. Specifically, the question was addressed 
whether patients previously infected with Beijing genotype strains experience 
more recurrent TB or more lung damage than those previously infected with 
other genotype strains.  
Chapter 7 focusses on a possible role of host immune genetics. Through co-
evolution, M. tuberculosis may have adapted to the immune system of particular 
human populations. I examined if specific gene polymorphisms of one host 
immune gene, SLC11A1 (formerly called NRAMP1), which has been linked with TB 
in many different settings, were more common in patients infected with Beijing 
genotype strains.  
Finally, in chapter 8 I performed a literature review on all possible factors that 
may contribute to the global spread of M. tuberculosis Beijing strains.  
Chapter 9 contains the summary and general discussion of the main findings of 
this thesis. An effort is made to look comprehensively at the mechanism 
underlying the global emergence of M. tuberculosis Beijing genotype strains. 
Hopefully, this will help TB control in Indonesia and elsewhere. 
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In a recent issue we read with interest the contribution of Zink et al. (1) on the 
characterization of Mycobacterium tuberculosis complex DNA in Egyptian 
mummies by spoligotyping (spacer-oligo-typing).  
Compared with other PCR-based methods that combine detection and typing of 
such DNA, spoligotyping is more sensitive, because it targets the direct repeats 
(DRs) present in multiple (sometimes up to 60) copies in the genomic DR locus of 
M. tuberculosis complex bacteria. The well-conserved 36-bp DRs are interspersed 
with nonrepetitive spacer sequences of 34 to 41 bp in length (2-4). The variation 
in the presence of these spacer sequences among strains of the M. tuberculosis 
complex allows for the genotyping of mycobacterial DNA directly isolated from 
clinical samples without the need to culture these bacteria. 
Kamerbeek et al. described spoligotyping for use with purified DNA from cultured 
strains  (2). However, when this method was used to target extracted DNA from 
M. tuberculosis complex bacteria in clinical samples, some of the spacers showed 
weak hybridization signals. We detected no hybridization signals with a few 
clinical samples. This is proven by the comparison of the spoligotyping patterns 
produced from bacteria on a Ziehl-Neelsen (ZN) slide (in dilution of 1:2, 1:4, and 
1:8) with those seen with the method described by van der Zanden et al (3). (see 
Fig. 1). Therefore, we optimized our PCR mixture for direct spoligotyping of M. 
tuberculosis complex DNA in clinical samples by using a concentration of 3.0 mM 
instead of 7.0 mM MgCl2, 15 mM instead of 5 mM Tris-HCl (pH 9.0), and 20 to 50 
pmol of primer in PCR. The use of this adjusted protocol yielded a complete 
spoligotyping pattern for bacteria in clinical samples as compared to that seen 
with cultured bacteria (3). 
We also successfully used the optimized spoligotyping on bacteria from paraffin 
wax-embedded tissues (4-6) and from the mummified remains of humans found 
in an 18th century Hungarian crypt (7). To our surprise, in the current study of Zink 
et al. (1) the nonoptimized protocol of Kamerbeek et al. (2) was applied to study 
samples from Egyptian mummies without any modification of the PCR reagents. 
Hence, in the spoligotyping patterns no hybridization with spacers 2, 14, and 39 
was found. We therefore again wish to emphasize that for a reliable and 
reproducible application of spoligotyping to M. tuberculosis complex bacteria in 
clinical samples, the optimized protocol (3, 7) should be used. 
 
 
Chapter 2 
13 
 
 
 
 
 
Figure 1.  Comparison of spoligotyping patterns after the application of spoligotyping 
directly to ZN-stained slides by using the protocols of Kamerbeek et al. (2) 
and van der Zanden et al. (3). The extracted DNA of the ZN slides was used 
in the dilutions 1:2, 1:4, and 1:8 in the spoligotyping. 
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Abstract 
Comparison of Mycobacterium tuberculosis genotype distribution in different 
areas might help to find determinants of the emergence of certain genotypes, like 
the Beijing family. In this study, M. tuberculosis isolates originating from patients 
from two Indonesian islands were genotyped, and possible associations with 
patients’ characteristics and drug resistance were explored.  
A high degree of genetic diversity was observed among the M. tuberculosis strains 
and a significant difference was found in the geographical distribution of genotype 
families. The predominant Beijing genotype family was isolated from 268 of 813 
patients from West-Java (33.0%) versus 12 of 84 patients from Timor (14.3%, 
p=0.002). Family F (EAI, 33.3%) and Family D (LAM, 20.0%) were more prevalent in 
Timor. No significant associations were found between genotype families and age, 
BCG vaccination, previous treatment, disease localization or drug resistance. 
Possible explanations for the differences in the geographical distribution of the M. 
tuberculosis genotypes are discussed.  
 
 
Introduction 
The introduction of DNA fingerprint methods in the early 1990s has greatly 
improved the possibilities to examine transmission of tuberculosis (TB) and the 
phylogeny of M. tuberculosis (1). The available genetic fingerprinting methods 
have different characteristics and applicability. Especially analysis of large 
chromosomal deletions (2), and single nucleotide polymorphisms can facilitate 
meaningful exploration of the population structure of the M. tuberculosis 
complex. However, these methods imply sophisticated and costly techniques. 
More widespread is the use of spoligotyping to examine the strain diversity of M. 
tuberculosis in given areas (1,3). With this method the presence of 43 spacers in 
the direct repeat (DR) region of M. tuberculosis complex can be detected. The loss 
of spacers in the DR region seems to be in line with the evolutionary development 
of the M. tuberculosis complex lineages and therefore, this currently appears to 
be the simplest approach to study the population structure of M. tuberculosis 
complex strains (4). Because a high number of spoligotype patterns have been 
added to a central database, many M. tuberculosis genotype families could be 
identified in the last 15 years, including the Beijing, the East African-Indian (EAI), 
the Haarlem (H), the Latin American and Mediterranean (LAM), and the Central 
Asian (CAS) genotype families (3).  
One of the best studied and most widespread evolutionary lineages of M. 
tuberculosis is the Beijing genotype family which was first found in China and has 
been reported worldwide (5,6). The emergence of Beijing genotype strains 
suggests that they may have a selective advantage over other M. tuberculosis 
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strains. Indeed, studies in animal models have shown enhanced virulence and 
distinctive histo-pathology following infection with M. tuberculosis Beijing 
genotype strains (7,8). Extrapolating from this, emergence of Beijing and other 
genotype families may be the consequence of the application of two major 
measures against tuberculosis in last century; BCG vaccination and anti-
tuberculosis treatment (1). Possibly, BCG-vaccination is less protective against 
(more virulent) Beijing genotype strains but so far, this has not been proven (9). 
Similarly, anti-TB treatment might be less effective in eradicating Beijing strains. 
Indeed, in one study failure of TB-treatment and subsequent relapse were more 
common in patients infected with Beijing strains (10). Studies examining a 
relationship between the Beijing genotype and drug-resistance have met with 
major differences in wide spread geographic areas, as systematically reviewed (5). 
After India and China, Indonesia has the third highest TB case load in the world, 
with an estimated 525,000 new cases and an estimated 90,000 deaths per year 
(11). So far, only one molecular epidemiological study on tuberculosis was 
performed in Indonesia, in 1998 (12). Among 94 tuberculosis patients, all from the 
capital city Jakarta, 32,4% were infected with Beijing genotype strains. The 
Indonesian archipelago consists of 17,504 islands, inhabited by many different 
ethnic groups. Comparison of the distribution of M. tuberculosis genotypes in 
different areas or different human populations and study of the patients’ 
characteristics might help to find determinants of the emergence of particular 
genotype families. Therefore, we have spoligotyped M. tuberculosis isolates from 
a large cohort of patients from two Indonesian islands; West Java and Timor. 
Furthermore, we have explored the distribution of M. tuberculosis genotype 
families and analyzed the possible association of these genotypes with age, sex, 
BCG-vaccination status, previous TB treatment, disease localization and drug-
resistance.  
 
 
Material and Methods 
Study population 
In Indonesia, M. tuberculosis culture is not routinely performed, and there is no 
national archiving of isolates. Therefore, we prospectively collected isolates from 
well-characterized patients in two different clinical studies. In West Java, from 
January 2001 through December 2006, consecutive patients over 16 years of age 
with microscopically proven pulmonary tuberculosis were included in two out-
patient clinics and two hospitals in Jakarta and Bandung (West Java), as part of a 
large case-control study examining host susceptibility to tuberculosis (13). The 
diagnosis of tuberculosis was based on clinical presentation, chest X-ray 
examination, microscopic detection of acid-fast bacilli by Ziehl-Neelsen stained 
sputum smear, and culture of M. tuberculosis on 3% Ogawa medium. As part of 
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the same study, a smaller cohort of microbiologically proven extra-pulmonary 
tuberculosis cases was included. All cultured M. tuberculosis isolates from 
patients with pulmonary (PTB; n=740) and extra-pulmonary (EPTB; n=73) disease 
were used for the current study. In addition, in West Timor, as part of a study on 
micronutrient supplementation in TB, 84 cultured isolates of pulmonary 
tuberculosis patients were included (Pakasi et al., in preparation). Of note; these 
were the first isolates ever cultured in this less-developed part of Indonesia. From 
all patients, age, history of previous TB treatment, the presence of a BCG-scar on 
the left deltoid muscle (as an approximation of BCG-vaccination status) and 
disease localization were recorded.  
 
Spoligotyping 
DNA was extracted by bringing two loops of bacterial mass from a M. tuberculosis 
culture in saline and subsequent heating at 95oC for 5 min. Spoligotyping was 
performed using a commercial kit (Isogen Bioscience BV, Maarssen, The 
Netherlands). The presence or absence of 43 spacers in the DR region of isolates 
of M. tuberculosis was detected as follows: the DR region was amplified by 
primers, one of which was biotinylated; the amplified products were 
reversehybridized to spacer sequence oligonucleotide probes immobilized on a 
Biodyne C membrane; and detection of spacer sequences was achieved with 
peroxidase-labeled streptavidin and enhanced chemiluminescence (14,15). 
Spoligotyping was done at the Hasan Sadikin Hospital, Bandung, Indonesia. For 
quality control, spoligotyping of 10% of the isolates, and all isolates lacking 
hybridization, was repeated at Gelre Hospital, Apeldoorn, the Netherlands.  
 
Phylogenetic reconstruction 
The spoligotyping results were recorded in octal and binary formats in an Excel 
spreadsheet and compared to the international SpolDB4.0 database (3). The 
phylogenetic analysis was done using the Bionumerics software (Applied Maths, 
Sint-Maartens-Latem, Belgium). Spoligotype patterns were imported into 
Bionumerics as a character type, similarities between the patterns were 
calculated by using the categorical coefficient and dendrograms were prepared by 
using UPGMA. 
 
Drug susceptibility testing 
Drug susceptibility testing (DST) was performed on cultured isolates using an 
absolute concentration method on 7H10 Middlebrook agar in 25-well plates with 
supranational control by the National Mycobacteria Reference Laboratory at the 
RIVM in Bilthoven, The Netherlands. In the Netherlands, this method has shown 
accuracy between 96 and 100% in 10 rounds of WHO/IUATLD proficiency testing 
(16). Approximately 10% of isolates from the current study were retested at the 
supranational reference laboratory in The Netherlands. 
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Data-analysis and statistics 
Spoligotype patterns were correlated with patient’s age, sex and BCG vaccination 
status (presence or absence of BCG scar), previous treatment, resistance to INH, 
rifampicine and both drugs (multidrug resistant TB). Differences between groups 
were statistically examined using non-parametric tests for continuous variables 
and Fisher’s χ2 test. To avoid possible confounding by geographical area, the 
above associations were examined separately for Java and Timor.  
 
 
Results 
Distribution of M. tuberculosis genotype families  
Eighty-four M. tuberculosis isolates from Timor and 813 isolates from West Java 
were collected. Among the isolates from West Java, 740 were isolated from 
pulmonary TB patients and 73 from patients with extrapulmonary TB. The latter 
category consisted of meningitis (n=42), lymphadenitis (n=9), pleuritis (n=13), and 
other (n=9).  
 A high degree of genetic diversity among the M. tuberculosis isolates was 
observed (Table 1). On the basis of the similarity of their spoligotype patterns, 
739 of the 897 isolates were grouped into nine major spoligotype groups of more 
than 20 isolates. These nine major spoligotype groups were designated family A to 
family I. Spoligotype patterns outside of those nine major groups were designated 
‘other’. The largest spoligotype group comprised the Beijing genotype (family I) 
and contained 280 strains (31.2%). The second largest group was family B (T1), 
which consisted of 100 isolates (11.1%). Families E and A, both representing the 
Haarlem genotype, contained 82 (9.1%) isolates. In this study 198 patterns were 
designated ‘orphan’ patterns, because they had no shared-type pattern in the 
international spoligo database SpolDB4 (Figure 1). No unique Indonesian strains 
were identified.  
The distribution of genotypes showed little variation over time. From 2000 to 
2006, between 28.9% and 32.7% of the strains belonged to the Beijing genotype 
family, with no obvious trend in the number of cases in time. As the distribution 
of genotypes in outpatient clinics and hospitals in Jakarta and Bandung was highly 
similar, those data were combined (‘West Java’). When the spoligotype patterns 
originating from West Java were compared to those from Timor, there appeared 
to be a significant difference in the distribution of genotype families. In West Java 
M. tuberculosis  Beijing genotype strains were the most predominant (33.0%, 95% 
CI 29.7-36.2%), but in Timor, Beijing strains were much less common (14.3%, 95% 
CI 6.8-21.8%; p=0.002). On the other hand, Family F (EAI) and Family D (LAM) 
were highly prevalent in Timor (33.3% respectively 20.0%) but uncommon in West 
Java (6.2% respectively 8.7%) (Figure 2). All these differences were statistically 
significant.  
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Association of genotype families with patient characteristics  
We compared the patient characteristic’s of different M. tuberculosis genotype 
families, including sex, age, BCG vaccination, previous treatment, and disease 
localization (PTB vs EPTB). Because of the strong geographic differences in the 
distribution of genotypes, data from West Java and Timor were analyzed 
separately. For the 813 patients included in West Java, the results are depicted in 
Table 2. The various genotype families were associated with slight differences in 
patient characteristics, none of which were statistically significant. BCG scar as an 
approximation of BCG vaccination was only found in 28.7% of patients. The 
smallest percentage of those who had BCG scar was found in patients infected 
with strains from family C (T) (16.3%) and the highest was found in patients 
infected with strains from family A (H) (46.3%), but these differences did not 
reach statistical significance. Similarly, different genotype families showed slightly 
different age distribution, percentage of extra-pulmonary localization and 
previous treatment, but none of these were statistically significant (Table 2). 
To relate the M. tuberculosis genotype and patients characteristics in Timor (not 
included in Table 2) we compared the two largest families there; family F (EAI) 
(33.3%) and family D (LAM) (22.0%), with the remaining group including all strains 
of other genotypes (46.7%). The median age of patients infected in the second 
largest genotype family (Family D/LAM), was significantly different than the 
median age of the other families (23 years vs. 29 and 32, p=0.010). No significant 
differences between genotype families were found among other patient 
characteristics. When the twelve (14.3%) patients infected with a Beijing genotype 
were analyzed separately, they appeared to be older than the patients infected 
with other strains (median 46 years, IQR: 24.3-57.5), but this was not statistically 
significant.  
 
Association of genotype families with drug resistance 
Drug resistance patterns were available for 694 isolates, 620 from West Java, and 
74 from Timor. Among the isolates of previously treated patients (n=77), 25.4% 
were INH resistant, 31.2% were rifampicin resistant, and 17.9% were MDR. 
Among newly treated patients (n=617) these rates were 7.5%, 6% and 2.6%, 
respectively. The various genotype families showed slightly different rates of drug 
resistance. Resistance to INH ranged from 2.7% to 10%, and resistance to 
rifampicin ranged from 2.7% to 11.2%. Because the number of drug resistant 
isolates per genotype family was too small no meaningful statistical analysis could 
be done on those differences between the nine genotype families. 
Several previous studies have reported an association between the Beijing 
genotype and drug-resistance, drug resistance patterns of 209 Beijing isolates 
(30.1%) and 485 non-Beijing isolates (69.9%) were not significantly different (table 
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2). Also when strains isolated from Java were analyzed separately, no association 
was found between the Beijing genotype and drug-resistance. 
 
 Table 1.  Spoligotype diversity and spoligotype family designation of 897 M. 
tuberculosis isolates from West Java and Timor. 
Spoligo family (SpolDB4) Spoligo family designation this study   
A B C D E F G H I Other Isolates Patterns 
BEIJING         275  275 6 
BEIJING-LIKE         5  5 2 
CAS          2 2 1 
CAS1_DELHI          3 3 1 
EAI2_MANILLA      13     13 3 
EAI2_NTB          7 7 1 
EAI3_IND      3     3 1 
EAI5      16     16 8 
EAI6_BGD1      1     1 1 
EAI1_SOM      16     16 4 
H1     20      20 6 
H3 40    9     1 50 9 
H3-T3  2         2 1 
LAM1    8      1 9 2 
LAM3    1       1 1 
LAM3 and S/convergent          2 2 1 
LAM6    3       3 2 
LAM8    28       28 1 
LAM9    15  1     16 5 
MANU2          3 3 1 
Orphan 1 17 15 33 8 24 7   108 213 198 
S  7        1 8 3 
T1  55 4 2 3     10 74 20 
T1(T4-CE1?)  1         1 1 
T2  9        1 10 4 
T2-T3  4         4 1 
T3  3 24        27 2 
T5_RUS1          1 1 1 
U  1   1  7 3  15 27 14 
U (LIKELYH3)       27    27 2 
U (likelyS)        26   26 1 
X1   1               3 4 3 
Total 41 100 43 90 41 74 41 29 280 158 897 307 
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Table 2.  M. tuberculosis genotype families and associated patient characteristics in 
West Java 
Spoligotype family A B C D E F G H I Other Total 
Spoligotype family 
SpolDB 4 
(H) (T) (T) (LAM) (H) (EAI) 
(U likely 
H3) 
(U likely 
S) 
(Beijing)   
 
41 
(5%) 
98 
(12.1%) 
43 
(5.3%) 
71 
(8.7%) 
40 
(4.9%) 
50 
(6.2%) 
37 
(4.6%) 
27 
(3.3%) 
268 
(33.0%) 
138 
(17.0%) 
813 
(100%) 
Age (yrs)            
Median 26.0 28.5 30.0 28.0 27.0 34.5 27.0 27.0 30.0 35.0 30 
IQR 
20.5-
36.0 
23.0-
42.0 
24.0-
46.0 
23.0-
39.0 
21.3-
41.8 
24.0-
46.3 
22.5-40.0
20.0-
41.0 
23.0-41.0 25.0-47.0 
23.0-
43.0 
Sex (male,  %) 43.9 58.2 48.8 56.3 52.5 52.0 54.1 48.1 49.3 50.7 51.4 
BCG-scar (%)* 46.3 24.5 16.3 29.6 30.0 22.0 24.3 22.2 28.0 35.5 28.7 
Previous TB-
treatment (%) 
12.2 16.3 4.7 8.5 10.0 20.0 10.8 18.5 9.7 12.3 11.7 
Disease localization            
extrapulmonary (%) 2.4 9.2 7.0 7.0 0.0 4.0 2.7 25.9 11.2 10.9 9.0 
pulmonary (%) 97.6 90.8 93.0 93.0 100.0 96.0 97.3 74.1 88.8 89.1 91.0 
Drug resistance 
(%)** 
           
Isoniazide (R+I) 17.1 14.3 11.6 7.0 17.5 14.0 10.8 11.1 13.1 9.4 12.3 
Isoniazide (Only R) 9.8 7.1 7.0 4.2 7.5 10.0 2.7 3.7 8.2 5.1 6.9 
rifampicin 7.3 11.2 4.7 5.6 10.0 8.0 2.7 7.4 5.6 7.2 6.9 
MDR 7.3 4.1 2.3 2.8 5.0 6.0 0.0 3.7 3.7 4.3 3.9 
* BCG-scar was evaluated in 565 patients; ** DST was successful in 694 isolates 
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Figure 1  Dendrogram (left) showing the similarity among the 198 orphan spoligotype 
patterns (middle) found in this study. On the right the number of isolates of 
a particular spoligotype is indicated. 
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Figure 2.  Distribution of M. tuberculosis genotype families in West Java and Timor.  
* p < 0.05. 
 
 
Discussion 
This is the second study on the molecular epidemiology of tuberculosis in 
Indonesia, involving the two most densely populated cities in West Java and a 
more rural area on Timor at the eastern end of the archipelago. Consecutive 
microscopically proven tuberculosis patients from a large cohort study in various 
clinics in 2001-2006 were included, and patients were carefully characterized and 
followed prospectively. Because the isolates only came from three areas, the 
study is not representative for Indonesia as a whole. However, the four clinics in 
West Java showed a very similar M. tuberculosis genotype family distribution, 
suggesting that these data are indeed representative for this area. 
A high genetic diversity among M. tuberculosis isolates was found in Indonesia: 
nine major M. tuberculosis genotypes were identified. This high genetic M. 
tuberculosis strain diversity is in contrast with studies from other higher 
prevalence areas, including e.g. Vietnam, where only two major genotype families 
were found: Beijing and EAI (10). The M. tuberculosis Beijing genotype family was 
the most prevalent genotype family in Indonesia (31.2%), and the proportion of 
Beijing strains was stable during the study period and similar to the prevalence 
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recorded in a previous, smaller study (32.4%) (12). In contrast to what has been 
reported in others studies (9,10,17), no association was found between the 
Beijing genotype and age, previous treatment and BCG vaccination. As 
demonstrated previously in other studies from Asia, no clear association was 
found between drug resistance and Beijing strains as reported in e.g. the Former 
USSR republics, Cuba, South Africa and Vietnam (6). 
Interestingly, a strong difference was found in the population structure of M. 
tuberculosis in West Java and Timor. The Beijing genotype family was found in 
33.0% of patients in Java, versus 14.3% of patients in Timor. This is in line with a 
recent observation in Vietnam, where in Ho Chi Minh City a density of 50% was 
notified for Beijing genotype strains, but in the Mekong Delta only 30% 
(unpublished observation). This suggests that transmission of Beijing genotype 
strains may benefit from highly dense populations. Inversely, in Timor, the EAI and 
LAM genotype families were predominant, while these genotypes were 
uncommon in Java. One can only hypothesize about the explanation for this 
difference. First, this difference may be due to a “founder effect”, with a higher 
chance of finding a particular genotype family closer to where it originated. 
Secondly, it may also indicate that particular mycobacterial lineages have adapted 
to particular human populations. This concept of genetic host-pathogen 
compatibility is supported by data showing preferential spread of particular 
lineages in patient populations from the same area, rather than from other areas 
(18,19). So far, no studies have been reported making direct associations between 
genetic characteristics of tuberculosis patients and their (own) mycobacterial 
isolate.   
Finally, the predominance of certain genotype families, particularly the Beijing 
genotype family, might also be explained by other mechanisms, such as higher 
transmission rate or ‘escape’ from BCG-vaccination. Our results do not support 
these hypotheses, as no significant associations were found between particular 
genotype families and patient characteristics, especially age and BCG-vaccination 
status. However, the coverage of BCG vaccination is very high in Indonesia. Hence, 
transmission from vaccinated to none-vaccinated subjects is so frequent, that 
differences in the population of strains in both groups will be diluted easily. 
Several studies, like one in Vietnam have reported a lower age of patients infected 
with Beijing strains (9), suggesting more recent transmission of Beijing strains. A 
second study from a different area in Vietnam has found a similar relationship 
between age and genotype (Buu, submitted), but, like others (17,20) we did not 
find this association. In fact, among patients from Timor, those infected with a 
Beijing strain were older, although the number was small. We also did not find an 
association with BCG-vaccination, like one study in Vietnam (9). The difference 
between Indonesia and Vietnam may be explained by the existence of different 
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evolutionary lineages of the Beijing genotype family, circulating in different 
geographic areas as has been demonstrated previously (21).  
In Indonesia, drug susceptibility testing of M. tuberculosis is a matter of concern. 
Indonesia is not included in international surveillance of drug resistance (22) and 
there is no national surveillance, or quality control system. We have previously 
compared the quality of conventional (proportional) DST, and the 25-well DST 
method (16) in Indonesia, and it was shown that the 25-well DST method used in 
this study showed a better performance on WHO reference strains (Alisjahbana et 
al., submitted for publication). However, the high rates of drug resistance which 
were found in this study are in contrast with the only recent peer-reviewed data 
on drug resistance in Indonesia, and rates in neighboring countries (23). Because 
most of the isolates in this study came from clinics, care should be taken with the 
interpretation of the high drug resistance rate observed. Drug resistance rates in a 
more nationally representative DST-survey may not be as high. It is clear that 
there is an urgent need for widespread implementation of quality-assured drug 
susceptibility testing in Indonesia. Because of the limited number of strains 
belonging to certain genotype families, a possible relationship between particular 
genotypes and drug resistance cannot be excluded.  
In conclusion, this molecular epidemiological study in Indonesia shows a 
considerable degree of heterogeneity among M. tuberculosis isolates, and a 
significant difference in population structure at the different geographical study 
sites. A nationwide survey can provide more detail on the distribution of different 
genotype families in Indonesia, and association of host and mycobacterial 
genetics may help to establish if differences in population structure of M. 
tuberculosis are caused by evolutionary adaptation of particular mycobacterial 
lineages to certain human populations.  
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Abstract 
Mycobacterium tuberculosis Beijing genotype strains are highly predominant in 
most parts of Asia suggesting they have a selective advantage such as drug 
resistance. We examined the possible association between the Beijing genotype 
and drug resistance gene mutations among isolates from Indonesian patients.  
We performed spoligotyping, sequencing of the rpoB-hotspot region and PCR for 
mutations in katG codon 315 and embB codon 306 on phenotypically drug-
resistant and –sensitive patient isolates.  
Among 108 Beijing and 203 non-Beijing M. tuberculosis isolates, rpoB-mutations 
were found in 33.3% respectively 18.7% (p = 0.004), the katG315 mutation in 
18.5% vs. 12.8% (p = 0.177), and the embB306 mutation in 16.5% vs. 6.1% (p = 
0.006). Among newly treated patients, rpoB-mutations were found in 19.7% of 
Beijing vs. 6.7% of non-Beijing strains (p = 0.005).  
The higher rate of mutations in rpoB, katG315 and embB306 among M. 
tuberculosis Beijing strains provides further evidence that drug resistance may 
contribute to the global predominance of Beijing strains. The strong association of 
Beijing and rpoB-mutations among new cases of TB reflects considerable 
transmission of resistant Beijing strains in Indonesia.                                           
 
 
Introduction 
Epidemiological genotyping studies of M. tuberculosis isolates from clinical 
patients have shown a predominance of particular genotypic families, like Beijing, 
CAS, EAI, Haarlem and LAM (1). The Beijing genotype is especially predominant in 
Asia, with prevalence ranging from 30% to more than 80% in different areas (2). 
Its wide distribution suggests the Beijing genotype family may have a selective 
advantage. First, Beijing genotype strains might be more easily transmitted. 
Alternatively, they might be more virulent, causing a higher proportion of infected 
individuals to develop active tuberculosis, or a lower proportion to be protected 
by BCG-vaccination. Studies exploring these hypotheses have shown conflicting 
results. Animal studies indeed suggest that Beijing strains are more virulent (3), 
but epidemiological studies examining associations between genotype and BCG-
vaccination (4-6) disease severity (6, 7) or radiological appearance (6-8) have 
shown contrasting results. Finally, Beijing genotype strains might more readily 
become or remain drug-resistant, thereby hampering their eradication. A 
systematic review (including studies using phenotypic drug susceptibility testing) 
found no clear association between the Beijing genotype and drug resistance (2). 
On the other hand, genotypic studies have reported a higher frequency of katG 
codon 315 mutations (responsible for 65 to 100% of resistance to isoniazid) 
among Beijing genotype strains (9-11). As a possible explanation for this 
Chapter 4 
33 
 
phenomenon, Beijing strains were found to have more mutations in DNA-repair 
genes, suggesting they may more easily develop mutations which lead to drug 
resistance (12), although this not been found in vitro (13).   
So far, it is uncertain if the Beijing genotype is associated with other drug 
resistance mutations besides katG315. We have addressed this question in 
Indonesia, which has the third highest tuberculosis case-load worldwide (14). We 
characterized a collection of M. tuberculosis  patient isolates to see if the Beijing 
genotype, found in 33% of Indonesian tuberculosis patients, (15) had a higher rate 
of mutations in katG315, the rpoB-hotspot region, which is responsible for >90% 
of resistance to rifampicin (10, 11, 16), and embB306, which accounts for 
resistance to ethambutol, and which may predispose M. tuberculosis to develop 
resistance to other antibiotics (17-20). 
 
Methods 
Mycobacterium tuberculosisisolates  
Genotyping and drug resistance testing (DST) of M. tuberculosis is not routinely 
performed in Indonesia, and there is no national or supranational quality control 
system. We collected patient isolates from four laboratories in Jakarta and 
Bandung that do perform DST for INH and rifampicin. Primary culture in these 
laboratories is done using solid medium (Ogawa 3%), and DST is done using a 
proportional method, and more recently in two laboratories using an absolute 
concentration method on 7H10 Middlebrook agar in 25-well plates (21).  
 
Spoligotyping  
Spoligotyping was performed on a total of 812 Mycobacterium isolates from 
West-Java (15). DNA was extracted from isolates by bringing two loops of 
bacterial mass in saline and subsequent heating at 95oC for 5 min. Spoligotyping 
was performed using a commercial kit (Isogen Bioscience BV, Maarssen, The 
Netherlands). The presence or absence of 43 spacers in the direct repeat (DR) 
region of isolates of M. tuberculosis was detected as follows: the DR region was 
amplified by primers, one of which was biotinylated; the amplified products were 
reverse-hybridized to spacer sequence oligonucleotide probes immobilized on a 
Biodyne C membrane. Detection of spacer sequences was achieved with 
peroxidase-labeled streptavidin and enhanced chemiluminescence. Spoligotyping 
was done at Hasan Sadikin Hospital, Bandung, Indonesia. For quality control, 
spoligotyping was repeated in the Netherlands for 10% of isolates, and for all 
isolates lacking hybridization.  
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Sequencing of rpoB-hotspot region  
Three hundred and twenty five spoligotyped isolates were rpoB sequenced, 116 
phenotypically rifampicin resistant strains, 178 random rifampicin sensitive 
isolates, and 31 strains for which sensitivity testing was unsuccessful. Sequencing 
of rpoB was done using 3100-Avant sequencer (Applied Biosystems). Amplification 
of a 437 bp fragment containing the rpoB hotspot region was carried out in PTC 
200 thermocycler (Biozym) by rpoB-F1 forward and rpoB-R1 reverse primer (22). 
The Sequencing results were compared to rpoB-hotspot wildtype using 
Bionumerics software (Applied Maths, St-Martin-Latern, Belgium). Sequence 
analysis (16S rDNA) blasting against the Genebank database showed that 14 
isolates (4.3%), 13 of whom were phenotypically rifampicin resistant, were non-
tuberculous mycobacteria, including Mycobacterium massiliense (n=4), M. 
fortuitum (2), M. abcessus (2), M. asiaticum (1), M. mageritense (1), M. 
perigrinum (2), M. chelonei (1) and undetermined mycobacterial species (1) . 
Spoligotyping of primary cultures from the same patients showed M. tuberculosis 
patterns, so it was concluded that these 14 isolates were most likely culture 
contaminants. These isolates were excluded for further analysis, leaving a total 
number of 311 isolates.  
 
Mutation analysis of katG315 and embB306  
DNA amplification/detection for katG315 was performed either on a ABI Prism® 
7000 Sequence Detection System (Applied Biosystems, Foster City, CA) or on a 
LightCycler480 (Roche Diagnostics, Indianapolis). For the ABI Prism® 7000, we 
amplified katG315 using a set of primers; forward primer (5’GGG CTT GGG CTG 
GAA GAG3’) and reverse primer (5’ACA ACA GTT TCC TGC AGA TCC TGT3’). 
Detection of katG315 wildtype was done by FAM-TAMRA labeled probe 
(5’CGCGATCACCAGCGGCATCG3’) and detection of katG315 mutation was done by 
VIC-TAMRA labeled probe (5’CGC GAT CAC CAC CGG CAT CG 3’). DNA 
amplification/detection was performed in 30μl reaction volume : template DNA, 
400nM of each primer and 200nM of each probe. The PCR-program consisted of 2 
min at 500C, 10 min at 950C, 45 cycles of 15 seconds at 950C, 1 min at 600C. For the 
LightCycler480 we amplified katG315 using the same primers and the same 
probes except with other labels namely : the wildtype probe was labeled with 
FAM-BBQ and the mutant probe with Cyano500-BBQ. DNA amplification / 
detection was performed in 30μl reaction volume : 20μl Taqman Universal PCR 
Master Mix (Applied Biosystems) and 10μl template DNA, 400nM of each primer 
and 200nM of each probe. The PCR program consisted of 2 min at 500C, 10 min at 
950C, 50 cycles of 15 seconds at 950C, 1 min at 600C.  
The detection of the embB306 mutation was performed on the ABI Prism® 7000. 
The primers used for amplification were forward primer embB1 (5’-
CGGCTTCCCCGACCCCAACCTG-3’) and reverse primer embB2 (5’-
GCTGTACCGCATGGACCGCTC-3’). Detection of embB306 was done by a FAM-
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TAMRA labelled LNA probe (5’FAM-CATGGCCCGAGTCGCC-TAMRA3’)and a control 
VIC-TAMRA labelled probe (5’VIC-GGCATGTCATCGGCGCGAAT-TAMRA3’). Instead 
of using a mutant probe a control probe was used. The wildtype (LNA) probe 
hybridizes if codon 306 contains no mutations. The control probe hybridizes to a 
specific piece of DNA without known mutations. The wildtype probe gives a signal 
when the strain contains no mutation on codon 306 and the control probe gives a 
signal if an amplification product with a mutation in codon 306 is present.  
  
Data analysis and statistics  
The frequency of gene mutations of M. tuberculosis Beijing and non-Beijing 
genotype isolates was compared using Pearson’s Chi-square. We considered P-
values < 0.05 as significant. Odds ratios (OR) and 95% confidence intervals (CI) for 
associations between genotype and particular drug resistance gene mutations 
were calculated. Using regression analysis, corrections were made for possible 
confounding by previous treatment. Data were analyzed using the Statistical 
Package for Social Sciences (SPSS Inc, Chicago, IL version 12.01).  
 
Results 
Mutations in rpoB 
Sequencing of rpoB showed mutations in 74 M. tuberculosis patient isolates. 
Mutations were mostly found in rpoB codon 531 (52.7%), codon 526 (31.1%), and 
codon 516 (8.1%), either as single or double mutations. The distribution of rpoB-
mutations is shown in Table 1. Among 48 patients with a history of previous 
tuberculosis treatment, 19 (39.6%) were infected with rpoB-mutant strains, 
compared to 23 of 205 (11.2%) of newly treated patients (OR 5.18; 95% CI 2.52 - 
10.68). From 103 phenotypically rifampicin-resistant strains M. tuberculosis, 42 
(40.8%) showed no rpoB-mutation while from 177 phenotypically rifampicin-
sensitive M. tuberculosis, 13 (7.3%) had a mutation in the rpoB gene. In line with 
the discrepancy between phenotypic and genotypic results, proficiency testing in 
2004/2005 in the participating laboratories using 30 WHO strains yielded a 
sensitivity and specificity of 89.2% and 85.1% for INH, and 89.5% respectively 
75.2% for rifampicin (B. Alisjahbana, personal communication). 
 
Mutations in katG315 and embB306 
Analysis of katG codon 315 showed mutations in 46 isolates (14.8%). Mutations 
were found in 2 of 175 INH-sensitive isolates (1.1%) and 41 of 105 INH-resistant 
isolates (39.0%). Mutations in katG315 were associated with previous treatment 
(OR 2.02; 95% CI 0.86 – 4.75), and also with mutations in rpoB (OR 7.41; 95% CI 
3.78 – 14.50). Among 262 isolates, a total of 26 (8.4%) showed a mutation in 
embB codon 306. Mutations in embB306 were more common among previously 
treated patients (OR 2.85; 95% CI 0.76 – 10.60), and strongly associated with 
Chapter 4 
36 
 
mutations in rpoB (OR 33.46; 95%CI 9.61 – 115.41), and katG315 (OR 5.45; 95% CI 
2.28 – 13.03). 
 
Associations between genotypic drug resistance and spoligotype 
The genotype distribution in this study was in line with spoligotyping of 812 
mycobacterial isolates from West-Java (15), showing a high genetic diversity, with 
nine different genotype families, and a prevalence of 34.7% of Beijing genotype 
strains. For all three genes examined, mutations were more common among M. 
tuberculosis Beijing genotype strains than among other genotype strains (Table 2). 
Mutations in rpoB were found in 33.3% of M. tuberculosis Beijing strains, 
compared with 18.7% of other genotype strains (OR 2.17; 95% CI 1.27 - 3.70; p = 
0.004). There was a difference in the distributions of specific rpoB-mutations 
between Beijing and non-Beijing strains (Table 1). The prevalence of mutations in 
rpoB codon 531 was lower in Beijing genotype than non-Beijing genotype strains 
(41.7% vs 63.2%), while the opposite was true for mutations in rpoB codon 526 
(36.1% vs. 26.3%), although these differences were not statistically significant. The 
association between Beijing genotype and rpoB-mutations was not due to 
confounding by previous treatment. Among 205 newly treated patients (new 
cases), rpoB-mutations were found in 19.7% of patients infected with Beijing 
strains, versus 6.7% of patients infected with other genotype strains (OR 3.41; 
95% CI 1.40 – 8.34; p = 0.005).  
Mutations in katG315 were more common among Beijing strains (Table 2), also 
when only new strains were examined (13.4% vs 8.7%), but neither of these 
associations was statistically significant. Mutations in embB306 were more 
common among Beijing genotype strains, and this was strongly significant (OR 
3.06; 95% CI 1.33-7.05; p=0.006) (Table 2).  
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Table 1.  Drug resistance gene mutations in M. tuberculosis Beijing and other 
genotype strains. 
   
Beijing genotype  
(n=108) 
other genotypes 
(n=203) 
Total 
(n=311) 
rpoB      
no mutation  72 (66.7%) 165 (81.3%) 237 (76.2%) 
single mutation  35 (32.4%) 35 (17.2%) 70 (22.5%) 
 513 Gly→Lys 1 1 2 
 516 Asp→Val 2 2 4 
 522 Ser→Leu 1 0 1 
 526  13 9 22 
  His→Arg     1     1     2 
  His→Leu     2     1     3 
  His→Asp     7     2     9 
  His→Tyr     3     3     6 
  His→Asn     0     2     2 
 531  15 23 38 
  Ser→Leu    12    19    31 
  Ser→Trp     3     4     7 
 535 Pro→His 2 0 2 
      Unknown  1  0  1  
double-mutations  1 (1.0%)  3 (1.5%)  4 (1.3%)   
 510,526 Gly→His / His→Pro     0     1     1 
 511,516 Leu→Pro / Asp→Ala     0     1     1 
 515,516 Deletion     1     0     1 
 530,531 Leu→Met / Ser→Leu     0     1     1 
katG315       
 no mutation  88 (81.5%) 177 (87.2%) 265 (85.2%) 
 mutation (Ser→Thr)  20 (18.5%) 26 (12.8%) 46 (14.8%) 
embB306 *      
 no mutation  81 (83.5%) 155 (93.9%) 236 (90.1%) 
 mutation  16 (16.5%)           10  (6.1%)       26  (9.9%) 
* PCR for embB was only performed in 97 Beijing and 165 other genotype strains 
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Table 2.  Association between M. tuberculosis genotype and drug resistance gene 
mutations  
Gene 
Beijing genotype 
(n=108) 
other genotypes 
(n=203) 
OR (95% CI) 
  
rpoB 36 / 108 (33.3%) 38 / 203 (18.7%) 2.17 (1.27-3.70) 
katG315 20 / 108 (18.5%) 26 / 203 (12.8%) 1.55 (0.82-2.92) 
embB306 16 / 97 (16.5%) 10 / 165 (6.1%) 3.06 (1.33-7.05) 
 
 
Discussion 
A higher frequency of drug resistance might contribute to the global 
predominance of the Beijing genotype family. Although a systematic review about 
the Beijing genotype found no association with phenotypic drug resistance (2), 
genotypic studies looking at katG315 did indeed report higher mutation rates 
among Beijing strains (11, 23, 24). For rpoB this is less clear, as studies comparing 
Beijing and other genotype strains have examined the distribution (exact genetic 
location), rather than the overall frequency of rpoB-mutations (9-11). In this study 
from Indonesia we report a higher rate of rpoB-mutations among Beijing strains, 
both among previously treated and newly diagnosed tuberculosis patients. 
Similarly, katG315 showed more mutations among Beijing strains, although this 
difference was smaller and did not reach statistical significance. Finally, for 
mutations in embB306, responsible for resistance to ethambutol, we found a very 
strong association with the Beijing genotype similar to a smaller study from Russia 
(25).  
If Beijing genotype strains are indeed associated with drug resistance gene 
mutations, what could be the explanation? Firstly, it might be due to a founder 
effect, with a particular strain with certain genetic characteristics circulating in a 
specific area. However, the strong genetic variability of M. tuberculosis isolates in 
this area (15), collected from different sites over a 6-year period of time, argues 
against bias of our findings by one particular (resistant) cluster. Second, Beijing 
genotype strains might show a higher mutation frequency. It was previously found 
that Beijing strains have alterations in so-called ‘mutator genes’, resulting in a 
defective DNA-repair system allowing an increased mutation rate (12, 26). One 
might also hypothesize that specific characteristics of the cell-wall structure of 
Beijing strains lead to suboptimal intracellular concentrations of antituberculous 
drugs and acquisition of drug resistance (27-29). Both these hypotheses need 
further proof: in vitro, Beijing strains did not appear to acquire drug resistance 
more easily (13, 26). 
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A third possible explanation for our findings is that Beijing strains with drug 
resistance mutations are more viable. At least for rpoB, acquisition of drug 
resistance seems to be associated with reduced fitness of M. tuberculosis (30, 31). 
Beijing genotype strains may be more virulent than non-Beijing strains (32), and 
this might compensate for the loss of fitness associated with mutations in drug 
resistance genes. This hypothesis is supported by differences we and others have 
found in the distribution of specific mutations in rpoB  (11). The most common 
mutation, Ser531Leu, which seems to have very little effect on fitness (30, 31), 
had a higher prevalence among non-Beijing strains, while other mutations 
(including those in codon 526), which seem to have a higher fitness ‘cost’ were 
more common among Beijing strains. Similar to a study among South African 
children, we found a stronger association of Beijing and rpoB-mutations among 
newly diagnosed patients than among previously treated patients, suggesting 
easier transmission (more ‘fitness’) of resistant Beijing strains (33). 
Mutations in embB306 may account for ethambutol resistance in M. tuberculosis 
(34, 35) but may also correlate with multiple drug resistance (17, 20, 34, 36). Also 
in our study, mutations in embB306 strongly correlated with mutations in rpoB 
and katG315. As our study is cross-sectional, we cannot determine a causal 
relationship between mutations in embB306, rpoB and katG315. Obviously, 
resistance to one drug increases the risk of acquiring resistance to another drug. 
Longitudinal studies with consecutive isolates from single patients may help to 
determine which mutations generally occur first. Irrespective of the underlying 
mechanism our study confirms that mutations in embB306 are highly predictive of 
multidrug resistance.     
The high rates of drug-resistance in this study should not be extrapolated to 
Indonesia, as we purposely selected resistant strains. However, our study does 
confirm the need for quality-assured drug susceptibility testing (DST) in this 
country. Established methods for DST (for at least rifampicin) may be inaccurate in 
this setting. DST is scarcely performed in Indonesia, mostly using the Canetti-
method which dates back to 1955. Indonesia is not included in international 
surveillance of drug resistance (35), and there is no national surveillance, or 
quality control system yet. RpoB-sequencing in our study confirmed that such a 
quality control system is urgently needed. Our sequencing results also showed the 
unexpected occurrence of atypical mycobacteria among cases which were 
considered rifampicin-resistant tuberculosis. We suspect that contamination like 
this may happen more often in low-resource settings, obviously affecting the 
reliability of DST.  
Genotypic testing might play a role in improving routine susceptibility testing. 
Sequencing of rpoB is no ideal option for Indonesia but a multiplex PCR combining 
the three most common targets would cover >90% of the resistance mutations. In 
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close collaboration with the WHO / TDR, a manual nucleic acid amplification test 
including these targets is being tested in low-resource settings 
(www.finddiagnostics.org).  
In conclusion, we have examined 311 well-characterized M. tuberculosis strains 
from West-Java (population 40 million). Our results showed a higher rate of drug 
resistance mutations among Beijing genotype strains, which make up one third of 
all strains in this area. This suggests that, at least in part, the predominance of 
Beijing strains in Indonesia may be related to drug resistance. Unlike most other 
studies, we have been able to correct our results for previous treatment, which is 
important, as recurrent tuberculosis is obviously associated with drug resistance, 
but possibly also with the Beijing genotype (37, 38). The strong association of 
Beijing and rpoB-mutations among new cases of tuberculosis reflects considerable 
transmission of resistant Beijing strains in this setting. Our data also underline the 
need for implementation of quality-controlled drug resistance testing in 
Indonesia. Further study is needed to ascertain the underlying mechanisms for 
the associations found as well as its possible implications for tuberculosis control 
in Indonesia and elsewhere. 
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Abstract   
Animal studies have shown that strains of the globally emerging Mycobacterium 
tuberculosis Beijing genotype are more virulent compared to other strains. We 
examined if the Beijing genotype is associated with severity of tuberculosis and 
treatment failure in Indonesia. Among consecutive patients, the M. tuberculosis 
Beijing genotype was responsible for 33.4% of 818 pulmonary tuberculosis cases 
and 28.4% of 134 tuberculous meningitis cases (NS). No clear association was 
found between Beijing genotype and disease presentation or chest X-ray 
abnormalities. Patients infected with Beijing genotype strains more often had a 
positive sputum culture after six months treatment (RR:1.95; CI 95%:1.25-3.02), 
and this was not caused by differences in drug resistance. These data suggest that 
M. tuberculosis Beijing genotype strains have a higher capacity to withstand 
tuberculosis treatment, even in the absence of drug-resistance. Further study is 
needed to explore the underlying mechanisms as well as the possible implications 
for tuberculosis treatment. 
 
 
Introduction  
Molecular epidemiology has helped to reveal the evolutionary origins and 
phylogenetics of Mycobacterium tuberculosis . Evidence indicates that distinct M. 
tuberculosis lineages (genotypes) differ in terms of transmissibility, virulence, drug 
resistance, and treatment response. One of the best studied and most widespread 
evolutionary lineages of M. tuberculosis is the Beijing genotype family strains  (1-
3). This genotype may have originated from the Beijing region of China, and 
appears to have spread and become established as a predominant and endemic 
M. tuberculosis genotype in East and Southeast Asia, but also South Africa and the 
former Soviet Union states (1, 4). All M. tuberculosis lineages have recently 
expanded, but the Beijing family has had by far the largest population increase (5). 
This suggests that Beijing strains may have a selective advantage over other M. 
tuberculosis strains such as enhanced transmissibility, a lower protective effect of 
BCG-vaccination, reduced sensitivity to antituberculous drugs, or increased 
virulence. With regard to virulence, Beijing strains have indeed shown increased in 
vitro outgrowth in human monocytes (6) and macrophages (7) and increased 
mycobacterial outgrowth, distinctive histopathology and higher mortality in 
murine models (8, 9). 
However, less is known about a possible correlation between causative M. 
tuberculosis genotypes like the Beijing family and clinical phenotype of 
tuberculosis, and different patient studies have met with conflicting results. For 
instance, in Russia and Vietnam, Beijing strains were associated with more severe 
chest X-ray abnormalities (10, 11), while in Singapore the opposite (12), and in the 
Netherlands no relationship was found (13). A higher virulence of M. tuberculosis 
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Beijing genotype strains might also result in more dissemination of mycobacteria 
leading to extrapulmonary tuberculosis. Indeed, a study conducted in Arkansas 
found that the Beijing genotype was associated with extrapulmonary TB (14). 
However, a study from South Africa failed to find such a relationship (15). Finally, 
the successful spread of Beijing genotype strains might also be caused by more 
treatment failures and relapse of tuberculosis. Indeed, patients in Vietnam 
showed a nearly three-fold higher rate of relapse and treatment failure when 
infected with M. tuberculosis Beijing genotype strains (16), and a higher rate of 
previous treatment was found among patients infected with Beijing strains in 
Russia (10). However, as the Beijing genotype has shown a relationship with drug-
resistance in a number of studies (1) it remains uncertain whether the higher rate 
of treatment failure and relapse is due to intrinsic properties of the Beijing 
genotype perse, or to its association with drug-resistance.  
As pointed out above, the degree to which the M. tuberculosis genotype 
influences the clinical phenotype of tuberculosis remains poorly understood. Few 
studies have combined detailed patient characteristics and treatment results with 
genotyping of M. tuberculosis isolates from sufficient numbers of patients, and so 
far only one longitudinal (retrospective) study has been reported (17). We have 
previously spoligotyped a large number of M. tuberculosis patient isolates from 
Indonesia, showing that 33% belonged to the Beijing genotype (18). In this 
prospective cohort study we have examined if Indonesian patients infected with 
Beijing genotype strains show a more severe clinical presentation, more 
disseminated tuberculosis, or more treatment failure compared to patients with 
other (non-Beijing) genotype strains. With relatively high number of patients we 
were able to examine drug resistance as a separate variable in multivariate 
analysis.  
 
Methods 
Setting and patients  
In the context of a study exploring the role of host susceptibility to tuberculosis, 
consecutive new pulmonary TB patients above 15 years of age were included from 
October 2000 until December 2005 in three outpatient clinics in Jakarta and 
Bandung (19). Written informed consent was obtained from all subjects, and the 
study was approved by the ethical committee of the Faculty of Medicine, 
University of Indonesia, Jakarta and the Faculty of Medicine, Padjadjaran 
University, Hasan Sadikin Hospital, Bandung. Tuberculosis was diagnosed based 
on clinical presentation and chest X-ray examination, confirmed by positive 
microscopic detection of acid-fast bacilli (AFB). Tuberculosis treatment consisted 
of a standard regimen of daily rifampicin, isoniazid (INH), pyrazinamid and 
ethambutol for two months (the intensive phase), and rifampicin and INH for 
another four months (the continuation phase), according to WHO guidelines. In 
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the same period, patients with bacteriologically proven TB meningitis was 
included in Hasan Sadikin hospital in Bandung.  
 
Characterization of pulmonary tuberculosis patients 
Before start of TB-treatment, we recorded signs and symptoms, and history of 
possible previous TB-treatment or other diseases. Microscopic examination of 
acid-fast bacilli (AFB) in sputum slides was done by Ziehl-Neelsen staining, and 
graded according to the International Union Against Tuberculosis and Lung 
Disease (IUATLD) scale. Chest X-rays were read independently by two experienced 
radiologist who were blinded to the spoligotyping results and clinical information. 
Radiological lesions were classified as minimal lesions (mild), moderately 
advanced, and far advanced lesions and the presence or absence of pulmonary 
cavities was recorded (20). Blood examination included complete blood count, 
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and fasting blood 
glucose. HIV-testing was performed after the study on recorded anonymous 
samples (Determine dipsticks, Abbott diagnostics, Hoofddorp, The Netherlands).   
Sputum microscopy and culture were repeated after the intensive phase (2 
months), and at the end of treatment (6 months). We measured adherence by 
interview and pill-count. Previously we have compared several methods for 
measurement of adherence to treatment. The results showed the mean 
adherence in this setting, as measured with Medication Event Monitoring System 
(MEMS), to be 94% (21). 
 
M. tuberculosis culture, drug susceptibility testing and genotyping 
Culture for Mycobacterium tuberculosis  was done on Ogawa 3% egg based media. 
Drug susceptibility testing was performed on cultured isolates using an absolute 
concentration method with supranational control. This method has shown 
accuracy between 96 and 100% in 10 rounds of  WHO/IUATLD proficiency testing 
(22). Previous comparison of this method used in Indonesia has shown good 
agreement for INH and rifampicin, but less for streptomycin and ethambutol 
testing (B. Alisjahbana, submitted for publication). For 173 isolates sequencing of 
the hotspot region of the rpoB gene was performed, cross-checking the 
phenotypic drug susceptibility testing for rifampicin (23, 24).  
From all patients with positive cultures, M. tuberculosis isolates were genotyped 
by spoligotyping. Spoligotyping of M. tuberculosis was done using a commercial 
kit (Isogen Bioscience BV, Maarssen, The Netherlands) according to the 
manufacturer’s protocol and performed on DNA extracted from fresh colonies on 
Ogawa 3% media by boiling method (25). M. tuberculosis Beijing genotype was 
defined as a spoligopattern showing hybridization to at least three of the nine 
spacers 35 to 43 and absence of hybridization to spacers 1 to 34 (26). If no 
hybridization was found after repeated spoligotyping, the patient was excluded. 
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Spoligotyping was done in Hasan Sadikin Hospital, Bandung, Indonesia, but for 
10% of isolates, and for all isolates not showing hybridization, spoligotyping 
results were confirmed in the Netherlands. Spoligotyping was repeated if M. 
tuberculosis cultures were still positive after two and / or six months of TB-
treatment.  
 
Data analysis and statistics 
We compared the clinical and laboratory findings between TB patients infected 
with M. tuberculosis Beijing strains and those infected with non-Beijing strains. 
We used Pearson’s Chi-square to compare ratios, student T-test for normally 
distributed continuous variables, and Mann-Whitney non parametric for non-
normally distributed continuous variables. Two-sided P-values < 0.05 were 
considered significant. Relative risks (95% confidence intervals) were calculated 
for bacterial response to treatment. Multiple regression was used to adjust for 
possible confounding. Data were analyzed using the Statistical Package for Social 
Sciences (SPSS Inc, Chicago, IL version 16.0).  
 
 
Results 
Genotyping of patients with pulmonary and meningeal tuberculosis  
M. tuberculosis isolates were collected from 844 patients with a positive sputum 
smear. Twenty six were excluded from further analysis because repeated 
spoligotyping of isolates showed no hybridization (n=25) and one isolate was 
contaminated. For comparison, M. tuberculosis isolates from 148 patients with 
tuberculous meningitis were used. Spoligotyping was successful in 134 patients 
(90.5%) in this group. Among the total number of 952 patients with successful 
spoligotyping included for further analysis, no statistical correlation was found 
between Beijing genotype and disease localisation. M. tuberculosis Beijing 
genotype strains were found in 273 patients (33.4%) with pulmonary tuberculosis, 
and 38 (28.4%) of patients with tuberculous meningitis (NS).  
 
Presentation of patients with pulmonary tuberculosis according to genotype 
Pulmonary tuberculosis patients infected by M. tuberculosis Beijing (n=273) and 
non-Beijing genotypes (n=545) showed a similar sex distribution, age, duration 
and nature of symptoms (Table 1). Malnutrition, defined as BMI < 18.5 kg/m2, was 
present in 59.7% of patients infected with Beijing genotype strains, and in 63.3% 
of patients infected with non-Beijing strains (NS). No association was found 
between genotype and radiological abnormalities. Mycobacterial load, as 
measured by sputum microscopy, was higher among patients infected with M. 
tuberculosis Beijing strains, although this was not statistically significant (P=0.06). 
Rates of drug resistance seemed higher among M. tuberculosis Beijing strains, but 
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this was not statistically significant for INH (P=0.31) nor rifampicin (P=0.59). No 
difference was found in inflammatory markers from laboratory examination 
(Table 1).  
Table 1.  Clinical characteristics of pulmonary tuberculosis according to M. 
tuberculosis genotype 
 Beijing genotype(n=273) 
Other genotypes 
(n=545) 
  
Male sex  57.1 53.8 
Age, median years (IQR) 30 (23-42) 30 (23-41) 
History of TB contact  51.7 52.9 
Previous treatment for TB 5.2 3.9 
  
Signs and symptoms  
Duration, median weeks (IQR)  8 (4-16) 8 (4-16) 
Cough 98.9 98.9 
Hemopthysis  39.6 44.1 
Dyspnea  71.8 67.3 
Weight loss  81.7 82.4 
Night-sweats   74.7 71.0 
Body temperature ≥ 38°C 17.9 15.3 
Median BMI (IQR)  17.8 (16.0-20.0) 17.8 (16.3-19.5) 
BCG-scar present  49.1 45.1 
Fever a 72.5 79.2 
Fever during treatment  21.8 14.8 
Chest X-ray severity  
Advanced b 53.7 55.4 
Cavity present c 65.0 64.0 
  
Sputum microscopy   
Positive + 27.1 35.4 
Positive ++ 23.8 21.8 
Positive +++ 47.6 40.9 
  
Drug resistance     
INH resistantd 10.3 7.7 
Rifampicin resistante 6.5 5.4 
Multidrug resistantd  4.0 3.4 
  
Laboratory test results (median, IQR)  
Hemoglobin, mg/dLf 12.0 (11.0-13.1) 12.0 (10.6-13.2) 
Leucocyte count, 103/mLg 11.0 (8.0-13.0) 11.0 (9.0-13.0) 
Blood sedimentation rate, mm/hourh 82 (62-105) 85 (60-107) 
C-Reactive Protein, mg/dLi 56 (30-94) 61 (29-86) 
  
Co-morbidity   
HIVj 1.4 0.9 
Diabetes mellitusk 16.6 16.5 
  
Note : Data are presented as %, unless indicated otherwise. BCG, Bacille Calmette-Guerin; BMI,body mass 
index; INH, isoniazid; int exclu, intermediate results were excluded, IQR, interquartile range; MDR, 
multidrug resistant. 
 a P = 0.035 
 bData were available for 244 patients infected with Beijing strains and 500 patients infected with other 
genotype strains. cBecause of insufficient quality of radiographs, the presence of cavities could only be 
evaluated for 117 patients (48.0%) infected with Beijing strains and 261 patients (52.2%) infected with 
other genotype strains. Data are for d165 patients infected with Beijing, and 316 patients with other 
genotype strains, e179 Resp. 347 pts, f254 resp 503, g239 resp. 481pts, h239 resp. 466pts, i105 resp 
232, j210 resp. 434pts, k193 resp 394. 
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Reponse to treatment 
During the intensive phase, mortality (0.4%), default (3.9%) and transfer (1.8%) 
were low and not different between groups. Adherence to treatment, as 
measured by patient’s reports and pill counts, was equally high in both groups 
(78.9.% in Beijing group and 81.6% in non-Beijing group). The proportion of 
patients infected with M. tuberculosis Beijing strains developing a febrile response 
(>38.0oC) during treatment was slightly higher among patients infected with 
Beijing strains (21.8% vs 14. 8%), as found earlier in Indonesia (27), although this 
difference was not statistically significant (P=0.11) Sputum microscopy after two 
months could be performed in 90.7% of patients who had started treatment, 
showing no difference between groups. Sputum culture after two months, 
performed in 71.1% of patients still in treatment, was more often positive in 
patients infected with M. tuberculosis Beijing strains, but this was not statistically 
significant (Table 2).  
After six months, more treatment failures were found among patients initially 
infected with M. tuberculosis Beijing genotype strains. Culture after six months 
was performed in 450 patients, 55.0% of those who were still in treatment at this 
point (Table 2). Almost twice as many patients who initially were infected with a 
Beijing genotype strain had a positive sputum culture after six months (RR 1.95; 
95% CI 1.25-3.02, P=0.003). This effect was not due to a higher rate of drug 
resistance among Beijing strains: patients initially infected with drug-sensitive 
Beijing genotype strains were also at higher risk of having a positive sputum-
culture after six months treatment (RR 1.74, 95% CI 1.08-2.80). Besides the Beijing 
genotype, other risk factors for treatment failure included rifampicin resistance 
(RR 4.11; 95% CI 2.03 – 6.83), and diabetes mellitus (RR 1.99; 95% CI 1.14 – 3.46), 
as previously reported (19).  Multiple regression showed that the Beijing genotype 
was an independent risk factor for a positive sputum culture after tuberculosis 
treatment (P=0.03). 
Spoligotyping of M. tuberculosis isolates from sputum collected during and after 
treatment confirmed the relation between the Beijing genotype and 
bacteriological response to treatment. Spoligotyping was successful among 65 
patients who had positive sputum cultures after two months treatment, and 50 
patients who had positive cultures at the end or shortly after tuberculosis 
treatment. At two months, the Beijing genotype was found in 40.6% of patients 
who had a positive sputum culture,  and at six months, this was true for 50% of 
patients with positive sputum cultures, compared to 32.7% before start of 
treatment, P=0.03.  
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Table 2.  Bacteriological reponse to treatment according to M. tuberculosis genotype. 
Bacteriology 
Beijing 
(273 patients) 
non-Beijing 
(545 patients) 
RR (95% CI) 
    
After 2 months treatment    
Sputum microscopy performed (no. patients) 243 499  
AFB-positive 16.0% 14.4% 1.09 (0.82-1.43) 
Sputum culture performed (no. patients)      172 374  
Culture positive for M. tuberculosis,  no. patients (%) 22.7% 18.2% 1.24 (0.85-1.78) 
After 6 months treatment     
Sputum microscopy performed (no. patients) 185 374  
AFB-positive 5.9% 4.3% 1.39 (0.61-3.10) 
Sputum culture performed (no. patients) 150 300  
Culture positive for M. tuberculosis, no. patients (%) 24.0% 12.3% 1.95 (1.25-3.02) * 
    
*p = 0.003 
 
 
Discussion 
We examined if the M. tuberculosis Beijing genotype was associated with an 
altered disease phenotype and treatment outcome among 954 tuberculosis 
patients in Indonesia. One third of patients were infected with M. tuberculosis 
Beijing genotype strains. We found no associations between Beijing genotype and 
disease localisation, clinical presentation or chest X-ray abnormalities. During 
prospective follow-up, patients infected with M. tuberculosis Beijing genotype 
strains experienced more treatment failure and more relapse, and this was not 
explained by differences in drug resistance. 
So far, most studies examining possible explanations for the successful global 
spread of M. tuberculosis Beijing strains have focused on drug resistance, with 
several studies indeed showing higher drug resistance rates among Beijing 
genotype strains. However, Beijing strains may have additional properties which 
give them a selective advantage. In animal models Beijing strains have shown a 
higher degree of virulence, as reflected in more outgrowth, tissue damage and 
lower survival (8, 9). Few studies have examined the clinical phenotype of the M. 
tuberculosis Beijing genotype in tuberculosis patients, and ours is only the second 
prospective cohort study.   
Our study provides no evidence to support our first hypothesis, that Beijing 
genotype strains would have a higher propensity for dissemination to the central 
nervous system. This is in line with research among adult patients in Vietnam (28) 
and children in South-Africa (29).  One might also hypothesize that more virulent 
M. tuberculosis strains would more easily reach the central nervous system, but at 
least for the Beijing genotype this is not supported by our data and the studies 
cited above. 
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The second hypothesis we have examined was if M. tuberculosis Beijing genotype 
strains cause more severe pulmonary tuberculosis. Our data suggest that this is 
not the case. Signs and symptoms were rather similar. No difference was found in 
duration of symptoms (a shorther duration would suggest a higher virulence), 
cachexia or hemoptysis reflecting tissue damage, or any other symptom recorded. 
Our study is one of the largest and most detailed reported so far, and its findings 
are generally in line with previous studies, none of which have found dramatic 
differences in terms of signs and symptoms between patients infected with 
Beijing and other genotype strains (10, 12, 17). Similar to signs and symptoms, no 
association was found between genotype and radiological appearance, which is in 
line with some (13, 17) but not all previous reports (10, 12).  
The third hypothesis we have examined is if Beijing strains are associated with a 
different response and outcome to tuberculosis treatment. Our data suggest that 
this is indeed the case. A higher proportion of patients infected with Beijing 
genotype strains developed fever during treatment, similar to what was found in a 
smaller study from Indonesia (27). The release of mycobacterial PAMPs (pathogen 
associated molecular patterns) during treatment may elecit a febrile response, 
and one might hypothesize that PAMPs from M. tuberculosis Beijing strains are 
more ‘immunogenic’ or released in higher quantities (30, 31).  
In addition, patients infected with Beijing strains had an almost two-fold higher 
risk of having a positive M. tuberculosis culture after completing tuberculosis 
treatment. Among 224 Taiwanese patients, in the only other prospective cohort 
published so far, the Beijing genotype was also associated with treatment failure, 
albeit only among elderly patients (17). Earlier cross-sectional studies have shown 
relations between the Beijing genotype and tuberculosis treatment failure in 
Russia and Vietnam (10, 16, 32). Our study provides further support for a relation 
between Beijing genotype and bacteriological response to treatment as Beijing 
genotype strains made up a larger proportion among patient isolates after two 
months rather than before treatment, and again larger after six months versus 
two months treatment. We are the first to show that the higher risk of treatment 
failure among patients infected with Beijing strains was not due to differences in 
drug-resistance. This finding suggests that this genotype has certain 
characteristics per se which render them more resistant to tuberculosis 
treatment.  
Our study has certain limitations. Data on drug resistance testing, chest X-ray 
examination and blood testing were incomplete, although this was equally a 
problem in both groups. Compared to other studies this study has several strong 
points. It is the second and largest comprehensive cohort study systematically and 
prospectively describing treatment outcome of patients infected with M. 
tuberculosis Beijing genotype strains. Very few patients were lost to follow-up, 
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and sputum culture, the most important endpoint was performed in a high 
proportion (71% of patients after two months, and 55% after six months). Patients 
without a culture had mostly recovered, rendering them unable to expectorate 
sputum. Adherence, which was well-monitored was high, excluding it as a 
confounder. Finally, other risk factors, including diabetes, HIV and drug-resistance 
were included in the analysis.  
In conclusion, our understanding of the relationship between genotype and 
phenotype is still far from complete, but this study lends further support to the 
idea that differences in mycobacterial genotype indeed result in differences in 
disease phenotype, which may contribute to the predominance of mycobacterial 
genotypes like Beijing. Tuberculosis treatment was less effective against Beijing 
genotype strains, and this was not explained by drug-resistance. Further research 
should be conducted to explore the underlying mechanisms as well as the 
possible implications for tuberculosis treatment.  
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Abstract 
After tuberculosis (TB) treatment, patients remain at increased risk of death and 
recurrent TB. We examined long-term effects of pulmonary TB by comparing ex-
TB patients with matched controls in Indonesia. Two-hundred ex-TB patients and 
200 matched healthy controls from a previous case-control study were re-
examined 1.5 to five years later. Measurements included survival, TB recurrence, 
chest-X-ray, pulmonary function, and sputum examination. 
Data could be retrieved from 146 ex-TB patients (73%, 359 personyears), and 178 
controls (89%, 388 personyears). All controls were alive, while three ex-TB 
patients had died after initial TB-treatment (p=0.055). Fourteen ex-TB patients 
developed recurrent TB, and three controls a first episode of TB (RR=5.2; 95% CI 
1.5 – 17.7). Functional measurements showed more pulmonary restriction (41% 
vs 11%) and airway obstruction (10% versus 1%) in ex-TB patients compared to 
controls. TB recurrence was more frequent and lung function impairment more 
severe in patients initially infected with Mycobacterium tuberculosis Beijing 
genotype strains. 
TB-patients remain at risk for recurrent TB and impaired pulmonary function. M. 
tuberculosis Beijing genotype strains seem more virulent. Follow-up of TB patients 
after treatment seems warranted and possible interventions to limit lung damage 
during TB-treatment should be examined. 
 
 
Introduction 
Tuberculosis (TB) is a major global health problem, killing about 1.7 million people 
every year (1). Treatment of tuberculosis is effective for the majority of patients. 
However, after successful treatment, TB may still impair health. First, patients die 
more frequently after treatment of TB compared to the general population. 
Reported mortality rates range from 1.5 – 10% in the first two years after end of 
treatment (2-6). Second, those who remain alive are at risk for TB recurrence, 
with a median recurrence rate 1780 per 10.000 personyears one year after 
treatment (7) reported rates ranging from 0.9% in pan-susceptible and mono-
resistant TB patients , up to almost 100% in MDR-TB cases roughly two years 
following treatment . Besides drug resistance other factors have been related to 
death and recurrent TB including HIV infection, older age, diabetes, M. 
tuberculosis genotype, smoking and non-compliance (2, 3, 5, 7-13).  
Third, as a result of destruction of lung tissue, TB can have long-lasting effect on 
general health. Shortly after TB treatment, pulmonary function is greatly impaired 
(14-16). One may postulate that patients will also suffer from more longstanding 
impairments. 
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We aimed to assess the long-term effects of pulmonary tuberculosis comparing 
ex-TB patients and matched healthy controls from a case-control study previously 
conducted in an ambulatory setting in Indonesia, which has the third highest TB-
case-load worldwide (1). We measured survival, incidence of (recurrent) TB and 
pulmonary function. 
 
 
Methods 
Subjects 
From a cohort of 481 TB-patients and 622 controls included in a case-control 
study conducted between 2001 and 2005 (17), 200 ex-TB patients and 200 
matched healthy subjects were included. In the initial study, all patients had 
bacteriological proven pulmonary tuberculosis, while none of the controls had 
symptoms or chest X-ray findings suggesting TB. Inclusion, matching and data 
collection in the initial study have been described elsewhere (17). Patients were 
treated with a standard four-drug regimen according to national guidelines. 
Patients were classified as successfully treated if their initial treatment outcome 
was ‘cure’ or ‘treatment completed’ according to standard definitions (1), and 
unsuccessfully treated if their initial treatment outcome was ‘failure’ or ‘default’. 
Characteristics of subjects at time of enrolment in the previous case-control study 
are summarized in Table 1. For the current study all study subjects were invited to 
the clinic by letter. For subjects that did not come to the clinic, follow-up phone 
calls and maximum two home visits were done by a social worker during which 
structured interviews were conducted and subjects were asked to visit the clinic.  
Oral and written informed consent was obtained, dated and signed for all 
participating study subjects. Ethical clearance for the study was granted by the 
review committee of the Medical Faculty, Padjadjaran University. 
 
Measurements 
Data collection took place from April 2007 until August 2007. For subjects 
presenting at the clinic, height and weight were measured, signs and symptoms 
were recorded and TB status in the period since the initial study was assessed. 
Fasting Blood Glucose (FBG) was measured, and diabetes mellitus (DM) was 
diagnosed if the FBG concentration was >126 mg/dl. Chest X-ray examination was 
performed in all subjects visiting the clinic except pregnant women. In subjects 
with suspected tuberculosis (cough > 3 weeks, haemoptysis and/or abnormalities 
suggestive of TB on chest X-ray), sputum microscopy and M. tuberculosis culture 
was performed using solid media (3% Ogawa) (18). A long-term negative 
treatment outcome was defined as: death or new/recurrent TB following previous 
inclusion (controls) or TB-treatment (ex-TB patients). Lung function was assessed 
by spirometry using SpirobankG (19). Subjects were asked to stand and use a nose 
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clip during measurements. Subjects performed the following manoeuvres twice: 
calm inspiratory vital capacity (IVC), calm expiratory vital capacity (EVC) and 
forced vital capacity (FVC). Curves were followed real-time and measurements 
were repeated if necessary. The best result, within 15% of the range of total six 
manoeuvres was taken as vital Capacity (VC). The second outcome parameter was 
FEV1 /FVC ratio (best FEV1 and a FVC within 15% of the range of total six 
manoeuvres). Reference values of VC were obtained from an Indonesian survey 
among 1892 males and 1636 females (Pneumobile project, Boehringer, 1992). For 
those who had died, verbal autopsy (VA) was obtained from the closest contact at 
time of death. The verbal autopsy form was constructed using the WHO Standard 
Verbal autopsy (20) as guidance. Using verbal autopsy the cause of death was 
classified by a medical doctor as due to bacteriologically confirmed TB, probable 
TB (treated or hospitalized for suspected TB), possible TB (symptoms suggesting 
TB), other natural causes, or no natural cause. 
 
Data analysis and statistics 
Binominal outcome variables were tested by logistic regression, resulting in an 
Odds Ratio (OR) or p-value or cross-tabs resulting in Relative Risk (RR) or p-value 
by Pearson chi-square of Fisher’s exact test. Continuous outcome variables were 
tested by linear regression or by student’s T-test. 
 Confidence intervals were calculated using single proportions or Poisson 
distribution for rare events. Differences in pulmonary function were determined 
using linear and logistic regression analysis. We included body mass index (BMI), 
smoking, age, gender, diabetes, and initial treatment outcome in the multivariate 
models. 
 
 
Results 
One hundred and forty-six of 200 ex-TB patients (73%) and 178 of 200 controls 
(89%) could be traced (Table 2). Ex-TB patients who were traced were similar in 
age, gender, initial treatment outcome, body mass index (BMI), diabetes 
prevalence and income at baseline to those who could not be traced and the 
same was true for controls (data not shown). Total follow-up time was 359 
personyears for ex-TB patients and 387 for controls, ranging from three months to 
five years after the initial study. Two ex-TB patients were found to have died 
during the initial TB-treatment and were not included in the calculations. None of 
the traced subjects was HIV positive at the time of the initial study. 
Three ex-TB patients (2.1%; 95% CI 0.4 - 6.0%) and none of the controls died 
during follow-up (p=0.055; Table 2). All deaths were due to TB, one after 
complete and two after incomplete TB-treatment. Based on treatment history and 
sputum examination, 14 ex-TB patients had developed recurrent TB, and three 
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controls a first episode of TB (RR=5.2; 95% CI 1.5 – 17.7). Nine ex-TB patients had 
a history of recurrent TB treatment, on average 1.6 years (95% CI 0.9 – 2.3) after 
their initial TB treatment, and two controls reported having had a first episode of 
TB (RR=5.8; 95% CI 1.3 – 26.5). Furthermore, of 233 study subjects who visited the 
clinic, six (5.5%) ex-TB patients and one (0.8%) control were found to have 
bacteriological positive TB, of whom one ex-TB patient already reported a TB 
episode after the initial study. Total negative long-term outcome was found in 17 
ex-TB patients (5.7/100 personyears), and three controls (0.87/100 personyears), 
(RR=6.2; 95% CI 1.9 – 20.4). Patients that were successfully treated for TB 
remained significantly more at risk of recurrence (RR=3.9, 95% CI 1.1 – 13.8) and 
negative long-term outcome (RR 4.2; 95% CI 1.2 -15.0). Ex-TB patients initially 
infected with M. tuberculosis Beijing genotype strains had a higher risk of a 
negative outcome than ex-TB patients infected with other genotype strains 
(OR=8.6: 95% CI 1.4 – 53.7), this was also true when ex-TB patients who had 
defaulted or failed initial treatment were excluded (OR=12.2: 95% CI 1.0 – 145). 
Smoking had an effect on the long-term treatment outcome but this was not 
statistically significant for a history of ever smoking (OR=2.3; p=0.19), nor for 
pack-years (OR=1.1; p=0.052). Of 14 individuals with diabetes who came to the 
clinic, two (14%) had a negative long-term outcome compared to 12 (6.2%) of 
non-diabetic subjects (p=0.25). Two ex-TB patients (50%) with an initial episode of 
rifampicin-resistant TB had a negative long-term outcome compared to 13 (19%) 
with an initial episode with a pan-susceptible strain (p=0.15). None of the ex-TB 
patients with recurrent TB had a previous episode of isoniazid-resistant TB. 
Spirometric examinations were done in 73 (37%) ex-TB patients and 84 (42%) 
controls. No differences in age, sex, initial treatment outcome, BMI, smoking, 
diabetes prevalence and income existed between ex-TB patients and controls who 
performed spirometry and those who did not. Adjusted to Indonesian reference 
values, Vital Capacity (VC) and FEV1/FVC (Forced Expiratory Volume in the first 
second/Forced Vital Capacity) were significantly lower for ex-TB patients than for 
controls (Table 2), also after exclusion of subjects with TB during follow-up. 
Among ex-TB patients, women had a lower VC than men (mean 78% vs. 85%, 
p=0.05), but this did not account for the significant difference in VC between ex-
TB patients and controls. VC was lower among ex-TB patients with abnormal X-
rays (74% vs. 91%; p<0.01). Pulmonary impairment did not change with increased 
smoking volume, and smoking did not account for the significant spirometric 
differences between ex-TB patients and controls (data not shown). Both VC and 
FEV1/FVC were significantly lower among 18 ex-TB patients initially infected with 
M. tuberculosis Beijing genotype strains compared to 33 ex-TB patients initially 
infected with strains belonging to other genotypes (VC: p<0.05; FEV1/FVC: 
p<0.05), and for VC this difference remained significant after exclusion of ex-TB 
patients with recurrent TB during follow up (p<0.05). More ex-TB patients than 
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controls had a VC below 80% of the predicted value (41% vs. 11%; OR=6.3; 95% CI 
2.7 – 14.9), and a FEV1/FVC below 70% (10% versus 1%; OR=8.7; 95% CI 1.0 – 
72.4). When only successfully treated ex-TB patients were compared to controls, 
significance remained for both outcome measures. Almost sixty percent of ex-TB 
patients had an abnormal X-ray; those ex-patients had a significantly lower VC 
than ex-TB patients with a normal X-ray. Functional impairment seemed 
permanent: differences in VC and FEV1/FVC were also found among subjects with 
more than four years of follow-up (data not shown). 
 
Table 1.  Baseline characteristics, collected in initial case-control study, of subjects 
that were invited in the follow-up study 
 
Ex-TB patients 
(n=200) 
Controls 
(n=200) 
Median age - years(IQR) 26 (22-36) 26 (22-37) 
Male sex 41.0 39.0 
Median BMI - kg/m2(IQR) #,** 18 (16-20) 21 (19-24) 
Diabetes Mellitus #,** 10.6 1.4 
Smoking 41.9 50.3 
HIV-positive 1.5 0 
Initial TB-treatment successful 84.8 NA 
Isoniazid resistance 0 NA 
Rifampicin-resistance 6.6 NA 
M. tuberculosis Beijing genotype 38.3 NA 
Table 1.  Data are represented as % unless stated otherwise. # Status of diabetes mellitus was 
known for 160 ex-TB patients and 146 controls, HIV-status for 197 ex-TB patients and 64 
controls, drug–resistance for 121 ex-TB patients, and spoligoytping results for 128 ex-TB 
patients. IQR = interquartile range; BMI = body mass index (kg/m2); NA= not applicable. 
P-values were based on student’s T-test (age, BMI), Fischer’s exact test (HIV) and chi-
square (sex, smoking, diabetes). 
 * p<0.05; ** p<0.01. 
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Table 2.  Characteristics of subjects that were traced during the follow-up study 
 Ex-TB patients Controls 
Number retrieved (%) 146 (73%) 178 (89%) 
Median follow-up - years 2.5 2.2 
Total follow-up - personyears 359 387 
   
Death 2.1 (0.4 – 6.0) 0 
Median BMI (IQR)* 21 (19-24) 22 (19-26) 
Reported TB-treatment during follow up period ** 7.4 (3.4 - 14.1) 1.3 (0.2 - 4.6) 
Chronic cough 3.6 (1.0 – 9.3) 1.6 (0.2 – 5.8) 
Haemoptysis 1.8 (0.2 – 6.6) 0 
Abnormal X-ray; possible TB ** 57.7 (47.9-67.6) 4.5 (0.6-8.3) 
   
Sputum examination n = 33 n = 1 
AFB-positive (n) 3 1 
Culture-positive (n) 5 1 
AFB or culture-positive (n) 6 1 
   
Lung function n = 73 n = 84 
mean VC - % predicted ** 81.2 95.4 
mean FEV1 / FVC ratio ** 81.6 86.6 
 
Table 2.  Data are represented as %, (95% Confidence Interval based on Poisson distribution) 
unless stated otherwise. BMI was assessed in 109 ex-TB patients and 123 ex-controls. 
Reported TB (yes / no) could be established in 121 ex-TB patients and 157 controls, signs 
and symptoms were recorded in 110 ex-TB patients and 124 controls, and chest X-ray 
examinations were done in 97 ex-TB patients and 112 controls. BMI= body mass index 
(kg/m2); AFB = acid-fast bacilli; VC=vital capacity; FEV1= forced expiratory volume in one 
second; FVC= forced vital capacity. P-values were based on Fischer’s exact test (death, 
chronic cough, haemoptysis), linear regression analysis (BMI, lung function), and logistic 
regression analysis (abnormal X-ray, reported TB).  
 * p<0.05; ** p<0.01. 
 
Discussion 
Our study shows that Indonesian ex-TB patients more often die or develop 
(recurrent) TB and longstanding lung damage compared to healthy controls, even 
after successful treatment. Interestingly, one particular M. tuberculosis lineage, 
the Beijing genotype was associated with more frequent recurrence of TB and 
more severe lung damage than other genotypes. 
Mortality during follow-up was higher among ex-TB patients than among healthy 
controls of similar background and (young) age, although this difference was not 
statistically significant. Mortality following TB-treatment in our study was 2.1%, 
which is lower than 6% mortality in a study in Vietnam (6), and 24% in Uzbekistan 
(2), while the follow-up in those studies was slightly shorter than ours (median 19 
and 22 months respectively). Our findings for mortality may be an underestimate 
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as only 73% of ex-TB patients could be retrieved. Another possible explanation for 
the difference with previous studies is that our ex-TB patients, recruited in 
ambulatory care, were in a better medical condition and mostly (92%) newly 
diagnosed. Severe malnutrition and drug resistance were uncommon, HIV 
incidence was very low, and death during initial treatment was <1% (21).  
Through anamnesis and active case-finding the risk of TB was six times higher in 
ex-TB patients than in healthy controls. To our knowledge, we are the first to 
compare risk of TB following treatment using matched healthy controls. Despite 
the fact that controls (in this endemic setting) were not screened nor treated for 
latent TB, they had a much lower risk of developing active TB than ex-TB patients 
who had received a full course of anti-TB drugs. This is an intriguing finding for 
which there are broadly three explanations. First, active TB may not have been 
fully eradicated during initial treatment, leading to relapse. Second, damage 
caused by an episode of active TB permanently impairs the first-line host defense 
of subjects, thereby making them more susceptible for recurrent TB due to 
reinfection. Finally, genetic and other factors affecting innate host defense may 
predispose subjects to progress to active TB following primary infection as well as 
following re-infection with M. tuberculosis after successful treatment. 
Immunogenetic and other studies are slowly unraveling why roughly 90% of 
individuals is able to contain M. tuberculosis infection, and 10% is not (22). The 
rate of reinfection after treatment of TB is higher than the rate of new TB in a high 
incidence setting (23), which might be explained by immunogenetic 
predisposition. 
Interestingly ex-TB patients initially infected with M. tuberculosis strains of the 
Beijing family had more recurrent TB. The Beijing genotype is found in more than 
30% of Indonesian TB-patients (23, 24) and is predominant in Asia (25). Its wide 
distribution suggests that the Beijing genotype family has a selective advantage. 
Beijing strains might acquire drug resistance more easily or might be more 
virulent, thereby hampering their eradication. This is consistent with our results 
and previous studies in Vietnam (9) and Singapore (26), which showed a higher 
relapse rate among patients infected with Beijing strains, even when corrections 
were made for drug resistance. 
The third endpoint of the study was lung function. History of TB was strongly 
associated with impaired lung function, even years after successful treatment. 
Apparently, treatment of TB did not prevent permanent damage in this setting, 
although it cannot be excluded that lung damage was already present before the 
TB period. The prevalence and pattern of lung function impairment was similar to 
what was reported in other studies during and after treatment (14-16), although 
less severe. This impairment was equally severe among ex-TB patients regardless 
of when the initial episode of TB took place, suggesting that lung damage is 
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longstanding or even permanent, an important finding given the young age of ex-
TB patients in this setting. The presence of functional impairment is in line with 
the fact that more than half of ex-TB patients had an abnormal chest X-ray, ex-TB 
patients with an abnormal X-ray having a significantly lower VC than ex-TB 
patients with a normal X-ray. Obstructive lung disease can be treated, but loss of 
lung tissue (restriction) cannot be repaired. Interestingly, also for lung function 
impairment M. tuberculosis Beijing genotype proved to be a risk factor, in line 
with animal studies (27). Beijing strains might elicit a different host response with 
more lung damage, but further studies in humans are needed to test this 
hypothesis. 
Retrieval of information from ex-TB patients and to a lesser extent from controls 
proved difficult in this setting. Although their disease severity and treatment 
response at time of initial treatment were similar, it is still possible that TB 
recurrence or death were more common among those who could not be traced 
back. Only a minority of subjects (none out of three controls and 15 out of 45 ex-
patients) who were asymptomatic but who had chest X-ray abnormalities 
presented for sputum examination, another reason why TB-recurrence may in fact 
have been higher. Prolonged and more intense follow-up of ex-TB patients, 
although difficult in settings like Indonesia, may help confirm our findings and 
lead to earlier detection and treatment of recurrent TB. 
In summary, we have found that Indonesian ex-TB patients, even after successful 
treatment, have a higher risk of developing recurrent TB, and that a history of TB 
causes long-term impairment of lung function. Both endpoints are associated with 
infection by a particular M. tuberculosis genotype family. Further study is needed 
to assess optimal management of lung function impairment after an episode of 
TB. 
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Abstract 
Differences in host immune genes may predispose to tuberculosis caused by 
particular Mycobacterium tuberculosis genotypes. We have examined this 
hypothesis in Indonesia by spoligotyping M. tuberculosis isolates from 336 
pulmonary tuberculosis patients, and typing the patients’ gene SLC11A1 (formerly 
called NRAMP1) which is involved in susceptibility to tuberculosis. The M. 
tuberculosis Beijing genotype, which made up 29.8% of all isolates, was strongly 
associated with two polymorphisms in SLC11A1; the D543N G allele (OR 2.15, 
P=0.005), and the 3’UTR ins/ins genotype (OR 2.5, P=0.0013). This supports the 
hypothesis of co-evolution of M. tuberculosis and the human immune system.  
 
 
Introduction 
Different evolutionary lineages of M. tuberculosis are strongly associated with 
specific geographical regions suggesting they have adapted to particular human 
populations. Indeed, particular M. tuberculosis lineages (also called: genotype 
families) have shown preferential spread in certain patient populations [1,2]. This 
may be due to differences in environmental exposure, but it might also be the 
result of co-evolution of host and pathogen. In this case, differences in host 
immune genes would confer increased susceptibility – or resistance – of certain 
human populations to particular M. tuberculosis genotype families. So far, only 
one study has tried to show a direct association between genetic characteristics of 
tuberculosis patients and their (own) mycobacterial isolates. In this study from 
Vietnam it was shown that a particular variation in toll-like receptor (TLR)2, a 
relevant receptor for M. tuberculosis, was more common among patients infected 
with strains belonging to the successful M. tuberculosis Beijing genotype than 
among patients infected with other genotype strains [3]. This study suggests that 
the outcome of exposure to M. tuberculosis depends on both human and bacterial 
genotype. We examined this hypothesis in Indonesia, which has the third highest 
global burden of tuberculosis. We have previously shown that 33% of tuberculosis 
patients in a large cohort in Indonesia were infected with strains belonging to the 
M. tuberculosis Beijing genotype [4], which globally is one of the most 
predominant families of M. tuberculosis [5]. In this same population we have now 
examined if infection with the Beijing genotype M. tuberculosis was linked to 
specific polymorphisms of SLC11A1, formerly called NRAMP1 (natural resistance-
associated macrophage protein 1), a gene that was reported to be associated with 
susceptibility to tuberculosis, especially among Asian subjects [6].  
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Methods 
From January 2001 through December 2006, consecutive patients over 16 years of 
age with microscopically proven pulmonary tuberculosis were included in two 
out-patient clinics and two hospitals in Jakarta and Bandung (West Java, 
Indonesia), as part of a case-control study examining host susceptibility to 
tuberculosis [7]. The diagnosis of tuberculosis was based on clinical presentation, 
chest X-ray examination, microscopic detection of acid-fast bacilli by Ziehl-
Neelsen stained sputum smear, and culture of M. tuberculosis on 3% Ogawa 
medium. All patients were tested for HIV-infection, and HIV-seropositive patients 
(1.8%) were not included in further analysis. The study was approved by the 
ethical committee of the Faculty of Medicine, University of Indonesia, Jakarta and 
the Faculty of Medicine, Padjadjaran University, Hasan Sadikin Hospital, Bandung. 
Spoligotyping was performed on M. tuberculosis sputum cultures from 769 
tuberculosis patients. Mycobacterial DNA was extracted by bringing two loops of 
bacterial mass from a M. tuberculosis culture in saline and subsequent heating at 
95oC for 5 min. Spoligotyping was performed using a commercial kit (Isogen 
Bioscience, Maarssen, The Netherlands). The presence or absence of 43 spacers in 
the DR region of isolates of M. tuberculosis was detected as described previously 
[4]. M. tuberculosis Beijing genotype was defined as a spoligopattern showing 
hybridization to at least three of the nine spacers 35 to 43 and absence of 
hybridization to spacers 1 to 34. Spoligotyping was done at the Hasan Sadikin 
Hospital, Bandung, Indonesia. For quality control, spoligotyping of 10% of the 
isolates, and all isolates lacking hybridization, was repeated at Gelre Hospital, 
Apeldoorn, the Netherlands. 
Typing of SCL11A1 polymorphism was performed in 342 patients of this cohort, 
but six HIV-infected patients were excluded from further analysis. Genomic DNA 
was isolated from EDTA blood. Two single nucleotide polymorphisms in the gene 
NRAMP1, D543N (1703G> A in exon 15 leading to an aspartate to asparagine 
substitution at codon 543, SNPid rs17235409) and INT4 (469 +14G>C in intron 4, 
SNPid rs3731865), as well as a TGTG insertion/deletion polymorphism in the 3’ 
untranslated region (1729+55ins/del4, SNPid rs17235416), denoted as 3’UTR were 
analysed as described before [8]. The Hardy–Weinberg equilibrium of each 
polymorphism was checked using the program HWE. The program CONTING was 
used to calculate χ2 and associated values for a contingency table. All statistical 
analyses were two-sided and P values <0·05 were considered as statistically 
significant. Associations of SCL11A1 polymorphisms with M. tuberculosis Beijing 
strain (as opposed to other or ‘non-Beijing’ strains) infection were expressed as 
odds ratios (95% confidence intervals).  
From January 2001 through December 2006, consecutive patients over 16 years of 
age with microscopically proven pulmonary tuberculosis were included in two 
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out-patient clinics and two hospitals in Jakarta and Bandung (West Java, 
Indonesia), as part of a case-control study examining host susceptibility to 
tuberculosis (1). The diagnosis of tuberculosis was based on clinical presentation, 
chest X-ray examination, microscopic detection of acid-fast bacilli by Ziehl-
Neelsen stained sputum smear, and culture of M. tuberculosis on 3% Ogawa 
medium. All patients were tested for HIV-infection, and HIV-seropositive patients 
were not included in further analysis. The study was approved by the ethical 
committee of the Faculty of Medicine, University of Indonesia, Jakarta and the 
Faculty of Medicine, Padjadjaran University, Hasan Sadikin Hospital, Bandung. 
Spoligotyping was performed on M. tuberculosis sputum cultures from 769 
tuberculosis patients. Mycobacterial DNA was extracted by bringing two loops of 
bacterial mass from a M. tuberculosis culture in saline and subsequent heating at 
95oC for 5 min. Spoligotyping was performed using a commercial kit (Isogen 
Bioscience, Maarssen, The Netherlands). The presence or absence of 43 spacers in 
the DR region of isolates of M. tuberculosis was detected as described previously 
(2). M. tuberculosis Beijing genotype was defined as a spoligopattern showing 
hybridization to at least three of the nine spacers 35 to 43 and absence of 
hybridization to spacers 1 to 34. Spoligotyping was done at the Hasan Sadikin 
Hospital, Bandung, Indonesia. For quality control, spoligotyping of 10% of the 
isolates, and all isolates lacking hybridization, was repeated at Gelre Hospital, 
Apeldoorn, the Netherlands. 
Typing of SCL11A1 polymorphism was performed in 342 patients of this cohort, 
but six HIV-infected patients were excluded from further analysis. Genomic DNA 
was isolated from EDTA blood. Two single nucleotide polymorphisms in the gene 
NRAMP1, D543N (1703G> A in exon 15 leading to an aspartate to asparagine 
substitution at codon 543, SNPid rs17235409) and INT4 (469 +14G>C in intron 4, 
SNPid rs3731865), as well as a TGTG insertion/deletion polymorphism in the 3’ 
untranslated region (1729+55ins/del4, SNPid rs17235416), denoted as 3’UTR were 
analysed as described before (3). The Hardy–Weinberg equilibrium of each 
polymorphism was checked using the program HWE. The program CONTING was 
used to calculate χ2 and associated values for a contingency table. All statistical 
analyses were two-sided and P values <0·05 were considered as statistically 
significant. Associations of SCL11A1 polymorphisms with M. tuberculosis Beijing 
strain (as opposed to other or ‘non-Beijing’ strains) infection were expressed as 
odds ratios (95% confidence intervals).  
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Results 
Among 336 patients included, the median age was 30 years (range 16 - 75), 57.4% 
were male, and 5.1% had a history of previous tuberculosis treatment. One 
hundred (29.8%) were infected with M. tuberculosis Beijing genotype strains. The 
remaining 236 patients were infected with genotypes T1 (11.1%), Haarlem (9.3%), 
LAM (6.3%), EAI (4.2%), U/H3 (3.6%), remaining genotypes (4.7%), and with 
‘orphan strains’ (31.0%), that had no shared-type with the international spoligo 
database SpolDB4. These results were representative for the total cohort of 740 
pulmonary tuberculosis patients which was previously described [4]. Patients 
infected with M. tuberculosis Beijing strains and other (‘non-Beijing’) genotype 
strains were not significantly different in terms of age, gender or history of 
previous tuberculosis treatment. All 336 patients were HIV-seronegative.  
The distribution of alleles and genotypes of three SCL11A1 polymorphisms among 
patients infected with M. tuberculosis Beijing genotype and other genotype 
strains is shown in table 1. Each polymorphism was in Hardy-Weinberg 
equilibrium in the total group of patients as well as in 363 controls analyzed in a 
previous study [8]. The variant allele of INT4 was present in less than 5% of 
subjects, and therefore not further analyzed. As can be seen, significant 
associations were found between infection with M. tuberculosis Beijing genotype 
strains, and the two remaining SLC11A1 polymorphisms. The G allele and the GG 
phenotype of the D543N polymorphism were significantly associated with 
infection by M. tuberculosis Beijing (P=0.01 and P=0.005 respectively). The 
association between M. tuberculosis Beijing genotype and the GG phenotype of 
D543N showed an OR of 2.15 (95% CI 1.25-3.70). Similarly, the ins allele and 
ins/ins genotype of the 3’UTR polymorphism were significantly associated with 
infection by M. tuberculosis Beijing genotype strains (P=0.01 and P=0.0013 
respectively). The association between Beijing genotype strains and the ins/ins 
genotype of 3’UTR showed an OR of 2.40 (95% CI 1.19-4.83). 
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Table 1.  SCL11A1 polymorphisms according to M. tuberculosis genotype strain 
Polymorphism Allele or genotype 
frequency in pts infected  
with Beijing strains, 
n (%) 
frequency in pts infected  
with other genotype strains,   
n (%) 
P-value 
D543N G 172 (87.8) 360 (79.3) 0.010 
 A 24  (12.2) 94 (20.7)  
 GG 76 (77.6) 140 (61.7) 0.005a 
 GA 20 (20.4) 80 (35.2)  
 AA 2  (2.0) 7 (3.1)  
INT4 C 193 (98.5) 457 (98.9) n.a. 
 G 3  (1.5) 5 (1.1)  
3’UTR ins 104 (88.1) 227 (77.7) 0.016 
 del 14 (11.9) 65 (22.3)  
 ins/ ins 48 (78.0) 87 (59.6) 0.0013b 
 ins/del 12 (20.3) 53 (36.3)  
 del/del 1 (1.7) 6 (4.1)  
a GA and AA genotypes and b ins/del and del/del genotypes combined for analysis 
 
 
Discussion 
We report a strong association between host and bacterial genotype among 
tuberculosis patients in Indonesia. Patients carrying the most common genotypes 
of two different polymorphisms of SLC11A1 had a much higher chance of having 
tuberculosis caused by M. tuberculosis Beijing genotype strains than patients 
carrying other genotypes of these SLC11A1 polymorphisms. The human gene 
SLC11A1, formerly known as NRAMP1, is one of the most important genes 
reported to be associated with susceptibility to tuberculosis [6], but this is the first 
study to show a relation between SLC11A1 / NRAMP1 polymorphisms and one of 
the most prevalent and most successful M. tuberculosis lineages, the Beijing 
genotype family. 
 
 The SLC11A1 / NRAMP1 gene has been extensively examined for its 
association with tuberculosis.[6] It encodes a transmembrane protein which is 
exclusively expressed in macrophages and polymorphonuclear leukocytes. Upon 
phagocytosis, the SCL11A1 protein is rapidly recruited to the phagolysosomal 
membrane, where it mediates transport of iron (Fe2+) and other cations. In 
addition, SLC11A1 / NRAMP1 has pleiotropic effects on macrophage activation. 
Microbial pathogens, including M. tuberculosis, have homologues of SLC11A1. 
Iron is essential for biological functions, both for host immune defense and for 
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mycobacterial growth, and iron transporters of the human host and the 
mycobacterium compete intracellularly for iron [9]. SLC11A1 / NRAMP1 may also 
play a role in susceptibility to other intracellular pathogens including Salmonella. 
 
 We found that polymorphisms of SLC11A1 / NRAMP1 were associated with 
tuberculosis caused by strains belonging to one particular lineage of M. 
tuberculosis, the Beijing genotype family. This genotype family is one of the most 
widespread evolutionary lineages of M. tuberculosis [5]. All M. tuberculosis 
lineages have expanded in the modern era, but the Beijing family has had by far 
the largest population increase [10]. This suggests that Beijing strains may have a 
selective advantage over other M. tuberculosis strains. Indeed, Beijing strains have 
shown increased in vitro outgrowth in human monocytes and macrophages [11] 
and enhanced virulence and distinctive histopathology in animal models [12]. In 
human patients, Beijing genotype strains were associated with treatment failure 
and relapse [13], and with a higher chance to progress to active tuberculosis [14]. 
  
 The association between the Beijing genotype and polymorphisms of 
SLC11A1 / NRAMP1 suggests these polymorphisms may increase susceptibility to 
infection or active tuberculosis caused by this particular genotype of M. 
tuberculosis. Little is known about the functionality of the various polymorphisms 
of SLC11A1 / NRAMP1. However, it is very interesting that Beijing genotype strains 
were linked to the most common (and therefore evolutionarily the most 
successful) alleles of SLC11A1 / NRAMP1. These selected genotypes might lead to 
differences in transcription or translation of the SLC11A1-gene, or in different 
variants of the SLC11A1 protein which is involved in the bactericidal properties of 
macrophages. One might hypothesize that the Beijing genotype strains is better 
equipped to resist these selected variants of the SLC11A1 gene or protein than 
other M. tuberculosis strains. In-vitro studies comparing outgrowth of different M. 
tuberculosis strains in human macrophages with different SLC11A1 / NRAMP1 
genotypes might help to further explore this hypothesis. Besides a direct effect 
from SLC11A1 / NRAMP1, the genetic association we have found might also 
indicate linkage to other immune genes in the vicinity of SLC11A1 / NRAMP1, such 
as the interleukin-8 receptors IL-8RA and IL-8RB. However, SLC11A1 / NRAMP1 
seems a more likely candidate as so far no study has reported a significant role for 
the IL-8R in susceptibility to tuberculosis.  
 
 Globally, M. tuberculosis shows strong geographical differences. We have 
previously typed M. tuberculosis isolates from 897 patients originating from two 
different islands in Indonesia, Java and Timor [4]. Interestingly, a difference was 
found in the population structure of M. tuberculosis. The Beijing genotype family 
was found in 33.0% of patients in Java, versus 14.3% of patients in Timor. 
Inversely, in Timor, the EAI and LAM genotype families were predominant, while 
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strains belonging to these genotypes were uncommon in Java. One could 
speculate about the explanation for these geographic differences. First, it may be 
due to a “founder effect”, with an increased chance of finding a particular M. 
tuberculosis genotype family closer to where it originated. Secondly, the 
predominance of certain genotype families might be explained by an easier 
transmission or ‘escape’ from BCG-vaccination. However, our previous study did 
not support the latter hypothesis.[4] Finally, as suggested by our current study, 
particular mycobacterial lineages may have adapted to specific properties of the 
immune system in particular human populations (‘genetic co-evolution’). Similar 
to geographical phylogenetic differences (‘phylogeography’) of M. tuberculosis, 
the host immune genes also show geographical differences; we ourselves have 
shown a unique global distribution of two functional polymorphism of TLR4, one 
of the key pattern recognition receptors for a variety of pathogens, including 
mycobacteria [15]. Similar to TLR4, SLC11A1 / NRAMP1 has a strong geographical 
variation [6], which might account for (part of) the geographical variation of M. 
tuberculosis. Other host genes might be involved as well, and the Indonesian 
archipelago provides an excellent setting to further test the concept of human-
mycobacterial ‘co-evolution’ as both M. tuberculosis and the human host 
inhabiting the many islands most likely show substantial genetic variation. 
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Abstract 
The wide geographic distribution of one clade of Mycobacterium tuberculosis, the 
Beijing genotype, and its genetic homogeneity suggests that strains belonging to 
this genotype may have a selective advantage over other M. tuberculosis strains. 
This hypothesis was addressed by reviewing molecular-epidemiological, 
experimental and clinical studies. Beijing strains represent 50% of strains in East-
Asia and at least 13% of strains globally. Their emergence may be linked to BCG-
vaccination, which seems less protective against Beijing strains, and to (multi-) 
drug resistance which is associated with the Beijing genotype in many areas. 
Different animal models have shown Beijing strains to be more virulent, causing 
more histopathology, higher outgrowth and increased mortality. At a molecular 
level, Beijing strains have specific properties in terms of protein and lipid 
structures and their interaction with the human immune system. Finally, the 
Beijing genotype has been linked to polymorphisms in a human immune gene, 
suggesting the possibility of human-mycobacterial co-evolution. All in all, the 
Beijing genotype family may represent an evolutionary response of M. 
tuberculosis making it more difficult to control through vaccination or antibiotic 
treatment. More research is needed to further unravel the mechanisms 
underlying the emergence of M. tuberculosis Beijing genotype strains, and 
examine the implications for tuberculosis control. 
 
 
Introduction 
The Mycobacterium tuberculosis Beijing genotype, which was first described in 
1995 (1) is one of the most successful clades in the current worldwide 
tuberculosis (TB) epidemic (2-5). Initially, the Beijing genotype was recognized on 
basis of the highly conserved spoligo patterns and characteristic IS6110 restriction 
fragment length polymorphism (RFLP) patterns of M. tuberculosis isolates from 
the Beijing region and Mongolia (1). Since then, multiple studies have pointed out 
that the M. tuberculosis Beijing genotype strains have spread worldwide, are 
emerging in various areas, and often in association with (multidrug) resistance (2, 
3, 5). As Beijing strains from different geographic areas show a remarkable degree 
of genetic conservation in comparison to other M. tuberculosis strains, one may 
hypothesize that this genetic lineage has selective advantages over other 
genotypes of M. tuberculosis, and have started spreading relatively recently. 
Previous reviews have described the spread and phylogeny of Beijing genotype 
strains (3, 5, 6), but this is the first comprehensive review bridging molecular-
epidemiological, experimental and clinical studies related to these strains. If 
selection of Beijing strains and perhaps also other predominant genotypes 
represents the evolutionary response of M. tuberculosis to the major measures to 
fight tuberculosis, this may have serious implications for future plans on 
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tuberculosis control. Increased understanding of the mechanisms underlying the 
success of M. tuberculosis Beijing strains may enable timely measures to prevent a 
further re-emergence of tuberculosis. 
 
 
Literature search strategy 
The literature reviewed was derived from an electronic search using Endnote 
database derived from Pubmed with the key words: (mycobacterium 
tuberculosis[mh] OR tuberculosis[mh] OR mycobacterium tuberculosis[ti] OR m 
tuberculosis[ti] OR tuberculosis[ti]) AND (beijing[tiab] OR w-beijing[tiab] OR w-
strain[tiab] OR w-variant[tiab]). Only articles published in English were selected. In 
total 292 articles were traced using these search terms. Additional studies were 
identified by searching the reference lists from existing articles.  
 
Phylogeny of M. tuberculosis Beijing genotype strains 
Beijing genotype strains represent group 1 of the original grouping of Sreevatsan 
based on a limited number of single nucleotide polymorphisms (7), but are 
considered a grouping of the “modern” lineage of M. tuberculosis according to the 
grouping of the M. tuberculosis complex based on large sequence polymorphisms 
(8). The Beijing clade consists of at least two major groupings; the “typical and 
“atypical” Beijing strains (9-12). This distinction seems relevant, because these 
two lineages may have different properties (10), as will be discussed below. 
Beijing strains can also be subdivided in various evolutionary lineages through 
large sequence polymorphisms (LSPs), which can be  used to divide this family into 
four monophyletic subgroups on basis of Regions of Difference (RD)105, RD181, 
RD150, and RD142 (13). The Beijing genotype of M. tuberculosis has recently also 
been recognized as the major part of  the ‘East-Asian lineage’ (14, 15). 
 
Recognition and molecular typing of Beijing strains 
In 1995, the Beijing genotype strains were defined on basis of their highly 
conserved spoligo patterns, revealing an almost invariable hybridization to the 
last nine spacers of the 43 spoligotyping spacers, and characteristic multi-banded  
IS6110 RFLP patterns (1). In terms of numbers, a minor sub-lineage of the Beijing 
genotype family, that caused multiple outbreaks among HIV positive patients in 
prisons and hospitals in New York in the 1990s was designated the “W” strain 
(16). However “W” strains only constitute a small branch on the phylogenetic tree 
of the Beijing genotype strains (11), and worldwide many of such phylogenetic 
branches exist. Therefore, we will refer to ‘Beijing strains’ as an indication of the 
worldwide Beijing genotype family as a whole.  
Numerous techniques have been used to identify Beijing genotype strains. In 
2004, based on extended study, M. tuberculosis Beijing strains were defined as 
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strains hybridizing to at least three of the nine spacers 35 to 43 in the first 
generation spoligo spacers and absence of hybridization to spacers 1 to 34 (9). In 
addition, a standard set of 19 IS6110 RFLP patterns of Beijing strains was made 
available (www.tuberculosis.rivm.nl) to help identify  Beijing strains in a IS6110 
RFLP database. Rapid identification of Beijing strains is also possible in 
MIRU/VNTR typing by mycobacterial interspersed repetitive unit locus 26 (17). 
The second generation spoligotyping was able to distinguish different types of 
Beijing strains (18). It is not yet clear how this finding fits in with analysis of other 
phylogenetic markers. In the USA, a “W-Beijing poly-probe” assay was developed 
which targets include the genomic dnaA-dnaN and NTF region and the Direct 
Repeat locus, that are also used in  spoligotyping. This method is highly sensitive 
and specific in the detection of Beijing strains among other M. tuberculosis strains 
(19). In 2005, a real time PCR which differentiates Beijing and non-Beijing strains 
was described (20).    
Several methods with more discriminatory power have been proposed for 
epidemiological studies of Beijing strains. IS6110 RFLP typing initially had a higher 
discriminative power among Beijing strains than standard VNTR typing (21, 22), 
even with the use of additional loci selected in the latest 24-loci VNTR typing. 
However, more discriminatory power for Beijing strains has been established 
using 14 particular VNTR loci in addition to the exact tandem repeats (ETR) loci A 
to E (21). A 12-locus VNTR typing used in Japan is reported being superior in 
typing of Beijing strains to the 15-locus and 24-locus typing, and therefore seems 
the best tool for genotyping of M. tuberculosis isolates in areas where Beijing 
family strains are predominant (23). 
In conclusion, Beijing strains from widespread geographic areas are genetically 
highly conserved. On the basis of various genetic markers we can clearly define M. 
tuberculosis Beijing strains and recognize its sublineages and individual strains.  
 
Current spread of Beijing genotype strains worldwide  
The fourth International Spoligotyping Database (SpolBD4), which classified 
39,295 strains of M. tuberculosis from 141 countries into 62 clades/lineages, 
indicated that the Beijing and the Beijing-like strains represent about 50% of 
strains in East Asia, and 13% of the isolates globally (4). However, to date, 
spoligotyping has mostly been used in western countries, and data from many 
high prevalence settings, especially in South-East Asia and the former Soviet 
Union states, are missing. As a result, the true contribution of Beijing strains to 
the worldwide epidemic may exceed 30%. In the worldwide survey conducted 
within the framework of a European project, the proportion of TB attributable to 
the Beijing genotype varied significantly between areas: the prevalence in Asia 
was high, apart from the Indian subcontinent, increasing further east; low in parts 
of Africa, Latin America, and Western Europe; intermediate in the United States 
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and Cuba; low in Eastern Europe (other than the former Soviet Union); and low in 
the Middle East (2).  
Several lines of evidence show that the Beijing genotype is emerging. First, a time 
trends analysis among non-immigrants from studies covering more than three 
years revealed a slight increase in the occurence of Beijing genotype in all 
Western European countries (although only reaching statistical significance in The 
Netherlands) (2). Emergence of Beijing strains in this large study was defined as 
significant correlation between the Beijing genotype and low age. Young age is 
suggestive of active spread as was confirmed with DNA fingerprinting in the 
Netherlands, which showed that unique DNA fingerprints are associated with 
advanced age and DNA fingerprint clusters with young age (24). Whether this 
difference in the natural history of a tuberculosis in different age categories can 
be extrapolated to high prevalence countries remains to be proven.  
As another approach to investigate possible dynamics in the population structure 
of M. tuberculosis, archived specimens have been used. In South Africa 
spoligotyping was applied to paraffin-embedded clinical material from 
consecutive time periods. In this area, Beijing strains were absent in histological 
samples from the period 1930–1965, rare in samples from 1966–1995, and 
increasingly common in samples from the period 1996–2005. The proportion of 
Beijing strains causing TB in children increased from 13% in 2000 to 33% in 2003 
(25). Finally, a recent study determined the time of divergence, population 
diversity and spread of M. tuberculosis complex by MIRU-typing of a collection of 
355 strains representing all well-defined primary branches of M. tuberculosis 
complex (26). Compared to other clades, the Beijing genotype displayed the 
largest population increase taken place in the last 180 years.  
In conclusion, the Beijing genotype is the most predominant M. tuberculosis 
genotype in the world and there is clear evidence for its increase in certain areas.  
 
Factors contributing to the global emergence of M. tuberculosis Beijing strains 
The emergence of Beijing genotype may be due to natural selection, possibly 
skewed by the two major measures against TB in the last century: Mycobacterium 
bovis BCG vaccination and anti-TB treatment (27). BCG vaccination may be less 
protective against Beijing genotype strains than against other strains. Similarly, 
anti-TB treatment maybe less effective in eradicating Beijing strains than other 
strains. However, it has been suggested that the spread of Beijing strains already 
started long before the introduction of vaccination and antibiotic treatment (26), 
which would suggest that these strains have an intrinsic advantage over other M. 
tuberculosis genotypes in terms of transmission, progression from latent to active 
tuberculosis, acquisition of drug resistance or disease chronicity (28). Specific 
characteristics of this genotype may render it more virulent or better capable of 
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resisting or evading the human host immune system. We will discuss the different 
possibilities in more detail. 
 
Beijing genotype as an escape variant of BCG vaccination 
BCG vaccination may be a selective force favouring the spread of the Beijing 
genotype. In a BALB/c mouse (29) and a rabbit model (30) BCG vaccination was 
less protective against subsequent infection by Beijing strains than to infection 
with strains of other lineages. Another study, using C57BL/6 mice, was unable to 
confirm strain-specific resistance to BCG-vaccination (31). Newly developed 
candidate vaccines might be more protective; for instance the recombinant 
Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin 
(ΔureC hly+ rBC) vaccine induced a strong protection against infection by Beijing 
strains while parental BCG failed to do so (32). If BCG vaccination is indeed less 
protective against infection with Beijing strains, one would expect to find a higher 
proportion of Beijing strains among BCG vaccinated subjects compared to non-
vaccinated individuals. This was indeed found in a study in Vietnam published in 
the year 2000, although the correlation was not statistically significant (33). 
Subsequent studies did not find any association (34-37). However when Beijing 
genotype isolates from The Netherlands and Vietnam were subdivided into a 
‘typical’ and ‘atypical’ lineage, typical Beijing strains were indeed isolated more 
frequently from BCG-vaccinated than non-BCG-vaccinated persons (10). We may 
therefore conclude BCG vaccination is less protective against that particular 
lineage of the Beijing strains and may thereby promote selection of these strains. 
The underlying mechanism for this observation are still unclear.  
 
M. tuberculosis Beijing strain and drug resistance 
In the current era of tuberculosis-treatment, drug resistance may drive the spread 
of a particular M. tuberculosis genotype. Epidemiological studies have examined 
the association of drug resistance with Beijing strain (Table 1). A comprehensive 
review on this issue revealed four patterns: 1) endemic prevalence of Beijing 
strains, not associated with drug resistance 2) epidemic, associated with drug 
resistance 3) epidemic but drug sensitive and 4) very low level or absent (2). The 
difference between these patterns may be related to the variation in treatment 
regimens, compliance to treatment protocols, and different quality of drugs. 
Alternatively, it may be due to spread of different and not yet distinguished sub-
lineages of the Beijing strains.  
With regard to multidrug resistant (MDR) tuberculosis, it was recently shown that 
in countries with a high prevalence of Beijing strains, such as Azerbaijan, Ukraine, 
Uzbekistan, Estonia, Latvia, Lithuania, Mongolia and China, more than 5% of new 
tuberculosis cases involve MDR-TB (38). In Europe, in the period of 2003 to 2007, 
a total of 2.494 MDR-TB isolates from 24 European countries were subjected to 
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IS6110 RFLP typing to investigate transmission of MDR-TB accross Europe (39) 
About 39% of the examined cases were attributable to clusters and 84% of these 
likely transmissions were caused by Beijing strains. This is remarkable, because 
only 6-7% of the susceptible strains in Europe belong to the Beijing genotype. 
Strikingly, one very large cluster of 174 MDR-TB cases associated with the spread 
of one Beijing strain, was identified.  
Logically, many researchers have examined possible associations between the 
Beijing genotype and the distribution of mutations in genes underlying resistance 
to anti-tuberculosis drugs (Table 2). Genotypic studies looking at katG315, the 
most important mutation encoding for resistance to INH, did indeed report higher 
mutation rates among Beijing strains (20, 40, 41). This is less clear for mutations in 
the rpoB gene, which account for >90% of drug resistance to rifampicin, as studies 
comparing Beijing and other genotype strains have examined the distribution 
(exact genetic location), rather than the overall frequency of rpoB-mutations. 
Some researchers found that the Beijing strains did not show significant 
differences in frequency of the most commonly encountered mutations in the 
rpoB gene compared to non-Beijing genotypes strains (42, 43). A significantly 
higher proportion of the rpoB S531L mutation in Beijing genotype strains was 
found in Germany and Russia. (20, 40), while in Korea researchers found the 
opposite (41). For mutations in the embB gene,  associated with ethambutol 
(EMB) resistance, a study in Russia found that Beijing strains had a significant 
higher rate of mutation in embB306 compared to non-Beijing strains, irrespective 
of their phenotypic susceptibility profiles. The Beijing genotype thus seems to 
acquire the most frequently arising (resistance) mutations more readily than do 
other genotypes, not only in embB306, but also in rpoB531 and katG315. On the 
other hand, EMB-susceptible, but MDR-TB, Beijing strains and non-Beijing strains 
showed similar rate of embB306 mutations. The author therefore hypothesized 
that an emergence of ‘silent’ embB306 mutations in EMB-susceptible strains may 
be predetermined not by the intrinsic genome structure (IS6110 RFLP profile) but 
rather by the previously acquired multidrug resistance (44). No studies have been 
published on associations of the Beijing genotype with other drug resistance 
genes like pncA, gyrA and rpsL/rrs, which are responsible for resistance against 
pyrazinamide, fluoroquinolone respectively streptomycin. Taking this information 
together, it is clear that more studies are needed to clarify this important issue.    
From a mechanistic point of view, there are several explanations for a possible 
association between the Beijing strains and drug resistance. First, Beijing 
genotype strains may show a higher mutation frequency. It was previously found 
that Beijing strains have alterations in so-called ‘putative mutator genes’, resulting 
in altered DNA-repair and an increased mutation rate (45, 46). However, more 
recently it was found that the M. tuberculosis MutT2 (MtMutT2) gene plays a role 
in general slowdown of metabolism when mycobacteria are deprived of essential 
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nutrients (47). Later studies on 3R genes (DNA repair, recombination and 
replication genes) revealed that also strains of other M. tuberculosis genotypes 
have mutations in these genes and it is therefore not yet clear whether alterations 
in these genes play a significant role in the adaptation of Beijing strains (48). A 
second hypothesis is that specific characteristics of the cell-wall structure of 
Beijing strains lead to suboptimal intracellular concentrations of anti-tuberculosis 
drugs and acquisition of drug resistance (49-51). Both these hypotheses need 
further proof: in vitro, Beijing strains did not appear to acquire drug resistance 
more easily when exposed to anti-tuberculosis drugs (45, 52). Alternatively, 
increased virulence might lead to more persistent infections and treatment 
failures with prolonged exposure of Beijing strains to anti-tuberculosis drugs, and 
therefore more time to develop resistance.  
In summary, many but not all epidemiological studies have shown associations 
between the Beijing genotye and drug resistance mutations. So far however, 
experimental studies and in-depth molecular studies have failed to reveal the 
underlying mechanisms for this association (as summarized in Table 1). 
 
Table 1.  Approaches to examine the relation of M. tuberculosis Beijing genotype with 
drug resistance  
Biochemical characteristics and immunogenecity of the Beijing genotype 
M. tuberculosis Beijing genotype strains may also be more virulent, as a result of 
intrinsic biochemical properties and their interaction with human host defense. In 
vitro studies have focused on protein expression, lipid structures and 
‘immunogenecity’ of different M. tuberculosis genotypes (Table 2).  
In a proteomic study, Beijing strains showed an increased expression of a-
crystallin  protein homolog or the 16-kDa protein, a M. tuberculosis virulence 
factor, and decreased expression of Hsp65, PstS1, and the 47 kDa protein 
compared to other clinical isolates and control strain H37Rv (53). Another 
proteomic study using human monocytic cell line U-937, showed that two 
proteins, Mb1363 (probable glycogen phosphorylase GlgP) and MT2656 
(Haloalkane dehalogenase LinB), had a higher expression after phagocytosis of M. 
No Approach Finding Reference 
1. 
Epidemiological studies of 
phenotypic drug resistance 
associations with drug resistance in certain parts of 
the world, but not all 
(2) 
2. Mutations in drug resistance genes 
higher rates of mutations reported for rpoB codon 
S531L, katG, embB 
different distributions of rpoB-mutations 
(20,40,41) 
3. In vitro exposure to anti-TB drugs no difference in acquisition of drug resistance (52) 
4. 
Examination of underlying molecular 
mechanisms 
more mutations in 'mutator genes' reported by some 
but not all 
 
(45,46) 
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tuberculosis K-strain (a Beijing strain) compared to H37Rv, H37Ra and M. bovis 
BCG. It can be hypothesized that highly expressed GlgP protein in K-strains 
induces macrophage migration inhibitory factor (MIF) activation, which may be 
advantageous for the bacteria. Although the role of these proteins is not clear yet, 
they may have a critical function in the pathogenesis of tuberculosis (54). 
Beijing strains also display differences in the cell-wall associated lipid structures. 
In vitro Beijing strains produce a biologically active lipid- a polyketide synthase-
derived phenolic glycolipid (PGL), which was found to inhibit the release of pro-
inflammatory mediators (55). In a more recent study, Beijing strains were found 
to accumulate large quantities of triacylglycerides in an in vitro aerobic culture. A 
particular glycolipid (PGL-tb), associated with lethal infection in animal models 
(55), was overexpressed in Beijing strains (50). Its expression coincided with 
upregulation of Rv3130c, a member of the DosR-controlled regulon of M. 
tuberculosis, which may confer an adaptive advantage for growth in 
microaerophilic or anaerobic environments during infection and thus may be 
related to the spread of this strain (50). However, PGL-tb was only synthesised by 
a subset of Beijing strains, so it is unlikely this is the only virulence factor.  
Another hypothesis is that Beijing genotype strains induce a different immune 
response, or undermine an effective host response. This has been the focus of in 
vitro research and animal studies (Table 2). Infection of human monocytic THP-1 
cells with Beijing genotype strains induced a lower production of several cytokines 
such as tumour necrosis factor-alpha (TNF-α), interleukin (IL)-6 and IL-12p40 
compared to other strains (56). On the other hand, macrophages infected with 
Beijing isolates expressed higher levels of mRNA for iNOS, IL-1b, TNF-α, IL-12 
cytokines and lower levels of IL-10 compared to cells infected with other genotype 
(57). This expression pattern has been associated with infection control, but 
during in vivo infection with Beijing strains progression to chronic phase was 
absent (57). Macrophages stimulated with lipid fractions of Beijing strains had a 
higher production of TNF-α  and IL-10, but down regulation of TLR2, TLR4 and 
MHC class II expression  (58). In contrast, lipids from a M. tuberculosis canetti 
strain induced lower amounts of TNF-α  and IL-10, and upregulation of TLR2 and 
TLR4, without modifying MHC class II expression (58). 
The highly virulent Beijing (‘K’) strain induced significantly higher levels of necrotic 
cell death rather than apoptosis in THP-1 cells than did H37Rv bacteria. These 
results suggest that Beijing strains keep cellular apoptosis as a host defense 
mechanism to a minimum and induce necrosis in macrophages (56). 
 
Beijing genotype strains in animal models 
Animal models indicate that Beijing genotype strains are more virulent and more 
effectively resist or evade the host immune response. BALB/c mice intratracheally 
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injected with Beijing strains showed more histopathology, bacterial outgrowth 
and higher and earlier mortality compared to animals infected with H37Rv and 
other genotype strains (29). This coincided with early TNF-α and inducible isoform 
of nitric oxide synthetase (iNOS) expression (29). 
Similarly, when  BALB/c mice were challenged with 19 different M. tuberculosis 
strains of 11 major genotype families, Beijing strains induced more severe 
histopathology and higher mortality (59). In a rabbit model, central nervous 
system infection with HN878 or W4 resulted in higher bacillary loads in the 
cerebrospinal fluid and brain, increased dissemination of bacilli to other organs, 
persistent levels of TNF-α, higher leukocytosis, and more-severe clinical 
manifestations compared the M. tuberculosis clinical isolate CDC1551 (a highly 
immunogenic strain) (51). Also in B6D2/F1 mice these same Beijing strains HN878 
and W4 strains induced higher mortality compared to the highly transmissible 
strain CDC1551, coinciding with higher levels of type I IFNs,  lower levels of TNF-α 
and IL-12 and reduced T cell activation (60). Intrathecal injection of BALB/c mice 
by a Beijing strain induced a twofold higher percentage of apoptotic activated 
macrophages than mice infected by H37Rv, and earlier progressive pneumonia 
which contained numerous macrophages, with vacuolated cytoplasm. Vacuolated 
macrophages might induce apoptosis of Th1 cells which favors disease 
progression, and is related to the virulence of the mycobacterial strains (61). 
There are also indications in animal studies that the immunological response after 
infection by Beijing strains is less adequate than after infection by other strains 
(29, 30, 59). This could affect the required synergistic effect of the immunological 
response of a patient and drug treatment to cure a patient from tuberculosis, and 
create a situation of prolonged time to sputum conversion which in turn increases 
the risk of development of  drug resistance.   
Put together, there is clear evidence that Beijing strains show altered expression 
of proteins, glycolipids and triglycerides, which may contribute to increased 
virulence, or to evasion or suppression of protective host defense mechanisms. 
However, no conclusive evidence has been put forward to explain the overall 
success of Beijing strains in circumventing the BCG-induced immunity or enabling 
the development of resistance.  
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Table 2.  Biochemical characteristics, immunogenicity and virulence of M. 
tuberculosis Beijing genotype strains.                                              
 Experimental Approach 
Control Strain 
used 
Findings associated with Beijing 
genotype strains Interpretation Reference 
Biochemical characteristics  
 
Proteomics F 23 strain,  H37Rv 
↑ of a-crystallin 
↓ of Hsp65, PstS1, 47 kDa protein 
Increased virulence  
Evasion of  host immune response (53) 
 Lipid 
expression 
CDC1551, 
NHN5 
↑ polyketide synthase-derived phenolic 
glycolipid (PGL)  
lower release of inflammatory 
mediators (55) 
 Lipid 
expression;  
gene 
expression 
H37Rv 
 
↑ triacylglycerides (TAG)  
↑ DosR regulon gene 
increased capability for latency and 
transmission. 
↑  survival within host tissues. 
(50) 
 
Proteomics 
 
H37Rv,H37Ra, 
Mtb. bovis 
BCG 
↑ Mb1363 (probable glycogen 
phosphorylase GlgP),  
↑ MT2656 (Haloalkane dehalogenase 
LinB)  
Not yet determined (54) 
Immunogenicity  
 Infection of 
murine 
macrophages  
Canetti, H37 
Rv  
↑ mRNA for iNOS, IL-1b, TNF- α, IL-
12  
↓ IL-10 
Pro-inflammatory cytokine response  (57) 
 Lipid fraction 
vs human 
monocyte-
derived 
macrophages 
H37Rv, Canetti 
↑ TNF- α, and IL-10,   
↓TLR2, TLR4 and MHC class II 
expression 
Pro-inflammatory cytokine response 
Reduced pattern recognition and 
antigen presentation 
(58) 
 Infection of 
human 
monocytic 
THP-1 cells 
H37Rv 
↓ TNF-α, IL-6 and IL-12p40  
↑ necrotic cell death 
Less apoptosis and more necrosis of 
infected macrophages (56) 
Virulence in animal models  
 
Intrathecal 
injection 
BALB/c mouse 
H37Rv  
↑ extensive pneumonia, early but 
ephemeral TNF- α, inducible (iNOS) 
expression, earlier mortality,  
↑ bacillary load 
increased virulence  (29) 
 Intrathecal 
injection 
BALB/c mouse 
H37Rv , 
Canetti 
severe pathological response, 
↑mortality, ↑bacillary load  increased virulence (59) 
 
intracisternal 
injection in 
rabbits 
CDC1551 
↑ bacillary load, ↑ dissemination of 
bacilli to other organs, persistent levels 
of TNF– α, ↑  leukocytosis, and more-
severe clinical manifestations 
increased virulence (30) 
 
Aerosol 
B6D2/F1 mice CDC1551 
↑ type I IFNs, ↓ TNF- α, IL-12, ↓ T 
cell activation,  
↓ survival 
increased virulence (60) 
 intratracheal 
injection 
BALB/c mice  
H37Rv 
↑The peak progressive increase of 
apoptotic Th1 lymphocytes 
 
increased virulence (61) 
↑= higher/increased/large/overexpressed/more, ↓= decreased/lower/downregulated 
Beijing lineage family included: HN878, Beijing strain 210,W10,W4, K-strain 
TBM= tuberculous meningitis 
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Clinical phenotype of Beijing strains: patient studies 
If Beijing strains are more virulent one would expect a higher proportion of 
infected patients to develop active tuberculosis. This hypothesis is supported by a 
study in the Gambia. In a cohort of tuberculosis patients and household contacts, 
transmission rates between patients exposed to M. tuberculosis and M. africanum 
were similar, but rates of progression to disease were significantly higher in 
contacts exposed to a Beijing family strain (28). Differences between Beijing 
genotype and other M. tuberculosis complex genotypes were less clear, and the 
overall number of investigated cases was relatively small. Still, this is a promising 
hypothesis which needs further exploration.   
Taking the relative success of Beijing strains into consideration one might also 
expect that patients infected with Beijing genotype strains present with a 
different or more severe clinical phenotype. Several studies have investigated this 
hypothesis. In a small study in Indonesia, patients infected with Beijing genotype 
strains more often developed fever unrelated to disease severity during the first 
stage of treatment (62), but this was not confirmed in studies from Singapore and 
Russia, which actually reported less fever and and night sweats in patients 
infected with Beijing strains (17, 57). 
Studies comparing chest X-ray abnormalities of patients infected with Beijing and 
other genotype strains have also met with conflicting results. In Russia and 
Singapore  associations were found between the extent and severity of 
radiological abnormalities (35, 37), while in The Netherlands, such associations 
were not found (34). However, it could be that the correlation between Beijing 
bacteria and resistance is much stronger in Former Soviet Union states than in The 
Netherlands, resulting in more persistent infections and, hence, more lung 
damage. A high bacterial load in sputum increases the risk of transmission but so 
far, no study has reported associations between bacterial load in the lung/sputum 
of patients infected with different genotype strains. 
If Beijing strains are more virulent, this might also be reflected in a higher 
proportion of patients with disseminated disease. In Arkansas patients with 
extrapulmonary TB were found to have three times more likely to be infected 
with Beijing strains after correcting for potential confounders, however, in 
children there was no evidence of such an association in Cape Town South Africa 
(63). In Vietnam, HIV-infected patients with meningeal tuberculosis caused by 
Beijing strains had a shorter duration of illness prior to presentation, and a lower 
cerebrospinal fluid leukocyte count than patients with meningitis caused by other 
M. tuberculosis genotype strains (64). In conclusion, in some but not all studies, 
patients infected with M. tuberculosis Beijing strain showed clinically more severe 
and more rapid disease progression than patients infected by non Beijing strain. 
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Co-evolution of the Beijing genotype and humans 
There must be an explanation for geographic differences in the population 
structure of M. tuberculosis. First, this may be due to a “founder effect”, with a 
higher chance of finding a particular genotype family closer to where it originated. 
The population structure may also be related to environmental factors or 
differences in TB control. Second, particular M. tuberculosis lineages may have 
adapted to specific properties of the immune system in particular human 
populations (‘genetic co-evolution’). Similar to geographical phylogenetic 
differences (‘phylogeography’) of M. tuberculosis, the host immune genes also 
show geographical differences. For instance, functional polymorphism in Toll-like 
receptor (TLR)4, one of the primary ‘pattern recognition receptors’ (PRR) for M. 
tuberculosis (65), show a unique global distribution (66). Several lines of research 
support the notion that the geographic variation of M. tuberculosis and the 
human host genotype are related. Particular M. tuberculosis lineages have shown 
preferential spread in particular patient populations (14, 67). However, people of 
the same background or immigration group tend to live together in a foreign 
country thereby spreading their ‘native strains’ to other people of the same 
ethnicity. On the other hand, preferential spread of a particular genotype in a 
specific ethnic group may also be the result of co-evolution of host and pathogen. 
However, so far only one study has tried to show a direct association between 
genetic characteristics of tuberculosis patients and the genotype of M. 
tuberculosis isolates. In this study in Vietnam it was shown that a particular 
mutation in TLR2, another key PRR for M. tuberculosis (65), was more common in 
patients infected with M. tuberculosis Beijing genotype strains than among 
patients infected with other genotype strains, suggesting that the outcome of 
exposure to M. tuberculosis can depend on both the human and bacterial 
genotype (68). These findings provide further support for the hypothesis that 
evolutionary adaptation of particular M. tuberculosis lineages to certain human 
populations contributes to the marked geographical variation M. tuberculosis 
genotypes, and that host gene polymorphisms, especially related to immune 
recognition of M. tuberculosis, confer increased susceptibility of certain 
populations to the Beijing genotype. Clearly, this concept of ‘genetic co-evolution’ 
needs further investigation. 
 
 
Conclusion 
Worldwide, there is an emergence of a genetically conserved genotype of M. 
tuberculosis; the Beijing strains, often in association with (multi-)drug resistance. 
This global change in the population structure of M. tuberculosis is most likely 
driven by man-made factors (antibiotic treatment and vaccination) and perhaps 
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also linked with intrinsic mycobacterial characteristics, as outlined in this review 
and summarized in Table 3. The Beijing genotype family has been studied most 
extensively so far. However, other predominant genotypes like the Haarlem and 
African genotypes may undergo similar changes. An evolutionary response of M. 
tuberculosis towards a new population of bacteria that are more difficult to treat 
and have a higher ability to circumvent vaccination will hamper our efforts to 
control tuberculosis. Therefore, there is an urgent need to better understand the 
mechanisms underlying the emergence of M. tuberculosis Beijing genotype 
strains, and examine the implications for tuberculosis control. 
Table 3.  Mechanisms contributing to the emergence of M. tuberculosis Beijing 
genotype strains 
No Mechanism Evidence Implication References 
1. 'escape' from BCG-vaccination 
BCG vaccination less protective against 
subsequent Beijing strains infection in animal 
models 
Typical Beijing strains more frequently from 
BCG-vaccinated patients  
more latent infection 
 
more active TB 
(29,30) 
 
(10) 
2. adaptation ('co-evolution') to human immune genes 
Association of TB caused by Beijing 
genotype with TLR-2 polymorphism in 
Vietnam  
more active TB (68) 
3. more progression from latent infection to active TB 
More active TB among case-contacts of 
patients infected with Beijing genotype in The 
Gambia  
more active TB (28) 
4. more drug resistance 
association of Beijing genotype with MDR-TB 
and drug resistance mutations in rpoB, katG, 
embB in cross-sectional studies  
slower or absent response 
to TB-treatment  (20,40,41,44) 
5. higher virulence Higher outgrowth and lower survival in animal studies  
more progression and 
chronicity of TB (with or 
without antibiotics); higher 
bacterial load 
 (59,60,61) 
6. higher immunogenicity 
Stronger pro-inflammatory cytokine 
response; more necrosis of infected 
macrophages 
more cavitary disease with 
higher sputum bacterial 
load 
 (29,30,59) 
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Tuberculosis remains a major global health problem with an estimated 9.3 million 
new cases (139 per 100.000 people), including 1.37 million (15%) cases among 
HIV-positive people. In that same year, there were an additional 1.16 million 
relapse or retreatment TB cases. Multi-drug resistant (MDR) TB, which is defined 
as TB resistant to at least isoniazide (INH) and rifampicin, occurred in more than 
half a million people worldwide (1). These data clearly show that TB is far from 
being eradicated, despite the availability of BCG vaccination and effective anti-TB 
treatment. Mycobacterium tuberculosis has adapted to TB-treatment (developing 
drug resistance), to vaccination, or to the immune system of host, and this 
adaptation has contributed to its evolutionary success. 
Since the development of molecular methods, it is clear that M. tuberculosis is not 
a single entity. To distinguish M. tuberculosis in more detail, several genotyping 
methods have been introduced. The most widely used techniques are restriction 
fragment length polymorphism (RFLP), spoligotyping and mycobacterial 
interspersed repetitive-unit–variable-number tandem repeat (MIRU-VNTR) typing  
(2-4). These methods allow us to detect certain M. tuberculosis genotypes, follow 
transmission between individual patients, study ‘outbreaks’ of tuberculosis, and 
distinguish relapse from re-infection in patients with recurrent tuberculosis. In 
addition, these methods have helped us to study the genetic relations 
(‘phylogenetics’) or dynamics of the population structure of M. tuberculosis 
complex. By MIRU typing, two major lineages have been defined, called clade 1 
and 2. A further geographic sub-structuring within clade 1 revealed distinct 
branches for the African (Uganda, Cameroon and S), Asian (Beijing and CAS), Latin 
American-Mediterranean and African-European populations (X, Ghana and 
Haarlem). Clade 2 consists of both animal and human pathogenic isolates. All M. 
tuberculosis complex populations from human sources have shown markedly 
constant expansion rates in the last 180 years. But the Beijing genotype family 
which is one of the most successful lineages at present, has shown by far the 
largest increase in population size (5). The Beijing clade comprises at least 2 major 
subgroups, which share the characteristic spoligotype pattern (6-8): typical and 
atypical Beijing strains. Typical (“modern”) (8, 9) Beijing strains, showed highly 
similar, multicopy IS6110 restriction fragment length polymorphism (RFLP) 
patterns (10), while atypical (“ancestral”) (8, 9) Beijing strains more closely 
resemble the common ancestor of the Beijing clade (6-8). 
Using spoligotyping for molecular genotyping, we found that the M. tuberculosis 
Beijing genotype is the predominant clade in Indonesia. The success of Beijing 
strains may be related to their ability to withstand tuberculosis treatment, or 
evade the host immune response. This is the focus of this thesis.  
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Summary of research findings  
M. tuberculosis Beijing strains are highly prevalent in Indonesia, accounting for 
one third of population structure of M. tuberculosis complex. This is the first study 
of its kind in Indonesia which has a third highest rank of TB after India and China. I 
will now summarize the main findings of each chapter.  
 
Before implementation, as this is the first molecular technique in a clinical 
laboratory in Bandung, Indonesia, I optimized spoligotyping for different sample 
sources by examining its reproducibility. In Chapter 2 I found that spoligotyping 
described  by Kamerbeek et al (11) when it was used for non cultured M. 
tuberculosis, showed weak hybridization signals in some of the spacers. Therefore, 
we optimized our PCR mixture for direct spoligotyping of M. tuberculosis complex 
DNA in clinical samples by using a different concentration MgCl2, Tris-HCl, and 
PCR-primers (12). The use of this adjusted protocol yielded complete 
spoligotyping patterns for M. tuberculosis complex in clinical samples as 
compared with cultured bacteria. 
 
The population structure of M. tuberculosis in Indonesia, and the prevalence of 
the Beijing genotype is the basis for this thesis. In Chapter 3 the distribution of 
various M. tuberculosis genotypes among almost 900 patients from two different 
islands was determined. A high degree of genetic diversity was observed among 
M. tuberculosis strains, and a significant difference was found in the geographical 
distribution of genotype families. The predominant Beijing genotype family was 
isolated from 33% of patients from West Java versus 14.3% of patients from 
Timor, with two other genotype families (East African-Indian and Latin American / 
Mediterranean) being more prevalent in Timor.  
 
Increased rates of drug resistance might be one possible explanation for the 
predominance of M. tuberculosis Beijing genotype strains. In Chapter 4 I 
examined the association between M. tuberculosis Beijing genotype and drug 
resistance gene mutations among isolates from over 300 Indonesian tuberculosis 
patients. Sequencing of the rpoB-hotspot region and PCR for mutations in katG 
codon 315 and embB codon 306 was performed on phenotypically drug-resistant 
and –sensitive patient isolates. More drug resistance gene mutation were found 
in M. tuberculosis Beijing strains compared to non-Beijing strains, both for rpoB 
(33.3% versus 18.7%), katG315 (18.5% vs. 12.8%), and embB306 (16.5% vs. 6.1%). 
This was not due to an overrepresentation of Beijing strains among patients with 
a history of previous TB-treatment: among newly treated patients, drug resistance 
gene mutations were also strongly associated with the Beijing genotype.  
Animal studies have shown that M. tuberculosis Beijing genotype are more 
virulent compared to other strains, but data from clinical studies are scarce. In a 
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prospective cohort study in Chapter 5, we examined if the Beijing genotype is 
associated with severity of tuberculosis and treatment failure in Indonesia. No 
clear association was found between Beijing genotype and disease presentation 
or chest X-ray abnormalities, but approximately twice as many patients who were 
initially infected with a Beijing genotype strain had a positive sputum culture after 
six months therapy. This effect was not due to a higher rate of drug resistance 
among Beijing strains. Multiple regression showed that the Beijing genotype was 
an independent risk factor for a tuberculosis treatment failure. 
 
After treatment of tuberculosis, patients remain at increased risk of death, 
recurrent TB, and permanent lung damage. The long-term effects of pulmonary 
TB caused by Beijing strains and non-Beijing strains was compared in Chapter 6. 
One hundred and forty six ex-TB patients and 178 matched healthy controls from 
a previous case-control study were re-examined 1.5 to five years later. Ex-TB 
patients initially infected with M. tuberculosis Beijing genotype strains had a 
higher risk of reccurent TB than ex-TB patients infected with other genotype 
strains. Lung function impairment was much more pronounced among 18 ex-TB 
patients initially infected with M. tuberculosis Beijing genotype strains compared 
to 33 ex-TB patients initially infected with strains belonging to other genotypes.  
Differences in host immune genes may confer increased susceptibility to 
particular M. tuberculosis genotypes, and this might be another contributing 
factor to the evolutionary success of Beijing strains. In Chapter 7 we examined 
this hypothesis by typing the human gene SLC11A1, formerly called NRAMP1 
(natural resistance-associated macrophage protein 1), which has been linked with 
susceptibility to tuberculosis in many settings, in 331 pulmonary tuberculosis 
patients. M. tuberculosis Beijing genotype, which was one third of all isolates, was 
strongly associated with two polymorphisms in SLC11A1; the D543N G allele and 
the 3’UTR ins/ins genotype.  
Indeed, certain genotypes of two different polymorphisms of SLC11A1 were 
strongly associated with infection with M. tuberculosis Beijing genotype strains. 
 
The wide geographic distribution of M. tuberculosis Beijing genotype strains, and 
its genetic homogeneity suggests that strains belonging to this genotype may 
have a selective advantage over other M. tuberculosis strains, as is supported by 
the studies presented in chapters 3-7. In Chapter 8 I reviewed all molecular-
epidemiological, experimental and clinical studies related to the Beijing genotype 
that have been published so far. From the scientific literature, it appears that the 
evolutionary success of Beijing genotype strains may be linked to BCG-vaccination, 
which seems less protective against Beijing strains, and to (multi-) drug resistance 
which is associated with the Beijing genotype in many areas. In addition, different 
animal models have shown Beijing strains to be more virulent, causing more 
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histopathology, higher outgrowth and increased mortality. At a molecular level, 
Beijing strains have specific properties in terms of protein and lipid structures and 
their interaction with the human immune system. Besides our finding that the 
Beiijing genotype was linked with polymorphisms in SLCA1/NRAMP1, Beijing 
strains  have also been linked to polymorphisms in the gene encoding for TLR2, an 
important pattern recognition receptor for mycobacteria, suggesting the 
possibility of human-mycobacterial co-evolution. In conclusion, the Beijing 
genotype family may represent an evolutionary response of M. tuberculosis 
making it more difficult to control through vaccination or antibiotic treatment.  
 
 
General Discussion 
Based on the separate studies as summarized above, we can make two important 
conclusions. First, the population structure of M. tuberculosis in Indonesia shows 
much heterogeneity, and geographical differences, but there is a strong 
predominance of strains belonging to a single clade, the Beijing genotype. This 
clearly suggests that this clade of M. tuberculosis has selective advantages over 
other clades. Second, several different factors may account for the predominance 
of Beijing genotype strains, including a higher virulence (especially a higher 
persistence during treatment), more drug resistance, and adaptation to the 
human innate immune system.  
I will now discuss these findings in more detail focussing on four aspects: 
epidemiology, molecular characteristics, clinical phenotype, and relation with the 
host immune system. 
The first major finding of this thesis was the high prevalence of M. tuberculosis 
Beijing genotype, which is remarkable given the strong heterogeneity of M. 
tuberculosis genotypes in Indonesia. This high genetic diversity of M. tuberculosis 
is in contrast with studies from other higher prevalence areas, including e.g. 
Vietnam, where only two major genotype families were found: Beijing (35-54%) 
and EAI (20%) (13-16). The M. tuberculosis Beijing genotype family was the most 
prevalent genotype family in Indonesia (33%), and the proportion of Beijing 
strains was stable during the study period from 2001 to 2006, and similar to the 
prevalence recorded in a previous, smaller study (32.4%) (17). Thus, the Beijing 
genotype seems to be an endemic strain circulating in Indonesia.  
Interestingly, the Beijing genotype was much less frequent in Timor, an island in 
the  eastern part of Indonesia,  than in Java. One can hypotesize about the 
underlying cause for this difference. First, it may be due to a ‘founder‘ effect with 
a higher chance of finding of particular genotype family closer to where it 
originated. As a second possibility, particular M. tuberculosis lineages may have 
adapted to specific properties of the immune system in particular human 
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population (genetic co-evolution). The results in chapter 7 support this hypothesis 
(18). Several studies have reported that the population structure of human 
pathogens is geographically structured, and this phenomenon has been linked to 
ancient human migration (5, 19, 20). The fact that there are different ethnic 
population in Java and Timor, suggest that there is an association of ethnic-
specific host genetic factors with TB susceptibility. As the highly prevalent 
genotype in Timor were EAI (East African Indian) lineage (33.3%) and LAM (Latin-
American-Mediterranean) lineage (20.0%) are also common in Far East Asia and 
Africa respectively (21), one can speculate that maybe these genotypes were 
associated with human migration from those areas (21). In contrast to what has 
been reported in others studies (13, 14, 16), no association was found between 
the Beijing genotype and age, previous treatment, phenotypic drug resistance and 
BCG vaccination.  
Regarding BCG vaccination, no correlation between M. tuberculosis Beijing and 
BCG vaccination, similar to other studies (22-25). Recently a study with strains 
from three different countries did find an association between the ‘typical’ (also 
called: ‘modern’) sublineage of Beijing strains and BCG-vaccination, suggesting 
that this sublineage can evade the immune protection induced by BCG-
vaccination (26). In our studies in Indonesia, we did not further differentiate the 
Beijing genotype “typical” (“modern”) Beijing strains, and “atypical” (“ancestral”), 
Beijing strains (8, 9). As mentioned that only typical M. tuberculosis Beijing strain 
was circumvent vaccine induced immunity (26). One can postulate that M. 
tuberculosis Beijing strains circulating in Indonesia belong to the “atypical” or 
“ancestral” Beijing clade. 
 
A second major finding in this thesis is the higher prevalence of mutations in drug 
resistance genes in M. tuberculosis Beijing genotype strains compared to non-
Beijing strains. More mutations were found in rpoB, katG315 and embB306, three 
genes which are responsible for resistance to rifampicin, isoniazide and 
ethambutol respectively. A first explanation for our finding is that Beijing 
genotype strains have a higher mutation frequency. It was previously found that 
Beijing strains have alterations in so-called ‘putative mutator genes’, resulting in 
altered DNA-repair and an increased mutation rate (27, 28). However, more 
recently it was found that the M. tuberculosis mutT2 (MtMutT2) gene plays a role 
in general slowdown of metabolism when mycobacteria are deprived of essential 
nutrients (29). Secondly, the high prevalence of drug resistance gene mutations in 
Beijing strain might be due to a founder effect, with a particular strain with 
certain genetic characteristics circulating in this area. However, the strong genetic 
variability of M. tuberculosis isolates in this area (24), collected from different 
sites over a 6-year period of time, argues against bias of our findings by one 
particular (resistant) cluster. We found a difference between Beijing and non-
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Beijing strains in the distribution of specific mutations in rpoB (30). The most 
common mutation, Ser531Leu, which seems to have very little effect on fitness 
(31, 32), had a higher prevalence among non-Beijing strains, while other 
mutations (including those in codon 526), which seem to have a higher fitness 
‘cost’ were more common among Beijing strains. Similar to a study among South 
African children, we found a stronger association of Beijing and rpoB-mutations 
among newly diagnosed patients than among previously treated patients, 
suggesting easier transmission (more ‘fitness’) of resistant Beijing strains (33). In 
addition, we also found a strong correlation between mutations in embB306 and 
mutations in rpoB and katG315. This finding is supported by previous studies 
which suggest that mutations in embB306 may not only account for ethambutol 
resistance but also correlate with multiple drug resistance (34-37). Irrespective of 
the underlying mechanism, our study confirms that mutations in embB306 are 
highly predictive of multidrug resistance.     
The higher rate of mutations in rpoB, katG315 and embB306 among M. 
tuberculosis Beijing strains provides further evidence that drug resistance may 
contribute to the global predominance of Beijing strains. The strong association of 
Beijing and rpoB-mutations among new cases of TB reflects considerable 
transmission of resistant Beijing strains in Indonesia.                                           
The third major finding in this thesis is that patients infected with M. tuberculosis 
Beijing strains are at increased risk for treatment failure and long term damage. 
One may postulate about the underlying cause for this finding. The difference in 
our study was not due to difference in adherence or drug resistance. In fact, our 
study was the first to show that the Beijing genotype was also associated with 
positive sputum cultures after treatment completion among patients without 
drug resistance. This finding suggests that this genotype has certain characteristics 
per se which render them more difficult to eradicate with tuberculosis treatment. 
Possibly, specific characteristics of the cell-wall structure of M. tuberculosis Beijing 
genotype strains contribute to their ability to withstand the host immune defense 
of tuberculosis treatment. For instance, the different cell wall may lead to 
suboptimal intracellular concentrations of anti-tuberculosis drugs and acquisition 
of drug resistance (38-41). These hypotheses need further proof: in vitro, Beijing 
strains did not appear to acquire drug resistance more easily when exposed to 
anti-tuberculosis drugs (27, 42). Alternatively, increased virulence might lead to 
more persistent infections and treatment failures with prolonged exposure of 
Beijing strains to anti-tuberculosis drugs, and therefore more time to develop 
resistance. Earlier cross-sectional studies have shown relations between the 
Beijing genotype and tuberculosis treatment failure in Russia (23) and Vietnam 
(16), but those two studies were done in specific populations, in prison and in 
elderly patients respectively. 
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Similar to a higher rate of treatment failure, patients infected with M. tuberculosis 
Beijing strains also had more recurrent TB and more (long term) lung damage. 
One can postulate why this is the case. First, active TB may not have been fully 
eradicated during initial treatment, leading to relapse. Second, damage caused by 
an episode of active TB may have permanently impaired the first-line host defense 
of subjects, thereby making them more susceptible for recurrent TB due to re-
infection. Finally, genetic and other factors affecting innate host defense may 
predispose subjects to progress to active TB following primary infection as well as 
following re-infection with M. tuberculosis Beijing strains 
As a fourth major finding, we found that polymorphisms of SLC11A1 / NRAMP1 
among tuberculosis patients were associated with infection by M. tuberculosis  
Beijing strains. SLC11A1 / NRAMP1 is the most widely examined candidate gene 
for susceptibility to tuberculosis (43). In this thesis, it was shown that patients 
with a particular genotype of SLC11A1, which has often been linked with 
susceptibility to tuberculosis, had a much higher chance to be infected with Beijng 
strains. Adaptation of M. tuberculosis (‘co-evolution’) probably underlies this 
finding (18, 44). It may also explain why the prevalence of the Beijing genotype 
shows strong geographic differences (obviously the genotype of the human host is 
also very different accross the Indonesian archipelago). So far, only one other 
study has similarly shown an association between M. tuberculosis genotype and 
host genotype (44).    
 
The success of Beijing strains – a conceptual framework  
From separate studies and discussion above we can generate a conceptual frame 
work of factors underlying the success of M. tuberculosis  Beijing genotype strains.  
In our study we did not find any association of Beijing genotype with BCG 
vaccination, but we still can not exclude that correlation. BCG vaccination may be 
less protective against typical Beijing genotype strains than against other strains. 
This will lead to more latent infection and more progression from latent infection 
to active TB (45-47). Similarly, anti-TB treatment maybe less effective in 
eradicating Beijing strains than other strains. Arguing against these two points, 
however, it has been suggested that the spread of Beijing strains already started 
long before the introduction of vaccination and antibiotic treatment. This would 
suggest that Beijing strains have an intrinsic advantage over other M. tuberculosis 
genotypes in terms of transmission, progression from latent to active tuberculosis, 
acquisition of drug resistance or disease chronicity (45). Specific characteristics of 
this genotype may render it more virulent as its associated with treatment failure 
and relapse (16, 23), and proven to cause more lung damage animal model or 
better capable of resisting or evading the human host immune system (39, 46-50). 
A conceptual framework of factors underlying the success of Beijing genotype is 
shown in Figure 1.  
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Figure 1.  A conceptual framework of factors underlying mechanism the success of 
Mycobacterium tuberculosis Beijing genotype.  
 
Overreaching issues 
Besides the specific questions addressed in this thesis, there are two overreaching 
or cross-cutting issues. First, the research findings have certain implications for 
public health and TB-control. Second, the theoretical framework and practical 
experience which are the basis for this thesis can help decide about the most 
effective way to implement or improve molecular typing of M. tuberculosis and 
mycobacteriology in general in Indonesia. I will now focus on these two 
overreaching issues: public health and laboratory aspects.  
 
Public health aspects 
In terms of public health, several issues warrant further discussion. This thesis 
focussed on the differences between M. tuberculosis Beijing and non-Beijing 
strains. But even without looking at these differences, important conclusions can 
be drawn.  
This thesis brings up several issues related to tuberculosis control in Indonesia. 
First,  the Beijing strain which is predominant in Indonesia, is related with the 
higher transmission and treatment failure. As such it is an additional risk factor for 
failure, next to HIV co-infection, diabetes, low nutritional state and so on. In our 
setting, drop out is low and adherence is high (51). Second, the treatment failure 
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rate is high compared with data from countries using one of two standardized 
initial regimens, where failure rates average 5.0% (in countries where prevalence 
of initial MDR exceeds 3%), or 1.6% (in countries where initial multidrug 
resistance prevalence is less than 3%) (52). Besides treatment failure, recurrent TB 
also seems common: in our study of long-term effects of pulmonary TB,  9.6% of 
146 ex-TB patients developed recurrent TB. 
The issue of high treatment failure and high transmission rate has not been fully 
considered by the National TB program because the current DOTS program is 
considered quite sucessfull with >70% coverage and a decrease in the prevalence 
of TB. As the Beijing strains may be most threatening to the TB control program, 
to combat the emergence of this strain, certain measures should be explored, like 
the need for higher dose or prolonged treatment. Besides, strain identification 
should be considered at population level, or even maybe at the level of individual 
patients.  
Third, significant rates of drug resistance were found. Although this is partly due 
to selection bias, this is still a matter of grave concern. So far, Indonesia has not 
been included in an international survey on TB drug resistance. Similarly, no 
national survey, and no single survey of sufficient size or quality has been 
published. In fact, so far only two laboratories have met international quality 
control. Both these laboratories only use the Canetti proportional method, which 
is 50 years old. Hardly any research and development is being done in drug 
susceptibility testing in Indonesia. Only this year, the national TB program has 
supported efforts to evaluate a commercially available genotypic method as a 
screening assay for drug resistant TB. Several years ago with help from the Dutch 
TB reference laboratory (RIVM) a 25-well plates method with transparent 
Middlebrook’s medium was introduced (53). Accuracy of this method was better, 
but it proved difficult to establish sustainable production of plates, and 
contamination during production and inoculation was a significant problem. As an 
alternative, we are now evaluating cheap in-house methods of genotypic drug 
susceptibility testing, and ‘MODS’ (Microscopic Observation Drug Susceptibility) 
assay for TB drug resistance, which is a very cost-effective method which has 
performed very well in other less-developed settings (54, 55).  
Lack of infrastructure, human resources and funding are some of the obstacles 
towards high-quality drug susceptibility testing for TB in Indonesia. There is an 
urgent need for a national reference laboratory which is responsible for 
standardized identification and TB drug susceptibility testing, education on TB and 
biosafety, as well as external quality assurance. Good surveillance of drug 
resistance does not only require good laboratory practice, but also good 
epidemiology and good quality patient data.  
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As shown in this thesis, both issues discussed above, drug resistance and 
treatment failure, are associated with the Beijing genotype. This is an important 
finding, but the implications for patient management and TB control remain to be 
determined.  
 
Laboratory technique aspects 
Application of molecular techniques in clinical service laboratories will help rapid 
detection of M. tuberculosis complex and might play a role in improving routine 
susceptibility testing. In this study we found that microscopy was not sufficient for 
TB detection as would have missed at least 17% of failure cases if only microscopy 
had been used. While culture is time consuming, a rapid TB molecular based 
detection may be a useful method in this setting. Molecular techniques have the 
advantage of being quick and accurate. Although not cheap, they might have a 
role in management of difficult cases.  
Molecular based drug susceptibility testing (DST) might have an even greater 
impact to TB control. Although techniques will be difficult to implement to all 
service laboratories in Indonesia, it could be done in provincial public health 
laboratories or provincial reference hospitals which are often equiped with 
molecular detection equipment. However, a supranational laboratory should be 
first established as a body responsible for quality assurance of molecular 
detection. 
While the quality of routine methods should be strengthened in primary care 
settings like the Puskesmas, some form of ongoing surveillance looking at the 
quality of this primary diagnosis and presence of drug resistance should be done 
in Provincial referral laboratories. The referral lab should be closely linked to care 
of complicated TB patients, e.g. those who default or have multidrug drug 
resistant TB. 
 
Remaining issues 
Several questions are still unanswered; 1) what are the underlying mechanism of 
virulence associated with Beijing strains? 2) what is the population structure of 
Mycobacterium tuberculosis complex in other Indonesian islands? 3) what is the 
clinical phenotype of TB caused by Beijing strains? 4) what are the implications of 
all of this for TB control in Indonesia? These issues certainly need further study.  
 
 
Academic collaboration 
The studies in this thesis could be done through a fruitfull collaboration between 
Universitas Padjadjaran/Dr. Hasan Sadikin Hospital and University Medical Center 
Nijmegen, The Netherlands. Beside official university collaboration, this network 
was extended to other institutions either in The Netherlands, also in Indonesia. 
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The benefit of this collaboration is beneficial for patient care, education and 
research, through knowledge transfer, supervision, training, and sharing 
experience in tuberculosis diagnosis and care. This collaboration has helped to 
strenghten laboratory capacity in tuberculosis diagnosis using both conventional 
and molecular methods. We were able to improve our microscopic and culture 
method and evaluate ‘MIC 25 micro well plate’ for TB drug susceptibility testing. 
We also successfuly established a molecular typing method, spoligotyping,  which 
has been done on more than thousands isolates. Now, we are able to assist 
National Institute of Health (Badan Penelitian dan Pengembangan Kesehatan) 
Ministry of Health of Indonesia as a consultant and reference laboratory  on   
National TB Molecular Epidemiology project, also contribute to evaluation phase 
of the Hain “GenoType® MTBDR plus” test for rapid detection of MDR-TB. 
Additional ongoing research under this collaboration are on molecular detection 
of M. tuberculosis, real time PCR for MDR-TB, MODS etc. aim for patients service. 
Hopefuly, in the future this collaboration will sustainable and extend, covering 
more staff of Medical Faculty Universitas Padjadjaran / Dr. Hasan Sadikin Hospital 
with mutual benefit and the ultimate goal to control TB. 
 
 
Concluding remarks 
This thesis helped to establish the clinical laboratory infrastructure and skills to 
address the molecular methods for detection, identification, drug resistance and 
epidemiology of M. tuberculosis complex. This contribute to increase 
understanding of the underlying mechanism of the emergence of M. tuberculosis 
Beijing strains. These comprehensive studies were only possible through good 
collaboration of many researchers and institutions in Indonesia and in The 
Netherlands. There is still much we should explore in order to more effectively 
fight TB. I therefore hope that this thesis can be another step in the understanding 
of TB, and in the development of new tools and strategies for TB control. 
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Tuberkulosis (TB) masih merupakan masalah kesehatan utama yang mendunia 
dengan perkiraan 9.3 juta kasus baru (139 per 100 000 penduduk) termasuk 1.37 
juta (15%) kasus diantara penderita positif HIV. Dalam tahun yang sama terdapat 
tambahan 1.16 juta kasus TB kambuh. Mycobacterium tuberculosis  resisten 
ganda (Multi Drug Resistant) yang didefinisikan sebagai M. tuberculosis yang 
resisten terhadap paling sedikit isoniazid (INH) dan rifampisin, ditemukan pada 
lebih dari setengah juta penduduk di seluruh dunia (1). Data tersebut dengan jelas 
memperlihatkan bahwa TB masih jauh dari eradikasi walaupun ada vaksinasi BCG 
dan pengobatan anti TB yang effektif. Mycobacterium tuberculosis telah 
beradaptasi terhadap pengobatan TB (munculnya galur yang resisten obat), 
terhadap vaksinasi atau terhadap sistem imun pejamu, dan adaptasi ini berperan 
kepada keberhasilan perkembangan evolusinya. 
Sejak perkembangan metode molekuler, jelas bahwa M. tuberculosis bukanlah 
mikroorganisme tunggal. Untuk membedakan M. tuberculosis secara lebih rinci, 
berbagai cara genotyping telah diperkenalkan. Teknik yang paling luas 
dipergunakan adalah Restriction fragment length polymorphism (RFLP), 
spoligotyping dan Mycobacterial interspersed repetitive-unit–variable-number 
tandem repeat (MIRU-VNTR) typing  (2-4). Berbagai metode ini dapat mendeteksi 
genotip M. tuberculosis tertentu, mengikuti transmisi antar pasien, menyelidiki 
sumber kejadian luar biasa (outbreaks) TB, dan membedakan kasus yang kambuh 
dibandingkan dengan yang infeksi berulang. Sebagai tambahan, metode metode 
ini telah membantu untuk meneliti kekerabatan genetik (‘phylogenetics’) atau 
dinamika struktur  populasi M. tuberculosis kompleks. Dengan MIRU typing, dua 
keturunan utama telah terdefinisi, disebut clade 1 dan 2. Pembagian secara 
geografis selanjutnya, clade 1  menghasilkan cabang cabang yang berbeda untuk  
Africa (Uganda, Cameroon dan S), Asia (Beijing dan CAS), Latin America-
Mediterranea dan populasi Africa-Eropa (X, Ghana and Haarlem). Clade 2 terdiri 
atas isolat patogen baik untuk manusia maupun hewan. Seluruh populasi  M. 
tuberculosis kompleks dari sumber manusia menunjukkan kecepatan ekspansi 
yang konstan pada 180 tahun terakhir ini. Tetapi genotip Beijing yang merupakan 
salah satu dari keturunan yang paling sukses pada saat ini menunjukkan 
penambahan populasi yang paling besar (5). Beijing clade terdiri dari paling sedikit 
2 subgrup utama yang mempunyai karakteristik pola spoligotype yang sama (6-8) 
yaitu galur Beijing typical dan atypical. Galur Beijing typical (“modern”) (8, 9), 
memperlihatkan kesamaan yang tinggi pada pola multicopy IS6110 restriction 
fragment length polymorphism (RFLP) (10), sedangkan galur Beijing atypical 
(“ancestral”) (8, 9)  lebih cenderung sama dengan nenek moyang Beijing clade (6-
8).  
Dengan spoligotyping, kami menemukan bahwa genotip M. tuberculosis Beijing 
merupakan clade yang paling banyak di Indonesia. Keberhasilan galur Beijing 
diduga berhubungan dengan kemampuannya untuk bertahan dari pengobatan TB, 
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atau menghindar dari respons imun pejamu. Hal inilah yang menjadi fokus dari 
tesis ini. 
 
 
Ringkasan temuan penelitian   
Populasi M. tuberculosis galur Beijing banyak ditemukan di Indonesia, merupakan 
sepertiga dari struktur populasi M. tuberculosis kompleks. Ini merupakan 
penelitian pertama kali di Indonesia, negara dengan peringkat TB ke tiga tertinggi 
setelah India dan China. Berikut ini adalah ringkasan temuan utama dari setiap 
bab.  
Teknik spoligotyping merupakan teknik molekuler pertama di laboratorium klinik 
di Bandung, Indonesia, oleh karena itu, pertama kali, kami melakukan optimasi 
teknik ini untuk berbagai sumber sampel yang berbeda dengan menguji 
reproduksibilitasnya. Dalam bab 2 saya menemukan bahwa spoligotyping yang 
telah dijelaskan oleh Kamerbeek dkk (11) ketika digunakan untuk M. tuberculosis 
yang bukan berasal dari hasil kultur, memperlihatkan sinyal hibridisasi yang lemah 
di beberapa spacer. Oleh karena itu, kami melakukan optimasi campuran PCR 
untuk spoligotyping DNA M. tuberculosis kompleks langsung dari spesimen klinik 
dengan menggunakan konsentrasi MgCl2, Tris-HCl, dan PCR-primers yang berbeda 
(12). Penggunaan protokol yang disesuaikan ini berhasil menunjukkan pola 
spoligotyping M. tuberculosis kompleks dengan lengkap pada sampel klinik 
sebanding dengan sampel yang berasal dari kultur. 
Struktur populasi M. tuberculosis di Indonesia, dan prevalensi genotip Beijing 
adalah dasar dari tesis ini. Dalam bab 3 diteliti distribusi dari berbagai genotip M. 
tuberculosis di antara hampir 900-an pasien dari dua pulau yang berbeda. 
Keragaman genetik yang sangat tinggi ditemukan diantara galur M. tuberculosis, 
dan ditemukan perbedaan yang bermakna pada distribusi geografisnya. Genotip 
Beijing ditemukan sebanyak 33% dari pasien yang berasal dari Jawa barat 
berlawanan dengan sejumlah 14.3% dari pasien yang berasal dari Timor, dengan 
dua genotip famili (East African-Indian dan Latin American / Mediterranean) lebih 
banyak ditemukan di Timor.  
Meningkatnya resistensi terhadap obat merupakan salah satu kemungkinan yang 
dapat menerangkan mengenai predominansi genotip M. tuberculosis galur 
Beijing. Dalam bab 4 saya menguji hubungan antara genotip M. tuberculosis 
Beijing dengan mutasi pada gen yang bertanggung jawab terhadap resistensi obat 
diantara isolat yang berasal dari 300-an pasien TB. Sekuensing regio hotspot rpoB 
dan PCR untuk mutasi pada gen katG kodon 315 dan gen embB kodon 306 
dilakukan pada isolat yang secara fenotipik resisten maupun sensitif. Mutasi pada 
gen resisten lebih banyak ditemukan pada M. tuberculosis galur Beijing 
dibandingkan dengan  galur non-Beijing, untuk rpoB (33.3% versus 18.7%), 
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katG315 (18.5% vs. 12.8%), dan  embB306 (16.5% vs. 6.1%). Hal ini tidak 
disebabkan oleh banyaknya  galur Beijing pada pasien dengan riwayat pengobatan 
TB sebelumnya, diantara pasien baru pun mutasi pada gen penyebab resistensi 
berhubungan sangat kuat dengan genotip Beijing. 
Percobaan binatang memperlihatkan bahwa M. tuberculosis genotip Beijing lebih 
virulen dibandingkan strain yang lain, tetapi data dari penelitian klinis masih 
kurang dapat memperlihatkan itu. Pada penelitian kohort prospektif dalam bab 5, 
kami menguji apakah genotip Beijing berhubungan dengan beratnya TB dan gagal 
pengobatan di Indonesia. Tidak ditemukan hubungan yang jelas antara genotip 
Beijing dengan manifestasi klinis atau kelainan pada gambaran radiologis paru, 
tetapi pasien yang sebelumnya terinfeksi oleh genotip Beijing, kultur sputum 
positif pada enam bulan setelah pengobatan dua kali lebih besar dibandingkan 
dengan pasien yang terinfeksi oleh genotip non-Beijing. Efek ini tidak disebabkan 
karena resistensi obat yang lebih tinggi pada galur Beijing. Hasil uji multipel 
regresi menunjukkan bahwa genotip Beijing merupakan faktor risiko independen 
untuk gagal pengobatan TB. 
Setelah pengobatan TB, pasien masih mempunyai risiko yang tinggi untuk 
kematian, kambuh dan mengalami kerusakan paru yang permanen. Efek jangka 
panjang TB paru yang disebabkan oleh galur Beijing dan galur non-Beijing 
dibandingkan dalam bab 6. Seratus empat puluh enam mantan pasien TB dan 178 
kontrol sehat yang sesuai dari sebuah penelitian kasus-kelola yang lalu diperiksa 
kembali setelah 1.5 sampai lima tahun kemudian. Mantan pasien TB yang pada 
awalnya terinfeksi oleh M. tuberculosis galur Beijing mempunyai risiko yang lebih 
tinggi untuk kambuh dibandingkan mantan penderita TB yang terinfeksi genotip 
lain. Kelainan fungsi paru lebih banyak ditemukan diantara 18 mantan pasien TB 
yang awalnya terinfeksi oleh M. tuberculosis genotip Beijing dibandingkan dengan 
33 mantan pasien TB yang terinfeksi oleh genotip lain.  
Perbedaan pada gen imun pejamu dapat meningkatkan kepekaan terhadap 
genotip M. tuberculosis tertentu, dan hal ini dapat menjadi faktor penyumbang 
lain dalam keberhasilan evolusioner galur Beijing. Dalam bab 7 kami menguji 
hipotesis ini dengan melakukan typing gen SLC11A1 pasien, yang sebelumnya 
disebut  NRAMP1 (natural resistance-associated macrophage protein 1), yang 
telah dikaitkan dengan kepekaan terhadap TB  di berbagai tempat, terhadap 331 
pasien TB paru. M. tuberculosis galur Beijing yang merupakan sepertiga dari 
seluruh isolat berhubungan erat dengan dua polimorfisme di SLC11A1; D543N G 
allele dan genotip 3’UTR ins/ins. Genotip tertentu dari dua polimorfisme yang 
berbeda dari SLC11A1 berhubungan kuat dengan infeksi oleh genotip M. 
tuberculosis galur Beijing. 
Distribusi geografis yang luas dari Mycobacterium tuberculosis genotip galur 
Beijing, dan kesamaan genetiknya mengesankan bahwa galur yang termasuk ke 
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dalam genotip ini mempunyai keuntungan selektif dibandingkan galur M. 
tuberculosis lainnya, seperti yang didukung oleh penelitian penelitian yang telah 
dipaparkan dalam bab 3-7. Di dalam bab 8 saya meninjau ulang seluruh penelitian 
epidemiologi molekuler, eksperimental dan klinik yang berhubungan dengan 
genotip Beijing yang sejauh ini telah dipublikasikan. Dari pustaka ilmiah, terlihat 
bahwa keberhasilan evolusi galur Beijing kemungkinan berhubungan dengan  
vaksinasi BCG, yang kelihatannya kurang bersifat protektif terhadap galur Beijing, 
dan juga berhubungan dengan resistensi atau resistensi ganda yang ditemukan di 
berbagai area. Sebagai tambahan, pada berbagai binatang percobaan terlihat 
bahwa galur Beijing lebih virulen, menyebabkan kerusakan histopatologi yang 
lebih luas, pertumbuhan dalam sel pejamu lebih meningkat dan lebih 
meningkatkan kematian. Pada tatanan molekuler, galur Beijing mempunyai sifat 
sifat spesifik dalam hal struktur protein dan lemak serta interaksinya dengan 
sistem imun manusia. Disamping temuan bahwa genotip Beijing dikaitkan dengan 
polimorfisme pada SLCA1/NRAMP1, galur Beijing juga telah dihubungkan dengan  
polimorfisme  di dalam gen pengkode TLR2, suatu reseptor pola pengenalan 
(pattern recognition receptor) yang penting untuk mikobakteria, mengesankan 
adanya kemungkinan ko-evolusi manusia-mikobakterial. Sebagai kesimpulan, 
genotip Beijing merupakan hasil evolusi dari M. tuberculosis yang menjadikannya 
lebih sulit untuk dikontrol baik melalui vaksinasi ataupun pengobatan dengan 
antibiotik.  
 
 
Pembahasan umum 
Berdasarkan berbagai penelitian yang telah diringkas di atas, dapat dibuat dua 
kesimpulan penting. 
Pertama, struktur populasi dari M. tuberculosis di Indonesia sangat heterogen 
disertai dengan perbedaan geografis tetapi ditemukan predominansi galur yang 
berasal dari clade tunggal yaitu genotip Beijing. Hal ini secara jelas membuktikan 
bahwa clade M. tuberculosis ini mempunyai keuntungan selektif dibandingkan 
dengan  clade yang lain. Kedua, beberapa faktor yang berlainan kemungkinan 
bertanggung jawab terhadap predominansi genotip galur Beijing, termasuk 
virulensi yang lebih tinggi (terutama tingginya persistensi bakteri ini selama 
pengobatan), lebih resisten obat, dan kemampuan adaptasinya terhadap sistem 
imun alamiah manusia.  
Berikut, akan didiskusikan temuan temuan di atas secara lebih rinci terutama 
difokuskan ke dalam empat aspek; epidemiologi, karakteristik molekuler, fenotip 
klinis, dan hubungannya dengan sistem imun pejamu. 
Temuan utama pertama dari tesis ini adalah tingginya prevalensi M. tuberculosis 
genotip Beijing, yang secara bermakna menyebabkan tingginya keragaman 
genetik M. tuberculosis di Indonesia. Keragaman genetik M. tuberculosis yang 
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tinggi ini berlawanan dengan hasil penelitian dari area lain yang mempunyai 
prevalensi tinggi termasuk Vietnam, yang hanya mempunyai dua genotip utama 
yaitu; Beijing (35-54%) dan EAI (20%) (13-16). M. tuberculosis genotip Beijing 
merupakan genotip yang paling banyak ditemukan di Indonesia (33%), dan 
proporsinya stabil selama periode penelitian ini yaitu dari tahun 2001 sampai 
2006, serta sama dengan prevalensi yang tercatat pada penelitian yang lebih kecil 
sebelumnya (32.4%) (17). Jadi, genotip Beijing kelihatannya merupakan galur 
endemik yang bersirkulasi di Indonesia.  
Yang menarik, genotip Beijing ditemukan jauh lebih sedikit di Timor, suatu pulau 
di bagian timur Indonesia, dibandingkan dengan di pulau Jawa. Dengan penemuan 
ini, dapat dibuat hipotesis mengenai sebab yang melandasi perbedaan tersebut. 
Pertama, kemungkinan disebabkan oleh efek ‘founder‘ dengan kesempatan yang 
lebih tinggi untuk menemukan genotip famili tertentu di tempat yang lebih dekat 
dengan asal muasalnya. Kemungkinan kedua, keturunan M. tuberculosis 
beradaptasi kepada sifat spesifik sistem imun pada populasi manusia tertentu 
(genetic co-evolution). Hasil dalam bab 7 mendukung hipotesis ini (18). Beberapa 
penelitian melaporkan bahwa struktur populasi patogen manusia secara geografis 
terstruktur, dan fenomena ini dikaitkan dengan migrasi manusia pada jaman dulu 
(5, 19, 20). Kenyataan bahwa ada perbedaan populasi etnis di pulau Jawa dan 
Timor, mengesankan bahwa ada hubungan antara faktor genetik pejamu yang 
spesifik etnik dengan kepekaan terhadap TB. Tingginya prevalensi genotip EAI 
(East African Indian) (33.3%) dan LAM (Latin-American-Mediterranean) (20.0%) di 
Timor yang juga banyak ditemukan berturut turut di Asia timur jauh dan Africa 
(21), kita dapat berspekulasi bahwa mungkin genotip ini berhubungan dengan 
migrasi manusia dari area tersebut (21). Kebalikan dari laporan peneliti lain (13, 
14, 16), tidak ditemukan hubungan antara genotip Beijing dengan umur, 
pengobatan sebelumnya, resistensi obat dan vaksinasi BCG. Tidak adanya 
hubungan antara vaksinasi BCG serupa dengan penelitian lain (22-25). Akhir akhir 
ini penelitian terhadap galur yang berasal dari tiga negara menemukan adanya 
hubungan antara galur Beijing ‘typical’ (disebut juga ‘modern’)  dengan vaksinasi 
BCG, menggambarkan bahwa galur ini dapat menghindar dari perlindungan 
imunitas yang diinduksi vaksinasi BCG (26). Dalam penelitian kami di  Indonesia, 
kami tidak membedakan lebih jauh genotip Beijing yang “typical” (“modern”) dan 
yang “atypical” (“ancestral”) (8, 9). Seperti telah diterangkan bahwa hanya M. 
tuberculosis genotip Beijing ‘typical’ yang dapat menghindar dari imunitas yang 
diinduksi vaksin (26), dengan demikian dapat disimpulkan bahwa  M. tuberculosis 
genotip Beijing yang beredar di Indonesia termasuk ke dalam “atypical” atau 
“ancestral” Beijing clade. 
Temuan utama kedua di dalam tesis ini adalah lebih tingginya prevalensi mutasi 
gen resistensi obat pada M. tuberculosis Beijing genotype strain dibandingkan 
dengan galur non-Beijing. Mutasi lebih banyak ditemukan pada gen rpoB, katG315 
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dan embB306, tiga gen yang bertanggung jawab berturut turut terhadap resistensi 
rifampisin, isoniazid dan etambutol. Penjelasan pertama temuan ini adalah, galur 
Beijing mempunyai frekuensi mutasi yang lebih tinggi. Sebelumnya telah 
ditemukan bahwa galur Beijing mengalami perubahan pada ‘putative mutator 
genes’ yang menyebabkan perubahan pada ‘DNA-repair’ dan peningkatan 
kecepatan mutasi (27, 28). Namun demikian temuan terbaru melaporkan bahwa 
gen M. tuberculosis mutT2 (MtMutT2) berperan di dalam penurunan metabolisme 
secara umum ketika mikobakteria kehilangan nutrien yang esensial (29). Kedua, 
tingginya prevalensi mutasi gen resistensi pada galur Beijing dapat disebabkan 
oleh ‘efek temuan’, galur tertentu dengan karakteristik genetik tertentu beredar 
di area ini. Namun, kuatnya keragaman genetik isolat M. tuberculosis di area ini 
(24), yang terkumpul dari tempat berbeda selama enam tahun membantah bias 
efek tersebut. Kami menemukan perbedaan antara galur Beijing and non-Beijing 
pada distribusi mutasi spesifik pada rpoB (30). Mutasi yang paling sering 
ditemukan, Ser531Leu, yang kelihatannya hanya memberikan efek sangat kecil 
terhadap ‘fitnes’ (31, 32), lebih banyak terjadi pada galur non-Beijing, sedangkan 
mutasi yang lain (termasuk pada kodon 526), yang kelihatannya lebih banyak 
merugikan fitnes lebih banyak ditemukan pada galur Beijing. Serupa dengan 
penelitian diantara anak anak di Afrika selatan, kami menemukan hubungan yang 
kuat antara Beijing dengan mutasi rpoB diantara pasien baru dibandingkan 
dengan pasien yang pernah mendapat pengobatan, mencerminkan transmisi yang 
lebih mudah (lebih ‘fitness’) pada galur Beijing yang resisten (33). Sebagai 
tambahan, kami juga menemukan hubungan yang kuat antara mutasi embB306 
dan mutasi rpoB dan katG315. Temuan ini mendukung penelitian sebelumnya 
yang melaporkan bahwa mutasi pada embB306 tidak hanya bertanggung jawab 
terhadap resisten etambutol tetapi juga berhubungan dengan resisten ganda (34-
37). Tanpa memperhatikan mekanisme yang mendasarinya, penelitian kami 
menegaskan bahwa mutasi pada embB306 merupakan prediksi yang kuat adanya 
resisten ganda obat. Angka mutasi yang tinggi pada rpoB, katG315 dan embB306 
diantara M. tuberculosis galur Beijing memberikan bukti yang lebih jauh bahwa 
resistensi dapat memberikan sumbangan terhadap predominansi global galur 
Beijing. Hubungan yang kuat antara Beijing dan mutasi pada gen rpoB diantara 
kasus TB baru menggambarkan adanya transmisi galur Beijing yang resisten di 
Indonesia.                                           
Temuan utama ketiga di dalam tesis ini ialah pasien yang terinfeksi M. 
tuberculosis galur Beijing mempunyai risiko lebih tinggi untuk gagal pengobatan 
dan kerusakan paru jangka panjang. Hal ini bukan disebabkan oleh 
ketidakpatuhan makan obat atau adanya resistensi obat. Penelitian kami adalah 
yang pertamakali membuktikan bahwa genotip Beijing berhubungan dengan 
kultur sputum positif sesudah selesai pengobatan pada mereka yang tidak 
resisten obat. Temuan ini menunjukkan bahwa genotip ini mempunyai 
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karakteristik tertentu yang menyebabkannya lebih sulit dieradikasi dengan 
pengobatan TB. Kemungkinan, karakteristik spesifik dari struktur dinding sel 
genotip M. tuberculosis Beijing berperan dalam kemampuannya untuk 
menghindar dari pertahanan sistem imun pejamu. Sebagai contoh, perbedaan 
pada dinding sel akan menyebabkan konsentrasi obat  anti-tuberkulosis 
intraselular yang suboptimal dan menjadi resisten obat (38-41). Hipotesis ini 
membutuhkan pembuktian lebih lanjut: in vitro, galur Beijing tidak lebih mudah 
menjadi resisten ketika terpapar obat anti-tuberkulosis (27, 42). Sebagai 
kemungkinan lain, peningkatan virulensi dapat menyebabkan infeksi yang lebih 
menetap dan gagal pengobatan dengan paparan yang lebih lama galur Beijing 
terhadap obat anti-tuberkulosis, sehingga memiliki lebih banyak waktu untuk 
mengembangkan mekanisme resisten. Penelitian cross-sectional sebelumnya 
memperlihatkan adanya hubungan antara genotip Beijing dan gagal pengobatan 
di Russia (23) dan Vietnam (16), tetapi penelitian tersebut dilakukan pada 
populasi yang spesifik yaitu di penjara dan pada pasien berumur tua. 
Serupa dengan tingginya angka gagal pengobatan, pasien yang terinfeksi M. 
tuberculosis galur Beijing juga banyak yang menjadi kambuh dan mengalami 
kerusakan paru yang lebih lama. Orang bisa mengambil kesimpulan mengapa hal 
ini terjadi. Pertama, TB aktif tidak ter-eradikasi secara sempurna selama 
pengobatan  pertama sehingga menyebabkan kekambuhan. Kedua, kerusakan 
karena episode TB aktif secara permanen telah merusak pertahanan lini pertama 
tubuh pejamu, oleh karena itu membuat mereka lebih rentan untuk kambuh 
karena re-infeksi. Akhirnya, genetik dan faktor lain yang mempengaruhi 
pertahanan tubuh alamiah pejamu dapat menjadi predisposisi seseorang untuk 
berkembang ke arah TB aktif baik setelah infeksi primer maupun setelah re-infeksi 
oleh M. tuberculosis galur Beijing. 
Sebagai temuan utama ke empat, kami menemukan bahwa polimorfisme gen 
SLC11A1 / NRAMP1 diantara pasien TB berhubungan dengan infeksi oleh M. 
tuberculosis galur Beijing. SLC11A1 / NRAMP1 adalah kandidat gen untuk 
kepekaan terhadap TB yang paling banyak diteliti (43). Di dalam tesis ini, telah 
dibuktikan bahwa pasien dengan genotipe SLC11A1 tertentu, yang sering 
dikaitkan dengan kepekaan terhadap TB, mempunyai kesempatan lebih besar 
untuk terinfeksi  galur Beijng. Adaptasi M. tuberculosis (‘co-evolution’) 
kemungkinan mendasari temuan ini (18, 44). Hal ini dapat juga menjelaskan 
mengapa prevalensi genotip Beijing berbeda bermakna secara geografis (genotip 
manusia pejamu juga sangat berbeda diantara kepulauan di Indonesia). Sejauh ini 
hanya satu penelitian lainnya yang memperlihatkan hubungan antara genotip M. 
tuberculosis dengan genotip pejamu (44).    
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Keberhasilan galur Beijing – suatu kerangka pemikiran:  
Dari berbagai penelitian dan diskusi di atas dapat dibuat suatu kerangka 
pemikiran mengenai faktor faktor yang mendasari keberhasilan M. tuberculosis 
genotip Beijing. Di dalam penelitian ini kami tidak menemukan hubungan antara 
genotip Beijing dengan vaksinasi BCG, tetapi kami belum dapat mengabaikan 
hubungan ini. Vaksinasi BCG mungkin kurang melindungi terhadap infeksi genotip 
Beijing yang tipikal dibandingkan dengan genotip lain. Hal ini akan menyebabkan 
infeksi yang lebih laten dan perkembangan yang lebih besar dari infeksi laten ke 
arah TB aktif (45-47). Hal yang sama, pengobatan anti-TB kemungkinan kurang 
effektif dalam mengeradikasi galur Beijing dibandingkan dengan galur yang lain. 
Bantahan terhadap dua hal tersebut, bagaimanapun juga diperkirakan bahwa 
penyebaran galur Beijing sudah dimulai jauh sebelum adanya vaksinasi dan obat 
antibiotik. Hal ini menunjukkan bahwa galur Beijing mempunyai keuntungan 
intrinsik dibandingkan dengan genotip M. tuberculosis lainnya dalam hal 
transmisi, perkembangan dari laten ke TB aktif, memperoleh sifat resisten obat 
atau kronisitas penyakitnya (45). Karena karakteristik spesifiknya, menyebabkan 
genotip ini lebih virulen seperti hubungannya dengan gagal pengobatan dan 
kambuh (16, 23), dan terbukti menyebabkan kerusakan paru yang lebih parah 
pada binatang percobaan atau kemampuan yang lebih baik dalam  menahan atau 
menghindar dari sistem imun pejamu (39, 46-50). Kerangka pemikiran dari 
berbagai faktor yang mendasari keberhasilan genotip Beijing terlihat pada 
Gambar 1.   
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Gambar 1.  Kerangka pemikiran mengenai berbagai faktor yang mendasari keberhasilan 
Mycobacterium tuberculosis genotip Beijing.  
Nilai tambah penelitian  
Disamping pertanyaan pertanyaan spesifik di dalam tesis ini, ada dua nilai tambah 
pada penelitian ini. Pertama, temuan penelitian ini mempunyai implikasi khusus 
kepada kesehatan masyarakat dan penanggulangan TB. Kedua, kerangka teoritis 
dan pengalaman praktis yang menjadi basis dari tesis ini dapat membantu 
memutuskan cara mana yang paling efektif untuk mengimplementasikan atau 
meningkatkan molecular typing M. tuberculosis dan mikobakteriologi secara 
umum di Indonesia. Berikut ini akan saya fokuskan ke dalam dua nilai tambah 
penelitian ini yaitu; aspek kesehatan masyarakat dan aspek laboratorium. 
Aspek Kesehatan Masyarakat 
Dalam bidang kesehatan masyarakat beberapa permasalahan membutuhkan 
diskusi lebih lanjut. Fokus dari tesis ini adalah pada perbedaan antara M. 
tuberculosis galur Beijing dan non-Beijing. Namun, bahkan tanpa melihat 
perbedaan tersebut, dapat ditarik kesimpulan penting.  
Tesis ini mengangkat beberapa permasalahan yang berhubungan dengan 
penanggulangan TB di Indonesia. Pertama, galur Beijing yang merupakan genotip 
terbanyak di Indonesia, berhubungan dengan penularan yang lebih tinggi dan 
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Latent infection 
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damage 
Sputum bacterial load 
Treatment failure and 
relapse 
Infectiousness & transmission 
* Protection from BCG-
vaccination
* 
* 
Chapter 9 
127 
 
kasus gagal pengobatan. Genotip ini merupakan tambahan faktor risiko untuk 
kegagalan, setelah ko-infeksi HIV, diabetes, dan status nutrisi yang rendah dll. 
Pada setting penelitian ini angka drop out rendah dan kepatuhannya tinggi (51). 
Kedua, angka gagal pengobatan cukup tinggi dibandingkan dengan data dari 
negara negara yang menggunakan dua regimen awal yang terstandarisasi yang 
mempunyai rerata angka gagal pengobatan sekitar 5.0% (di negara negara yang 
mempunyai prevalensi MDR lebih dari 3%), atau 1.6% (di negara negara yang 
mempunyai prevalensi MDR kurang dari 3%) (52). Disamping gagal pengobatan, 
kekambuhan juga kelihatannya cukup banyak: pada penelitian kami mengenai 
efek jangka panjang TB paru, 9.6% dari 146 mantan penderita TB mengalami 
kekambuhan. 
Permasalahan tingginya gagal pengobatan dan tingginya angka penularan belum 
menjadi pertimbangan program nasional penanggulangan TB, karena program 
DOTS saat ini dianggap cukup sukses dengan >70% cakupan dan penurunan 
prevalensi TB. Karena galur Beijing dapat menjadi ancaman utama program 
penanggulangan TB, untuk memberantas kemunculan galur ini harus dilakukan 
berbagai upaya, misalnya kebutuhan akan dosis yang lebih tinggi atau 
perpanjangan masa pengobatan. Selain itu, identifikasi galur ini harus 
dipertimbangkan di tingkat masyarakat atau bahkan secara individual.  
Ketiga, angka resistensi yang cukup bermakna ditemukan dalam penelitian ini. 
Walaupun sebagian disebabkan oleh bias seleksi, hal ini tetap merupakan 
permasalahan yang harus diatasi. Sejauh ini, Indonesia belum termasuk ke dalam 
survey internasional resistensi TB, juga tidak ada survey nasional, dan tidak ada 
satupun survey dengan jumlah dan kualitas yang memadai yang dipublikasikan. 
Pada kenyataannya hanya dua laboratorium yang memenuhi kontrol kualitas 
secara  internasional. Kedua laboratorium ini menggunakan metode proporsional 
Canetti yang sudah berumur 50 tahun. Hampir tidak ada penelitian dan 
pengembangan yang dilakukan untuk uji resistensi obat TB di Indonesia. Hanya 
tahun ini program nasional TB mendukung upaya untuk mengevaluasi metode 
genotipik komersial sebagain uji skrining untuk resistensi TB. Beberapa tahun 
silam, dengan bantuan laboratorium rujukan TB Belanda (RIVM) metode 25-well 
plates dengan media Middlebrook yang transparan telah diperkenalkan (53). 
Akurasi metode ini lebih baik, tetapi sulit untuk memproduksi plate yang 
berkesinambungan, karena kontaminasi selama produksi maupun inokulasi 
merupakan permasalahan yang besar. Sebagai alternatif, saat ini kami sedang 
mengevaluasi metode ‘in-house’ molekular yang murah untuk uji kepekaan obat, 
dan pemeriksaan ‘MODS’ (Microscopic Observation Drug Susceptibility) untuk uji 
resistensi TB, yang sangat ‘cost-effective’ dan hasilnya sangat baik di daerah yang 
kurang berkembang (54, 55).  
Kekurangan infrastruktur, sumberdaya manusia dan dana adalah rintangan 
rintangan untuk menuju uji kepekaan obat TB yang berkualitas tinggi di Indonesia. 
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Adalah kebutuhan yang penting untuk didirikannya Laboratorium rujukan nasional 
yang bertanggung jawab terhadap standarisasi identifikasi dan uji kepekaan obat 
TB, pendidikan TB dan biosafety, juga untuk external quality control. Surveilans 
yang baik untuk resistensi obat tidak saja membutuhkan ‘good laboratory 
practice’, tetapi juga epidemiology dan kualitas data pasien yang baik.  
Seperti diperlihatkan pada tesis ini, permasalahan resistensi obat dan gagal 
pengobatan keduanya berhubungan dengan genotip Beijing. Hal ini merupakan 
temuan penting, namun implikasi untuk penatalaksanaan pasien dan 
penanggulangan TB masih perlu ditentukan.  
 
Aspek teknik Laboratoris 
Penerapan tehnik  molekuler di laboratorium klinik untuk pelayanan akan 
membantu deteksi cepat M. tuberculosis kompleks dan dapat berperan penting 
dalam meningkatkan kualitas uji kepekaan obat. Dalam penelitian ini kami 
menemukan bahwa pemeriksaan mikroskopik saja tidak cukup untuk deteksi TB 
karena kita akan kehilangan paling sedikit 17% kasus gagal pengobatan. Karena 
biakan memerlukan waktu yang lama, deteksi TB secara molekuler akan sangat 
berguna karena lebih cepat dan akurat. Walaupun tidak murah, metode ini dapat 
berperan di dalam penatalaksanaan kasus kasus sulit.  
Uji kepekaan obat metode molekuler bahkan memberikan dampak yang besar 
untuk penanggulangan TB. Walaupun tehnik ini akan sulit untuk diterapkan di 
semua laboratorium pelayanan di Indonesia, namun dapat dilaksanakan di 
laboratorium kesehatan masyarakat provinsi atau laboratorium rumah sakit 
rujukan yang saat ini sebagian sudah dilengkapi peralatan biomolekuler. Akan 
tetapi, laboratorium supranasional harus dibentuk lebih dahulu sebagai badan 
yang menjamin kualitas pemeriksaan deteksi molekuler. Bila kualitas metode yang 
rutin harus diperkuat di tingkatan Puskesmas, surveilans untuk mencari kualitas 
dari diagnosis awal dan resistensi obat seharusnya dilakukan di laboratorium 
rujukan provinsi. Selain itu, laboratorium rujukan seharusnya bekerjasama dengan 
fasilitas kesehatan yang menangani kasus kasus sulit misalnya putus berobat atau 
MDR-TB.  
Permasalahan yang tersisa  
Beberapa pertanyaan masih belum terjawab; 1) apa mekanisme yang mendasari 
virulensi yang berhubungan dengan galur Beijing? 2) bagaimana struktur  populasi  
Mycobacterium tuberculosis kompleks di pulau pulau lain di Indonesia? 3) 
bagaimana gambaran klinis TB yang disebabkan oleh galur Beijing? 4) apa 
implikasi semua ini untuk penanggulangan TB di Indonesia? Permasalahan ini 
membutuhkan penelitian lebih lanjut.  
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Kolaborasi akademik 
Penelitian penelitian di dalam tesis ini dapat terlaksana berkat kolaborasi yang 
baik antara Universitas Padjadjaran / Rumah sakit Dr. Hasan Sadikin dan 
University Medical Center Nijmegen, The Netherlands. Disamping kolaborasi 
resmi antar universitas, jaringan kerjasama ini telah meluas ke berbagai institusi 
baik di Belanda maupun di Indonesia. Kolaborasi ini telah memberi keuntungan 
untuk penatalaksanaan pasien, pendidikan dan penelitian melalui alih 
pengetahuan, supervisi, pelatihan, dan berbagi pengalaman di bidang diagnostik 
dan penatalaksanaan TB. Kolaborasi ini telah membantu meningkatkan 
kemampuan laboratorium dalam diagnostik TB menggunakan metode 
konvensional maupun molekuler. Kami telah mampu meningkatkan kualitas 
pemeriksaan mikroskopik dan kultur dan mengevaluasi ‘MIC 25 micro well plate’ 
untuk uji kepekaan obat TB. Kami juga berhasil melakukan metode molecular 
typing, spoligotyping pada lebih dari seribu isolat. Saat ini kami dapat membantu 
Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan RI 
sebagai konsultan dan laboratorium rujukan untuk proyek epidemiologi 
molekuler, juga berkontribusi dalam fase evaluasi uji resistensi molekuler untuk 
MDR-TB; Hain “GenoType® MTBDR plus” yang dilelenggarakan program 
penanggulangan TB nasional.  
Penelitian yang sedang berlangsung di bawah kolaborasi ini adalah untuk deteksi 
molekuler M. tuberculosis, real time PCR untuk  MDR-TB, MODS dll.yang ditujukan 
untuk pelayanan pasien. Harapan kami, di masa yang akan datang, kolaborasi ini 
dapat berkesinambungan dan terus meluas melibatkan lebih banyak staf Fakultas 
Kedokteran Universitas Padjadjaran / R.S. Dr. Hasan Sadikin dan institusi-institusi 
yang terkait dengan keuntungan untuk semua pihak dan untuk tujuan 
penanggulangan TB lebih baik. 
 
Kesimpulan 
Tesis ini telah membantu mendirikan infrastruktur laboratorium klinik dan 
keterampilan metode molekuler untuk deteksi, identifikasi, uji resistensi dan 
epidemiologi M. tuberculosis kompleks. Semua ini memberikan sumbangan untuk 
meningkatkan pengertian mengenai mekanisme yang mendasari kemunculan M. 
tuberculosis galur Beijing. Penelitian komprehensif ini hanya dapat terlaksana 
melalui kerjasama yang baik antara berbagai peneliti dan institusi di Indonesia dan 
di Belanda. Masih banyak yang harus diteliti untuk memberantas TB secara 
efektif. Untuk itu saya berharap bahwa tesis ini dapat merupakan salah satu 
langkah dalam memahami TB dan dalam pengembangan alat diagnostik baru 
serta strategi untuk penanggulangan TB.  
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